WO2008134474A2 - Compositions and methods including cell death inducers and procaspase activation - Google Patents
Compositions and methods including cell death inducers and procaspase activation Download PDFInfo
- Publication number
- WO2008134474A2 WO2008134474A2 PCT/US2008/061510 US2008061510W WO2008134474A2 WO 2008134474 A2 WO2008134474 A2 WO 2008134474A2 US 2008061510 W US2008061510 W US 2008061510W WO 2008134474 A2 WO2008134474 A2 WO 2008134474A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- procaspase
- alkyl
- hydrogen
- pac
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 70
- 230000004913 activation Effects 0.000 title abstract description 66
- 239000000203 mixture Substances 0.000 title abstract description 33
- 230000030833 cell death Effects 0.000 title abstract description 20
- 239000000411 inducer Substances 0.000 title description 2
- 108090000397 Caspase 3 Proteins 0.000 claims abstract description 308
- 150000001875 compounds Chemical class 0.000 claims abstract description 290
- 102000003952 Caspase 3 Human genes 0.000 claims abstract description 249
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 126
- 201000011510 cancer Diseases 0.000 claims abstract description 95
- 238000011282 treatment Methods 0.000 claims abstract description 30
- 229910052739 hydrogen Inorganic materials 0.000 claims description 89
- 239000001257 hydrogen Substances 0.000 claims description 89
- 230000006907 apoptotic process Effects 0.000 claims description 56
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 56
- 125000003118 aryl group Chemical group 0.000 claims description 55
- 125000000217 alkyl group Chemical group 0.000 claims description 47
- -1 C1 -C6 alkyl Chemical group 0.000 claims description 36
- 229910052736 halogen Inorganic materials 0.000 claims description 30
- 150000002367 halogens Chemical class 0.000 claims description 30
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 28
- 108090000567 Caspase 7 Proteins 0.000 claims description 27
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 27
- 125000003342 alkenyl group Chemical group 0.000 claims description 26
- 239000012190 activator Substances 0.000 claims description 25
- 229910052760 oxygen Inorganic materials 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 19
- 102000004041 Caspase 7 Human genes 0.000 claims description 17
- 230000034994 death Effects 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 16
- 229910052717 sulfur Inorganic materials 0.000 claims description 16
- 230000001939 inductive effect Effects 0.000 claims description 15
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 13
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 13
- 239000001301 oxygen Substances 0.000 claims description 13
- 230000003213 activating effect Effects 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- 125000001072 heteroaryl group Chemical group 0.000 claims description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 8
- 230000004962 physiological condition Effects 0.000 claims description 8
- 239000011593 sulfur Substances 0.000 claims description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 7
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 6
- 125000000262 haloalkenyl group Chemical group 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims 21
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 5
- 125000006643 (C2-C6) haloalkenyl group Chemical group 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 12
- 230000006698 induction Effects 0.000 abstract description 10
- 238000003786 synthesis reaction Methods 0.000 abstract description 7
- 230000006882 induction of apoptosis Effects 0.000 abstract description 3
- 230000004048 modification Effects 0.000 abstract description 3
- 238000012986 modification Methods 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 264
- YQNRVGJCPCNMKT-LFVJCYFKSA-N 2-[(e)-[[2-(4-benzylpiperazin-1-ium-1-yl)acetyl]hydrazinylidene]methyl]-6-prop-2-enylphenolate Chemical compound [O-]C1=C(CC=C)C=CC=C1\C=N\NC(=O)C[NH+]1CCN(CC=2C=CC=CC=2)CC1 YQNRVGJCPCNMKT-LFVJCYFKSA-N 0.000 description 213
- 229960005552 PAC-1 Drugs 0.000 description 208
- 101000838335 Homo sapiens Dual specificity protein phosphatase 2 Proteins 0.000 description 206
- 101001080401 Homo sapiens Proteasome assembly chaperone 1 Proteins 0.000 description 206
- 102100027583 Proteasome assembly chaperone 1 Human genes 0.000 description 206
- 230000000694 effects Effects 0.000 description 87
- 102100029855 Caspase-3 Human genes 0.000 description 65
- 108090000623 proteins and genes Proteins 0.000 description 37
- 238000012360 testing method Methods 0.000 description 35
- 102000004169 proteins and genes Human genes 0.000 description 33
- 235000018102 proteins Nutrition 0.000 description 30
- 230000001640 apoptogenic effect Effects 0.000 description 29
- 210000001519 tissue Anatomy 0.000 description 27
- 238000003776 cleavage reaction Methods 0.000 description 25
- 230000007017 scission Effects 0.000 description 25
- 150000003384 small molecules Chemical class 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 24
- 125000004432 carbon atom Chemical group C* 0.000 description 24
- 102000011727 Caspases Human genes 0.000 description 22
- 108010076667 Caspases Proteins 0.000 description 22
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 22
- 229960005420 etoposide Drugs 0.000 description 22
- 125000001424 substituent group Chemical group 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 238000000338 in vitro Methods 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 18
- 201000005202 lung cancer Diseases 0.000 description 18
- 208000020816 lung neoplasm Diseases 0.000 description 18
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 17
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 17
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 17
- 238000003556 assay Methods 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- 230000035772 mutation Effects 0.000 description 16
- 230000000861 pro-apoptotic effect Effects 0.000 description 16
- 238000001727 in vivo Methods 0.000 description 15
- 230000027829 mitochondrial depolarization Effects 0.000 description 15
- 239000000758 substrate Substances 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 12
- 230000001413 cellular effect Effects 0.000 description 12
- 208000029742 colonic neoplasm Diseases 0.000 description 12
- 238000012216 screening Methods 0.000 description 12
- 102100038902 Caspase-7 Human genes 0.000 description 11
- 108010062466 Enzyme Precursors Proteins 0.000 description 11
- 102000010911 Enzyme Precursors Human genes 0.000 description 11
- GGXRLUDNGFFUKI-ORGXJRBJSA-N (4s)-4-[[(2s)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2s)-1-[[(2s)-3-carboxy-1-(4-nitroanilino)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC(=O)C[C@H](NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)NC1=CC=C([N+]([O-])=O)C=C1 GGXRLUDNGFFUKI-ORGXJRBJSA-N 0.000 description 10
- 101710134671 Executioner caspase Proteins 0.000 description 10
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 10
- 239000002246 antineoplastic agent Substances 0.000 description 10
- 239000012131 assay buffer Substances 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 10
- 230000017854 proteolysis Effects 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 101000793880 Homo sapiens Caspase-3 Proteins 0.000 description 9
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 9
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 201000001441 melanoma Diseases 0.000 description 9
- 230000035945 sensitivity Effects 0.000 description 9
- 229910052725 zinc Inorganic materials 0.000 description 9
- 239000011701 zinc Substances 0.000 description 9
- 102000004039 Caspase-9 Human genes 0.000 description 8
- 108090000566 Caspase-9 Proteins 0.000 description 8
- 108010038407 acetyl-aspartyl-glutamyl-valyl-aspartic acid p-nitroanilide Proteins 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 239000000651 prodrug Substances 0.000 description 8
- 229940002612 prodrug Drugs 0.000 description 8
- 230000004614 tumor growth Effects 0.000 description 8
- 238000011144 upstream manufacturing Methods 0.000 description 8
- 108090000672 Annexin A5 Proteins 0.000 description 7
- 102000004121 Annexin A5 Human genes 0.000 description 7
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 7
- 206010006187 Breast cancer Diseases 0.000 description 7
- 208000026310 Breast neoplasm Diseases 0.000 description 7
- 206010009944 Colon cancer Diseases 0.000 description 7
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 239000007983 Tris buffer Substances 0.000 description 7
- 210000001185 bone marrow Anatomy 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 125000001188 haloalkyl group Chemical group 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 6
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 208000008839 Kidney Neoplasms Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 206010029260 Neuroblastoma Diseases 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 125000000304 alkynyl group Chemical group 0.000 description 6
- 238000003782 apoptosis assay Methods 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 230000028161 membrane depolarization Effects 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 230000005522 programmed cell death Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 235000001508 sulfur Nutrition 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 5
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 5
- 108091007065 BIRCs Proteins 0.000 description 5
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 5
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 5
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000005775 apoptotic pathway Effects 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 239000012148 binding buffer Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- 229940125898 compound 5 Drugs 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 210000001700 mitochondrial membrane Anatomy 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000002194 synthesizing effect Effects 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102000018813 CASP8 and FADD Like Apoptosis Regulating Protein Human genes 0.000 description 4
- 108010027741 CASP8 and FADD Like Apoptosis Regulating Protein Proteins 0.000 description 4
- 102000047934 Caspase-3/7 Human genes 0.000 description 4
- 108700037887 Caspase-3/7 Proteins 0.000 description 4
- 102000004091 Caspase-8 Human genes 0.000 description 4
- 108090000538 Caspase-8 Proteins 0.000 description 4
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 4
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 4
- 206010038389 Renal cancer Diseases 0.000 description 4
- 230000001594 aberrant effect Effects 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000003704 aspartic acid Nutrition 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000010428 chromatin condensation Effects 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 4
- 239000000710 homodimer Substances 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 201000010982 kidney cancer Diseases 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 238000011275 oncology therapy Methods 0.000 description 4
- 238000003305 oral gavage Methods 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000019419 proteases Nutrition 0.000 description 4
- 230000002797 proteolythic effect Effects 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 108090000426 Caspase-1 Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 101000741014 Homo sapiens Caspase-7 Proteins 0.000 description 3
- 102100020870 La-related protein 6 Human genes 0.000 description 3
- 108050008265 La-related protein 6 Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- KYIKRXIYLAGAKQ-UHFFFAOYSA-N abcn Chemical compound C1CCCCC1(C#N)N=NC1(C#N)CCCCC1 KYIKRXIYLAGAKQ-UHFFFAOYSA-N 0.000 description 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000005059 dormancy Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 229960002584 gefitinib Drugs 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000012447 xenograft mouse model Methods 0.000 description 3
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 2
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- 239000012103 Alexa Fluor 488 Substances 0.000 description 2
- 239000012114 Alexa Fluor 647 Substances 0.000 description 2
- WSWYMRLTJVKRCE-ZLUOBGJFSA-N Asp-Ala-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O WSWYMRLTJVKRCE-ZLUOBGJFSA-N 0.000 description 2
- 229940123169 Caspase inhibitor Drugs 0.000 description 2
- 102100035904 Caspase-1 Human genes 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 102000009058 Death Domain Receptors Human genes 0.000 description 2
- 108010049207 Death Domain Receptors Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102100032347 Poly(ADP-ribose) glycohydrolase Human genes 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000003172 aldehyde group Chemical group 0.000 description 2
- 125000002877 alkyl aryl group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000001510 aspartic acids Chemical class 0.000 description 2
- 108010078837 aspartyl-glutamyl-valyl-aspartyl-p-nitroanilide Proteins 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000000069 breast epithelial cell Anatomy 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000007541 cellular toxicity Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000034725 extrinsic apoptotic signaling pathway Effects 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000012105 intracellular pH reduction Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000034727 intrinsic apoptotic signaling pathway Effects 0.000 description 2
- 230000006623 intrinsic pathway Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000000803 paradoxical effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 108010078356 poly ADP-ribose glycohydrolase Proteins 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 101100462537 Caenorhabditis elegans pac-1 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000004046 Caspase-2 Human genes 0.000 description 1
- 108090000552 Caspase-2 Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 description 1
- 101710101225 Diablo IAP-binding mitochondrial protein Proteins 0.000 description 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 230000037057 G1 phase arrest Effects 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101001113483 Homo sapiens Poly [ADP-ribose] polymerase 1 Proteins 0.000 description 1
- 241000713321 Intracisternal A-particles Species 0.000 description 1
- 102100027670 Islet amyloid polypeptide Human genes 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 238000000719 MTS assay Methods 0.000 description 1
- 231100000070 MTS assay Toxicity 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 101100117764 Mus musculus Dusp2 gene Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102100037925 Prothymosin alpha Human genes 0.000 description 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical group [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000012203 high throughput assay Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000004987 nonapoptotic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229940127255 pan-caspase inhibitor Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108010014750 prothymosin alpha Proteins 0.000 description 1
- 230000025915 regulation of apoptotic process Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000011255 standard chemotherapy Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000002653 sulfanylmethyl group Chemical group [H]SC([H])([H])[*] 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Chemical group 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- Apoptosis or programmed cell death, plays a central role in the development and homeostasis of all multicellular organisms (Shi Y, 2002, Molecular Cell 9:459-470).
- a frequent hallmark of cancer is resistance to natural apoptotic signals. Depending on the cancer type, this resistance is typically due to up- or down-regulation of key proteins in the apoptotic cascade or to mutations in genes encoding these proteins. Such changes occur in both the intrinsic apoptotic pathway, which funnels through the mitochondria and caspase-9, and the extrinsic apoptotic pathway, which involves the action of death receptors and caspase-8.
- alterations in proper levels of proteins such as p53, Bim, Bax, Apaf-1 , FLIP and many others have been observed in cancers.
- the alterations can lead to a defective apoptotic cascade, one in which the upstream pro-apoptotic signal is not adequately transmitted to activate the executioner caspases, caspase-3 and caspase-7.
- procaspase-3 is a homodimer of heterodimers and is produced by proteolysis of procaspase-3. In vivo, this proteolytic activation typically occurs through the action of caspase-8 or caspase-9.
- procaspase- 3 has a 12 amino acid "safety catch” that blocks access to the IETD site (amino acid sequence, ile-glu-thr-asp) of proteolysis. See Roy, S. et al.; Maintenance of caspase-3 proenzyme dormancy by an intrinsic "safety catch” regulatory thpeptide, Proc. Natl. Acad. Sci. 98, 6132-6137 (2001 ).
- This safety catch enables procaspase-3 to resist autocatalytic activation and proteolysis by caspase-9. Mutagenic studies indicate that three consecutive aspartic acid residues appear to be the critical components of the safety catch. The position of the safety catch is sensitive to pH; thus, upon cellular acidification (as occurs during apoptosis) the safety catch is thought to allow access to the site of proteolysis, and active caspase-3 can be produced either by the action of caspase-9 or through an autoactivation mechanism.
- procaspase-3 is upregulated.
- procaspase-3 is upregulated in certain neuroblastomas, lymphomas, and liver cancers (Nakagawara, A. et al., 1997, Cancer Res. 57:4578-4584; Izban, K. F. et al., Am. J. Pathol. 154:1439-1447; Persad, R. et al., Modern Patholo. 17:861 -867).
- compositions and methods including small molecules capable of inducing cell death.
- compositions and methods involve compounds which can interact directly or indirectly with programmed cell death pathway members such as procaspase-3.
- the invention broadly provides compounds, methods of therapeutic treatment, methods of screening for compounds, and methods of screening for cell and patient suitability for treatment in connection with modifiers of procaspases.
- the modifiers are inhibitors.
- the modifiers are activators.
- the invention provides such compounds and methods in connection with activators of procaspase-3 and procaspase-7.
- the inventions are applicable in the context of a variety of cancer diseases and cancer cell types such as breast, lymphoma, adrenal, renal, melanoma, leukemia, neuroblastoma, lung, brain, and others known in the art.
- embodiments of compounds and methods of the invention may act via the mechanism of modulation of apoptosis or programmed cell death to be effective in the treatment of cancer cells.
- the modulation of apoptosis is by induction of apoptosis.
- the modulation of apoptosis is by inhibition of apoptosis.
- the invention provides a method of selectively inducing apoptosis in a cancer cell, comprising: (a) administering to said cancer cell an effective amount of a compound capable of modifying a procaspase-3 molecule of said cancer cell; and (b) modifying said procaspase-3 molecule so as to induce apoptosis.
- said cancer cell is in a patient in need of treatment.
- compounds and methods may act indirectly in connection with a programmed cell death pathway member, e.g., procaspase-3, such as by chelating or otherwise interacting directly or indirectly with a molecule which is necessary for the pathway member.
- the molecule is a metal such as zinc.
- said compound is of formula Z:
- n 0, 1 or 2;
- each R independently of other R, is selected from hydrogen, halogen, alkyl, alkoxy or alkenyl;
- R 3 is selected from hydrogen, halogen, alkyl, haloalkyl, alkenyl, alkenol, alkanol, or haloalkenyl;
- R 4 and R5 are both N; R 4 is N and R5 is CH; R 4 is CH and R5 is N or R 4 and R5 are both CH; R 6 is hydrogen or alkyl;
- A oxygen or sulfur
- B is aryl, heteroaryl or R 9 -O-CO-, where Rg is alkyl or aryl.
- R 3 is allyl.
- R 2 X is OH.
- R 2 X is NH 2 .
- aryl groups are phenyl groups substituted with one or more R groups as defined above.
- alkyl groups are C1 -C6 alkyl groups or C1 -C3 alkyl groups.
- alkenyl groups are C2- C6 alkenyl groups or C2-C4 alkenyl groups.
- alkenyl groups are allyl groups.
- B is a R 9 -O-CO-.
- B is a phenyl substituted with one or more R substituents.
- R 9 is a t-butyl group.
- R 6 is hydrogen or methyl.
- n is O and B is R 9 - O-CO-.
- n is 1 or 2 and B is aryl.
- A is O.
- R is hydrogen.
- at least one R or R 3 is a substituent other than hydrogen.
- at least one R is a substituent other than hydrogen.
- R 2 X is OH and R 3 is allyl.
- n is 1 and B is pyridinyl. In a specific embodiment of formula Z, n is 1 and B is 2-pyridinyl. In a specific embodiment of formula Z, n is 1 and B is 3-pyridinyl. In a specific embodiment of formula Z, n is 1 and B is 4- pyridinyl. In specific embodiments of formula Z, n is O and B is R 9 -OCO- and R 9 is alkyl. In specific embodiments of formula Z, n is O and B is R 9 -OCO- and R 9 is t- butyl.
- said compound is of formula ZA:
- each R independently of other R, is selected from hydrogen, halogen, alkyl, or alkenyl
- R 3 is selected from hydrogen, halogen, alkyl, haloalkyl, alkenyl, alkenol, alkanol, or haloalkenyl;
- R 4 and R 5 are both N; R 4 is N and R 5 is CH; R 4 is CH and R 5 is N or R 4 and R 5 are both CH;
- Re is hydrogen or alkyl
- A oxygen or sulfur
- R 9 is alkyl or aryl.
- R 3 is allyl.
- R 9 is an alkyl group.
- R 9 is an C1 -C6 alkyl group.
- R 9 is a t-butyl group.
- R 2 X is OH.
- R 2 X is NH 2 .
- aryl groups are phenyl groups substituted with one or more R groups as defined above.
- alkyl groups are C1 -C6 alkyl groups or C1 -C3 alkyl groups.
- alkenyl groups are C2-C6 alkenyl groups or C2-C4 alkenyl groups. In specific embodiments of formula ZA, alkenyl groups are allyl groups. In specific embodiments of formula ZA, R 6 is hydrogen or methyl. In a specific embodiment of formula ZA, A is O. In a specific embodiment of formula ZA, R is hydrogen. In a specific embodiment of formula ZA, at least one R or R 3 is a substituent other than hydrogen. In a specific embodiment of formula ZA, at least one R is a substituent other than hydrogen. In a specific embodiment of formula ZA, R 2 X is OH and R 3 is allyl.
- said compound is of formula ZZ:
- n 1 or 2;
- Ra, Rb, Rc, Rd, and Re are independently selected from hydrogen, halogen, alkyl, alkenyl, alkoxy, and aryl and other variables are as defined in formula Z.
- n is 1.
- R 2 X is OH.
- R 2 X is NH 2 .
- A is O.
- R 3 is allyl.
- R 6 is hydrogen.
- R is hydrogen.
- one or two of Ra, Rb, Rc, Rd and Re are C1 -C3 alkyl, C1-C3 alkoxy or halogens and the remaining groups are hydrogens.
- Rc is a C1 -C3 alkyl or a C1 -C3 alkoxy and Ra, Rb, Rd, and Re are all hydrogens. In a specific embodiment, all of Ra, Rb, Rc, Rd and Re are hydrogens. In a specific embodiment, Rc is fluorine and Ra, Rb, Rc, Rd and Re are all hydrogens.
- R 2 X is chlorine. In a specific embodiment, R 2 X is OH. In a specific embodiment, R 2 X is SH. In a specific embodiment, R 2 X is CH 3 S. . In a specific embodiment, R 2 X is HO-CO-. . In a specific embodiment, R 2 X is CH 3 O-CO-.
- R 4 and R 5 are both N, A is oxygen, and other variable groups are as defined above.
- R 4 and R 5 are both N, A is oxygen, R 2 is hydrogen, and other variable groups are as defined above.
- R 4 and R 5 and both N A is oxygen, R 2 is hydrogen, R 3 is allyl, and other variable groups are as defined above.
- one of R is a fluorine.
- at least one R or R 3 is a substituent other than hydrogen.
- at least one R is a substituent other than hydrogen.
- R 2 X is OH and R 3 is allyl.
- at least one of Ra-Re is a substituent other than hydrogen.
- at least one R or R3 is a substituent other than hydrogen, and at least one of Ra-Re is a substituent other than hydrogen.
- the invention provides compounds of formula ZB:
- m is 1 -4 and other variables are as defined for formula Z.
- m is 2.
- R 4 and R 5 are both N.
- R 3 is allyl.
- B is aryl.
- B is Rg-O-CO-.
- R 2 X is OH.
- R 2 X is NH 2 .
- aryl groups are phenyl groups substituted with one or more R groups as defined above.
- alkyl groups are C1 -C6 alkyl groups or C1 - C3 alkyl groups.
- alkenyl groups are C2-C6 alkenyl groups or C2-C4 alkenyl groups.
- alkenyl groups are allyl groups.
- R 9 is a t- butyl group.
- R 6 is hydrogen or methyl.
- n is 0 and B is Rg-O-CO-. In specific embodiments, n is 1 or 2 and B is aryl. In a specific embodiment of formula ZB, R is hydrogen.
- At least one R or R 3 is a substituent other than hydrogen. In a specific embodiment of formula ZB, at least one R is a substituent other than hydrogen. In a specific embodiment of formula ZB, R 2 X is OH and R 3 is allyl.
- the invention provides compounds of formula ZC:
- q is 2.
- R 3 is allyl.
- R 2 X is OH.
- R 2 X is NH 2 .
- aryl groups are phenyl groups substituted with one or more R groups as defined above.
- alkyl groups are C1 -C6 alkyl groups or C1 - C3 alkyl groups.
- alkenyl groups are C2-C6 alkenyl groups or C2-C4 alkenyl groups.
- alkenyl groups are allyl groups.
- B is a R 9 -O- CO-. In specific embodiments of formula ZC, B is a phenyl substituted with one or more R substituents. In specific embodiments of formula ZC, Rg is a t-butyl group. In specific embodiments, R 6 is hydrogen or methyl. In specific embodiments of formula ZC, n is 0 and B is R 9 -O-CO-. In specific embodiments of formula ZC, n is 1 or 2 and B is aryl. In a specific embodiment of formula ZC, A is O. In a specific embodiment of formula ZC, R is hydrogen. In a specific embodiment of formula ZC, at least one R or R 3 is a substituent other than hydrogen. In a specific embodiment of formula ZC, at least one R is a substituent other than hydrogen. In a specific embodiment of formula ZC, R 2 X is OH and R 3 is allyl.
- the invention provides compounds of formula ZD:
- R 6 and R' 6 is independently selected from hydrogen or alkyl and other variables are as defined in formula Z.
- R 6 is hydrogen or methyl and R' 6 is hydrogen. In specific embodiments of formula ZD, R' 6 is hydrogen. In specific embodiments of formula ZD, n is 1 and B is aryl. In specific embodiments of formula ZD, n is 1 and B is phenyl substituted with one or more R groups as defined above. In specific embodiments of formula ZD, A is O.
- the invention provides compounds of formula ZY:
- Y is selected from any one of :
- Y5 -CH 2 -CO-NH-CH 2 -CH 2 -
- Y6 -CH 2 -CO-NH-CH 2 -
- R5 is CH or N and other variables are as defined in above formulas.
- n is 1 and B is aryl or heteroaryl. In specific embodiments of formula ZX, n is 1 and B is phenyl, R-substituted phenyl or pyridinyl. In specific embodiments of formula ZX, Y is Y2, Y3, or Y4. In specific embodiments of formula ZX, Y is Y5 or Y6. in specific embodiments, R 5 is CH or N. IN specific embodiments, R5 is N. In specific embodiments, Y is Y1 , n is O and B is R9-O-CO-. In specific embodiments, n is 0 and B is B is R9-O-CO-.
- R 2 X is OH. In specific embodiments, R 2 X is -NH 2 . In specific embodiments R 2 X is OH and R 3 is allyl. In specific embodiments, R 2 X is -NH 2 and R3 is allyl. In specific embodiments, at least one of R is a non-hydrogen substituent. In specific embodiments, Re is hydrogen or methyl. In specific embodiments, R' ⁇ is hydrogen.
- the invention provides compounds of formula GX:
- Y is Y1. In other specific embodiments, Y is Y1 and B is aryl. In other specific embodiments R 5 is N. In other specific embodiments, R and R 3 are all hydrogens. In other specific embodiments, B is aryl. In other specific embodiments, n is 1 or 2. In other specific embodiments, B is phenyl and R A represents substitution with hydrogens on the phenyl ring. IN other embodiments, Y is Y1 , A is O and R 6 is hydrogen. In other specific embodiments, Y is Y1 , n is 1 , B is optionally substituted phenyl. In other embodiments, B is R9-COO-.
- Rg is C1 -C6 alkyl and more specifically is t-butyl.
- Y is Y1 , R5 is N, n is 0 and B is optionally substituted phenyl.
- Y is Y1 , R 5 is N, n is 0 and B is Rg-COO-.
- Y is Y2 or Y4.
- Y is Y1 or Y3.
- Y is Y5 or Y6.
- a compound is provided wherein B is a phenyl with at least one substituent other than hydrogen.
- a compound is provided wherein the aromatic ring shown on the right side of compound ZY (or its analogous equivalent in other compounds described herein) has at least one substituent other than hydrogen.
- a compound is provided wherein both rings have at least one substituent other than hydrogen.
- the method further comprises the step of assessing a procaspase-3 or caspase-3 parameter in a cancer cell; wherein said parameter is one or more of a semi-quantitative or quantitative amount, a functional amount, and an activity level of said procaspase-3 or caspase-3.
- the invention provides a method of direct in vitro screening for a compound capable of modifying a procaspase-3 molecule, comprising: (a) providing a test compound; (b) providing a purified procaspase-3; (c) exposing the test compound to the purified procaspase-3; (d) measuring a procaspase-3 activity following exposure to the test compound; (e) identifying a modifying compound by comparing a test activity upon the exposure to the test compound with an unmodified activity in the absence of exposure to the test compound; thereby screening for a compound capable of modifying a procaspase-3 molecule.
- the method further comprises comparing said modified activity or said unmodified activity with a reference activity; wherein said reference activity is due to exposure of procaspase-3 to a compound selected from the group consisting of structural formula Z, ZA, ZB, ZC, ZD, ZZ, PAC-1 or Compound 5.
- the invention provides a method of screening for a compound capable of activating procaspase-3 comprising: a) providing procaspase- 3; providing a test compound, preferably a small molecule; b) reacting the procaspase-3 with the test compound, thereby putatively generating caspase-3; and c) measuring caspase-3 activity.
- the measuring caspase-3 activity employs a substrate, Ac-DEVD-pNA.
- the measuring uses a wavelength readout parameter of about 410 nm.
- the screening is carried out in parallel using multiple test compounds.
- the invention provides a method of screening which uses the detection of a subunit of procaspase-3 as an indicator that the full length
- the subunit has a molecular weight of about 19kD as measured by a protein gel migration technique, for example in a Western blot.
- the invention provides a method of in cellular screening for a compound capable of modifying a procaspase-3 molecule, comprising: (a) providing a test compound; (b) providing a cell, wherein the cell putatively expresses procaspase-3; (c) exposing the cell to the test compound; (d) measuring a cell parameter following exposure to the test compound; wherein said parameter comprises one or more of cell viability, apoptotic indicator, and other parameters; (e) identifying a modifying compound by comparing a tested cell parameter upon the exposure to the test compound with an unmodified cell parameter in the absence of exposure to the test compound; thereby screening for a compound capable of modifying a procaspase-3 molecule.
- the method further comprises comparing said modified activity or said unmodified activity with a reference activity; wherein said reference activity is due to exposure to a compound selected from the group consisting of formula Z, ZA, ZB, ZC, ZD, or ZZ or subsets of compounds of such formula, PAC-1 , and Compound 5.
- the invention provides a method of identifying or diagnosing a potential susceptibility to treatment for a cancer cell with a procaspase activator compound, comprising (a) assessing a procaspase parameter in said cancer cell; and (b) determining if said parameter allows an increased susceptibility to activation of a procaspase.
- said procaspase parameter is a procaspase-3 level and said procaspase is procaspase-3.
- said procaspase parameter is a procaspase-7 level and said procaspase is procaspase- 7.
- a level can be a semi-quantitative or quantitative amount, or functional amount (e.g. an activity-based amount, e.g. a standardized unit or international unit).
- the invention provides a method of treating a cancer cell, comprising (a) identifying a potential susceptibility to treatment of a cancer cell with a procaspase activator compound; and (b) exposing said cancer cell to an effective amount of the procaspase activator compound.
- the procaspase activator compound is selected from the group consisting of formula ZZ or subsets of compounds of such formula, PAC-1 , and Structure 5.
- the method of claim 16 wherein said procaspase activator compound is capable of activating procaspase-3, procaspase-7, or both procaspase-3 and procaspase-7.
- the invention provides a method of synthesizing PAC-1 , comprising the steps of Scheme 1.
- the invention provides a method of synthesizing Compound 5, comprising the steps of Scheme 1 with appropriate modification.
- the invention provides a method of synthesizing compounds of the formula Z as disclosed herein and as would be understood in the art.
- the invention provides compounds of the formula Z1 , ZA1. ZC1 or ZZV.
- R 2 X is OH.
- both R 4 and R 5 are N.
- R 6 is hydrogen.
- R 3 is allyl.
- at least one R or R 3 is a substituent other than hydrogen.
- R is a substituent other than hydrogen.
- R 2 X is OH and R 3 is allyl.
- one or two of Ra, Rb, Rc, Rd or Re are halogens, C1 -C3 alkyl or C1 -C3 alkoxy groups and the remaining groups are hydrogens.
- all of Ra, Rb, Rc, Rd, and Re are hydrogens.
- GXX1 , R 3 and R are all hydrogens. In specific embodiments of GXX1 , R a , Rb, Rc, Rd, and Re are all hydrogens. In specific embodiments of GXX1 , n is 1. In specific embodiments of GXX1 , R 6 is hydrogen.
- the invention provides compounds of formula DX1 , DX2, DX3, DX4, DX5, DX6, DX7, DX8, DX9, DX10, DX11 , DX12, DX13, DX14, DX15, DX16, or DX17.
- the invention provides compounds of formulas illustrated in Figure 12. [0046] In specific embodiments, the invention provides compounds of formulas FX1 , FX2, FX3, FX4, FX5, FX6, FX7, FX8, and FX9.
- the invention provides a compound of formula GX1.
- the invention provides a therapeutic composition
- a therapeutic composition comprising one or more compounds of any of the formulas herein and for each compound a pharmaceutically acceptable salt or ester thereof; wherein the compounds are present in the composition in an amount or in a combined amount effective for obtaining the desired therapeutic benefit.
- the therapeutic compositions of this invention optionally further comprise one or more pharmaceutically acceptable components, for example carriers and excipients as known in the art.
- the invention provides a method of screening a candidate cancer patient for possible treatment with a procaspase activator by identifying an elevated level of a procaspase in the candidate, comprising obtaining a cell or tissue test sample from the candidate, assessing the procaspase level in the test sample, and determining whether the procaspase level is elevated in the test sample relative to a reference level, thereby screening a candidate cancer patient for possible treatment with a procaspase activator.
- the procaspase is selected from the group consisting of procaspase-2, -3, -6-, -7, -8, and -9.
- the procaspase is procaspase-3.
- an elevated level of the test sample is at least about 2- fold greater than the reference level. In an embodiment, an elevated level of the test sample is at least about 4-fold greater than the reference level. In an embodiment, the reference level is from a second test sample from the same patient. In an embodiment, the reference level is from a normal cell or tissue sample. The reference level can be from a cell line, such as a cancer cell line or a normal cell line. In an embodiment, the reference level is an absolute threshold amount. See Svingen, P.A. et al., Clin. Cancer Res. 10:6807-6820 which describes various amounts of levels of procaspases including numbers of molecules per cell.
- the invention provides a method of inducing apoptosis in a cell, comprising administering to said cell a compound of the invention.
- the cell is a cancer cell.
- the compound has structural formula Z, ZA, ZB, ZC, ZD or ZZ.
- the invention provides a method of inducing death in a cancer cell, comprising administering to said cancer cell a compound capable of activating a procaspase molecule of said cancer cell.
- the procaspase is one or more of procasepas-3 and procaspase-7.
- the procaspase is procaspase 3.
- the compound has structural formula Z, ZA, ZB, ZC, ZD or ZZ.
- the invention provides a medicament comprising one or more compounds of formulas Z, ZA, ZB, ZC, ZD, or ZZ as well as a method for making a medicament comprising such compounds. More specifically, the medicament further comprising a pharmaceutically acceptable carrier suitable for a selected means of administration of the medicament. In a more specific method of making the medicament, one or more compounds of the recited formulas are combined with the selected pharmaceutically acceptable carrier.
- the invention provides compositions and methods where a compound of the composition or method is not a compound disclosed in: U.S. Provisional Application Serial 60/684,807 filed May 26, 2005; U.S. Provisional Application Serial 60743878 filed March 28, 2006; US Patent Application Serial 11/420,425 filed May 25, 2006 (published as US 20070049602, March 1 , 2007); PCT International Application Serial PCT/US 06/020910 filed May 26, 2006 (published as WO2006/128173, 30 November 2006).
- said compound is not a compound of formula is of formula ZZX;
- FIG. 1 A) Activation of mutants in the "safety catch" region of procaspase-3 by PAC-1.
- PAC-1 has an EC 50 for activation of 0.22 ⁇ M on wild type procaspase-3 (DDD), and corresponding EC 5 O values of 2.77 ⁇ M (DAD), 113 ⁇ M (DDA), and 131 ⁇ M (ADD) for certain mutants.
- DDD wild type procaspase-3
- DDA 113 ⁇ M
- ADD 131 ⁇ M
- B) PAC-1 activates procaspase-7 with an EC 5O of 4.5 ⁇ M.
- FIG. 3 PAC-1 induces apoptosis in HL-60 cells.
- FIG. 4 A) Mitochondrial membrane depolarization (MMP) and caspase-3 like activity in HL-60 cells treated with 10 ⁇ M etoposide. B) Mitochondrial membrane depolarization (MMP) and caspase-3 like activity in HL-60 cells treated with 100 ⁇ M PAC-1. C) PAC-1 treatment (100 ⁇ M) induces a rapid decrease in cellular PARP activity in HL-60 cells, consistent with an immediate activation of cellular caspase-3/- 7. In contrast, etoposide (10 ⁇ M) treated cells show a decrease in PARP activity at much later time points. D) PAC-1 induces cell death in a procaspase-3 dependent manner.
- MMP Mitochondrial membrane depolarization
- MMP Mitochondrial membrane depolarization
- caspase-3 like activity in HL-60 cells treated with 100 ⁇ M PAC-1 C) PAC-1 treatment (100 ⁇ M) induces a rapid decrease in cellular PARP activity in HL-60 cells, consistent with
- Fig. 5A illustrates relative procaspase-3 levels in normal and cancerous cells from several patients.
- Fig. 5B illustrates IC50 levels for PAC-1 in a variety of cell types having a range of relative procaspase-3 levels.
- Fig. 5C illustrates the effect of treating animals with PAC-1 on outcomes of tumor growth.
- Fig. 5D illustrates the effect of oral treatment of animals with PAC-1 on outcomes of tumor growth.
- Fig. 5E illustrates results of progression of cancer in a lung cancer model for control, PAC-1 , and gefitinib (IressaTM; AstraZeneca) treatment groups.
- Tumor cells were injected into mice by i.v. administration; Iressa and PAC-1 were given orally at 100 mg/kg.
- Fig. 6A illustrates relative procaspase-3 levels in normal and cancerous cells of three patients.
- Fig. 6B illustrates the sensitivity of normal and cancerous cells from Patient 3 to treatment with PAC-1.
- FIG. 7 illustrates results of administering PAC-1 intraperitoneal ⁇ in the context of a mouse model of lung cancer.
- Fig. 8A and 8B illustrate structures for compounds of PAC-1 derivatives and a combinatorial library.
- Fig. 9 illustrates a nucleotide sequence for Homo sapiens caspase 3, apoptosis-related cysteine peptidase (CASP3), transcript variant alpha, mRNA (Accession No. NM_004346; 2689 bp mRNA linear; obtained from http://www.ncbi.nlm.nih.gov/entrez).
- Fig. 10 illustrates a nucleotide sequence for Homo sapiens caspase 7, apoptosis-related cysteine peptidase (CASP7), transcript variant alpha, mRNA (Accession No. NM_001227; 2605 bp; mRNA linear; obtained from http://www.ncbi.nlm.nih.gov/entrez).
- Fig. 11 illustrates structures for compounds designated DX1 -DX17 (see, e.g., Examples 9 and 10).
- Fig. 12 illustrates activity levels (IC50 values) next to structures of compounds DX1 -17 from apoptosis induction assays using HL-60 cells.
- Fig. 13 illustrates results of testing certain compounds for the ability to effect activation of procaspase-3.
- Fig. 14 illustrates the structures of certain compounds including FX1 -FX9 and GXL
- Fig. 15 illustrates results from activity testing of compounds including such in the series DX, FX, and GX.
- Test conditions used 2.5 ⁇ M procaspase-3 (D 3 A) with the indicated test compound at 100 ⁇ M (filled columns); and further with 10 ⁇ M zinc (open columns).
- Fig. 16 illustrates results from activity testing of compounds in the series DX and FX, plotted as percent activity versus compound concentration.
- IAP inhibitor of apoptosis
- PAC-1 procaspase activating compound 1
- PARP Poly(ADP-ribose) polymerase.
- chemotherapeutic agent refers to any substance capable of reducing or preventing the growth, proliferation, or spread of a cancer cell, a population of cancer cells, tumor, or other malignant tissue. The term is intended also to encompass any antitumor or anticancer agent.
- the term "effective amount” is intended to encompass contexts such as a pharmaceutically effective amount or therapeutically effective amount.
- the amount is capable of achieving a beneficial state, beneficial outcome, functional activity in a screening assay, or improvement of a clinical condition.
- cancer cell is intended to encompass definitions as broadly understood in the art.
- the term refers to an abnormally regulated cell that can contribute to a clinical condition of cancer in a human or animal.
- the term can refer to a cultured cell line or a cell within or derived from a human or animal body.
- a cancer cell can be of a wide variety of differentiated cell, tissue, or organ types as is understood in the art.
- alkyl refers to a monoradical branched or unbranched saturated hydrocarbon chain preferably having from 1 to 22 carbon atoms and to cycloalkyl groups having one or more rings having 3 to 22 carbon atoms.
- Short alkyl groups are those having 1 to 6 carbon atoms including methyl, ethyl, propyl, butyl, pentyl and hexyl groups, including all isomers thereof.
- Long alkyl groups are those having 8-22 carbon atoms and preferably those having 12-22 carbon atoms as well as those having 12-20 and those having 16-18 carbon atoms.
- cycloalkyl refers to cyclic alkyl groups of from 3 to 22 carbon atoms having a single cyclic ring or multiple condensed rings. Cycloalkyl grouos include those having 3-8 member rings and those having 5 and 6 member rings. Cycloalkyl groups include, by way of example, single ring structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl, and the like, or multiple ring structures such as adamantanyl, and the like.
- alkenyl refers to a monoradical of a branched or unbranched unsaturated hydrocarbon group preferably having from 2 to 22 carbon atoms and to cycloalkenyl groups having one or more rings having 3 to 22 carbon atoms wherein at least one ring contains a double bond.
- Preferred alkenyl groups are those having 1 or 2 double bonds.
- Short alkenyl groups are those having 2 to 6 carbon atoms including ethylene (vinyl) propylene, butylene, pentylene and hexylene groups, including all isomers thereof.
- Long alkenyl groups are those having 8-22 carbon atoms and preferably those having 12-22 carbon atoms as well as those having 12-20 carbon atoms and those having 16-18 carbon atoms.
- Cycloalkenyl groups include, by way of example, single ring structures such as cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclooctenyl, cylcooctadienyl and cyclooctathenyl.
- alkynyl refers to a monoradical of an unsaturated hydrocarbon preferably having from 2 to 22 carbon atoms and having one or more triple bonds (CDC).
- Alkynyl groups include ethynyl, propargyl, and the like.
- Short alkynyl groups are those having 2 to 6 carbon atoms, including all isomers thereof.
- Long alkynyl groups are those having 8-22 carbon atoms and preferably those having 12-22 carbon atoms as well as those having 12-20 carbon atoms and those having 16-18 carbon atoms.
- aryl refers to a group containing an unsaturated aromatic carbocyclic group of from 6 to 22 carbon atoms having a single ring (e.g., phenyl), one or more rings (e.g., biphenyl)or multiple condensed (fused) rings, wherein at least one ring is aromatic (e.g., naphthyl, dihydrophenanthrenyl, fluorenyl, or anthryl).
- Aryls include phenyl, naphthyl and the like.
- Aryl groups may contain portions that are alkyl, alkenyl or akynyl in addition to the the unsaturated aromatic ring(s).
- alkaryl refers to the aryl groups containing alkyl portions, i.e., -alkylene-aryl and -substituted alkylene-aryly. Such alkaryl groups are exemplified by benzyl (- CH 2 -phenyl), phenethyl and the like.
- Alkyl, alkenyl, alkynyl and aryl groups are optionally substituted as described herein (the term(s) can include substituted variations) and may contain 1 -8 non-hydrogen substituents dependent upon the number of carbon atoms in the group and the degree of unsaturation of the group.
- variable as described herein can be unsubstituted (in which any variables groups that can be hydrogen are hydrogen) or substituted with one or more non-hydrogen substituents selected from halogen, including fluorine, chlorine, bromine or iodine, C1 -C3 haloalkyl, hydroxyl (OH), thiol (HS-), C1 -C6 alkyl, C1 -C3 alkyl, C1 -C6 alkoxy, C1 -C3 alkoxy, phenyl, benzyl, alkenyl, C2-C4 alkenyl, alkynyl, C2-C4 alkynyl, -NH 2 , -NR 1 H, -NR 1 R", R 1 CO-, R 1 R 11 NCO-, R 1 CO-NH-, or R 1 CO-NR 1 -, where R 1 and R" are C1 -C6 alkyl, C1 -C3 alkyl or phenyl.
- halogen
- amino refers to the group -NH 2 or to the group -NR 1 R" where each R 1 and R" is independently selected from the group consisting of hydrogen, alkyl or aryl groups.
- Haloalkyl refers to alkyl as defined herein substituted by one or more halo groups as defined herein, which may be the same or different.
- Representative haloalkyl groups include, by way of example, trifluoromethyl, 3-fluorododecyl, 12,12,12-trifluorododecyl, 2-bromooctyl, 3-bromo-6-chloroheptyl, and the like.
- heteroaryl refers to an aromatic group of from 2 to 22carbon atoms having 1 to 4 heteroatoms selected from oxygen, nitrogen and sulfur within at least one ring (if there is more than one ring). Heteroaryl groups may be optionally substituted. Heteroaryl grouos include among others those having 5 and 6-member rings and those having one or two nitrogens in the ring, those having one or two oxygens in the ring as well as those having one or two sulfurs in the ring.
- heterocycle or “heterocyclic” refers to a monoradical saturated or unsaturated group having a single ring or multiple condensed rings, from 2-22 carbon atoms and from 1 to 6 hetero atoms, preferably 1 to 4 heteroatoms, selected from nitrogen, sulfur, phosphorus, and/or oxygen within at least one ring.
- Heterocyclic groups may be substituted. Rings preferably have 3-10 members and more specifically have 5 or 6 members.
- esters refers to chemical entities as understood in the art and in particular can include groups of the form (RCO-).
- RCO- groups of the form
- any of the above groups which contain one or more substituents it is understood, that such groups do not contain any substitution or substitution patterns which are sterically impractical and/or synthetically non-feasible.
- the compounds of this invention include all novel stereochemical isomers arising from the substitution of disclosed compounds.
- the invention provides compounds of the formula Z excluding PAC-1 , wherein the structure of PAC-1 is:
- the invention provides a compound of compound 5, which is:
- the invention provides a compound of formula Z other than compound 5.
- the invention provides a compound having the formula Z2:
- Ri and R 2 independently represent substitution on the indicated rings with one or more hydrogen, halogen, alkyl, allyl, haloalkyl, alkenyl, alkenol, alkanol, or haloalkenyl.
- Ri and R 2 independently represent substitution on the indicated rings with one or more hydrogen, halogen, allyl, or C1 -C3 alkyl.
- the invention provides a compound selected from the group consisting of a PAC-1 derivative combinatorial library comprising a hydrazide compound combined with an aldehyde compound.
- the hydrazide compound is selected from the group consisting of hydrazides generated from AX compounds described herein.
- the aldehyde compound is selected from the group consisting of BX compounds described herein.
- the hydrazide compound is selected from the group consisting of AX compounds described herein and the aldehyde compound is selected from the group consisting of BX compounds described herein.
- the invention provides a method of synthesizing a PAC-1 derivative compound comprising providing a hydrazide compound, providing an aldehyde compound, and reacting the hydrazide compound with the aldehyde compound, thereby synthesizing a PAC-1 derivative compound.
- the hydrazide compound has the formula ZZ3:
- Ri represents substitution on the indicated ring of one or more R groups as defined in formula Z.
- the aldehyde compound has the formula ZZ4:
- R2 represents substitution on the indicated ring of one or more R3 or R groups as defined in formula Z.
- the hydrazide compound has the formula ZZ3 and the aldehyde compound has the formula ZZ4.
- the invention provides a compound selected from the group consisting of: L01 R06, L02R03, L02R06, L08R06, L09R03, L09R06, and L09R08.
- a composition of the invention is a chemotherapeutic agent.
- the invention provides compounds and methods involving effective concentrations preferably from about 10 nM to about 100 ⁇ M of the disclosed structural formulas. In another preferred embodiment, the effective concentrations are from about 200 nM to about 5 ⁇ M. In an embodiment, the effective concentration is considered to be a value such as a 50% activity concentration in a direct procaspase activation assay, in a cell apoptosis induction assay, or in an animal clinical therapeutic assessment. In a preferred embodiment, such value is less than about 200 ⁇ M. In a preferred embodiment, the value is less than about 10 ⁇ M.
- Compounds of the invention and compounds useful in the methods of this invention include those of the disclosed formulas and salts and esters of those compounds, including preferably pharmaceutically-acceptable salts and esters.
- the invention provides prodrug forms of compositions.
- Prodrugs of the compounds of the invention are useful in the methods of this invention. Any compound that will be converted in vivo to provide a biologically, pharmaceutically or therapeutically active form of a compound of the invention is a prodrug.
- Various examples and forms of prodrugs are well known in the art.
- a biomolecule such as a precursor protein or precursor nucleic acid can be a prodrug. Examples of prodrugs are found, inter alia, in Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985), Methods in Enzymology, Vol. 42, at pp. 309-396, edited by K. Widder, et. al.
- composition of the invention is in a form that is isolated or purified. [00111] It is recognized that regardless of the ultimate correctness of any mechanistic explanation or hypothesis believed or disclosed herein, an embodiment of the invention can nonetheless be operative and useful.
- Molecules disclosed herein may contain one or more ionizable groups [groups from which a proton can be removed (e.g., -OH, -COOH, etc.) or added (e.g., amines) or which can be quaternized (e.g., amines)]. All possible ionic forms of such molecules and salts thereof are intended to be included individually in the disclosure herein. With regard to salts of the compounds herein, one of ordinary skill in the art can select from among a wide variety of available counterions those that are appropriate for preparation of salts of this invention for a given application. For example, in general any anions can be employed in the formation of salts of compounds herein; e.g.
- halide sulfate, carboxylate, acetate, phosphate, nitrate, trifluoroacetate, glycolate, pyruvate, oxalate, malate, succinate, fumarate, tartarate, citrate, benzoate, methanesulfonate, ethanesulfonate, p-toluenesulfonate, salicylate and others.
- the invention can encompass all such isomers, individual enantiomers, as well as mixtures of cis and trans isomers, mixtures of diastereomers; non-racemic and racemic mixtures of enantiomers (optical isomers); and the foregoing mixtures enriched for one or more forms; except as stated otherwise herein.
- the configuration (cis, trans or R or S) of a compound (or of an asymmetric carbon) then any one of the isomers or a mixture of more than one isomer is intended.
- the processes for preparation can use racemates, enantiomers, or diastereomers as starting materials.
- enantiomeric or diastereomeric products When enantiomeric or diastereomeric products are prepared, they can be separated by conventional methods, for example, by chromatographic or fractional crystallization.
- the inventive compounds may be in the free or hydrate form.
- PAC-1 In contrast to many known anti-cancer drugs, cells treated with PAC-1 show an immediate activation of procaspase-3, and the toxicity of PAC-1 is shown to be directly proportional to the amount of procaspase-3 contained in a cell. Thus PAC-1 directly activates procaspase-3 to caspase-3 in vivo, allowing this compound to induce apoptosis even in cells that have defective apoptotic machinery.
- PAC-1 is the first small molecule known to directly activate procaspase-3; the direct activation of executioner caspases is a novel anti-cancer strategy that may prove beneficial in a variety of cancers, including the many cancers in which procaspase-3 is u p regulated.
- Procaspase-3 was expressed and purified in E. coli (Roy et al., 2001 ). Procaspase-3 (at a concentration of 50 ng/mL) was added to the wells of a 384-well plate, and the compounds were added to a final concentration of approximately 40 ⁇ M. Each plate was then incubated for two hours at 37 0 C, after which the caspase-3 peptidic substrate Ac-Asp-Glu-Val-Asp-p-nitroanilide (Ac-DEVD-pNa) was added to a concentration of 200 ⁇ M. The formation of the p-nitroaniline chromophore was followed at 405 nm over the course of two hours.
- Procaspase-3 has an N-terminal pro domain (residues 1 -28), followed by a large subunit (17 kDa) and a small subunit (12 kDa) that are separated by an intersubunit linker (Pop et al., 2003).
- procaspase-3 monomers assemble to form a catalytically inactive homodimer that can be activated by cleavage at D175 in the intersubunit linker.
- the precise role of the pro domain is unclear, and it has been shown that cleavage in the intersubunit region alone is sufficient for full catalytic activity (Stennicke, H. R. et al., 1998).
- procaspase-3 is catalytically competent, it is highly resistant to autoactivation due to the presence of the 12 amino acid safety catch; however, when the safety catch is mutated significant autoactivation of procaspase-3 is observed (Roy et al., 2001 ). Compounds that interact with this important regulatory region or at other positions can allow the autoactivation of procaspase-3. [00125] To directly assess the ability of PAC-1 to catalyze the autoactivation of procaspase-3, the procaspase-3 protein was incubated with 100 ⁇ M of PAC-1 for time points ranging from one to five hours.
- caspase-7 Like caspase-3, caspase-7 also exists as an inactive zymogen that is activated by proteolysis. Caspase-3 and caspase-7 are both executioner caspases and have considerable sequence and structural homology (Denault, J. -B. et al., 2003). Procaspase-7 may also have a similar safety catch region, although it has only two aspartic acids in the key triad (Asp-Thr-Asp), instead of three. As indicated by the data in Figure 2B, PAC-1 can also activate procaspase-7, although in a less efficient manner than its activation of procaspase-3 (EC 50 of 4.5 ⁇ M versus 0.22 ⁇ M for procaspase-3 activation).
- the white blood cells derived from the bone marrow of a healthy human donor are among those with the lowest amount of procaspase-3, and PAC-1 is comparatively less toxic to these cells.
- PAC-1 is most potent versus the lung cancer cell line NCI-H226, with an IC50 of 0.35 ⁇ M. In accordance with data in the literature (Svingen et al., 2004), we found this cell line to have a concentration of procaspase-3 that is greater than five times that of the non-cancerous control.
- etoposide showed no such correlation between potency in cell culture and cellular levels of procaspase-3.
- etoposide was ineffective (IC 50 >50 ⁇ M) in inducing death in three of the melanoma cell lines (UACC-62, CRL-1872, and B16-F10), the breast cancer cell line (Hs 578t), and the lung cancer cell line (NCI-H226); these cell lines have procaspase-3 levels of 1.0, 2.4, 1.9, 3.7, and 5.3, respectively.
- Etoposide was effective (IC 50 ⁇ 1 ⁇ M) versus HL-60, U-937, SK-N-SH and PC-12, which have procaspase-3 levels of 4.3, 4.0, 4.7, and 4.4, respectively. Thus, overall there is no correlation between procaspase-3 levels and IC50 for etoposide.
- Cancerous cells typically have a reduced sensitivity to proapoptotic signals due to the mutation or aberrant expression of an assortment of proteins in the apoptotic cascade. As such, many types of cancer are notoriously resistant to not only the endogenous signals for apoptotic cell death, but also to chemotherapeutic agents that act through similar mechanisms.
- the paradoxical upregulation of procaspase-3 expression levels in certain cancers provides an opportunity to use this existing intracellular pool of protein to directly induce apoptosis, thus bypassing the often non-functional or compromised upstream portion of the cascade.
- procaspase-3 is notorious for its relative inability to undergo autoactivation, it is dependent upon a 12 amino acid safety catch to keep itself in the inactive state.
- PAC-1 induces the autoactivation of procaspase-3 in vitro, and this activation is greatly diminished by mutation of the key tri-aspartate region of the safety catch. This data is consistent with the notion that PAC-1 is directly interfering with the ability of the safety catch to maintain procaspase-3 dormancy.
- PAC-1 treatment induces rapid caspase-3-like activity. It is likely that the caspase-3 mediated cleavage of anti-apoptotic proteins (Bcl-2, BcI-XL, etc.) then induces depolarization of the mitochondrial membrane and amplifies apoptosis. Further, the potency of PAC-1 toward a variety of cancer cell lines is directly proportional to the concentration of procaspase-3 in the cell.
- Ni-NTA resin and anti-Penta His Alexa Fluor 647 antibody was purchased from Qiagen (Valencia, CA).
- Bradford dye was purchased from Bio-Rad (Hercules, CA).
- Pin transfer devices were purchased from V & P Scientific (San Diego, CA).
- the reagent z-vad-fmk was purchased from Calbiochem (San Diego, CA).
- Rosetta E. coli was purchased from Novagen (Madison, Wl).
- Anti-caspase-3 antibody was purchased from Sigma (St. Louis, MO).
- Annexin V Alexa Fluor 488 conjugate, JC-9, and propidium iodide were purchased from Molecular Probes (Eugene, OR).
- IPTG and MTS/PMS CellTiter 96 Cell Proliferation Assay reagent were purchased from Promega (Madison, Wl). Fetal Bovine Serum was purchased from Biomeda (Foster City, CA). 96 and 384-well microtiter plates, microscope slides, microscope coverslips, horse serum and all other reagents were purchased from Fisher (Chicago, IL).
- the cell lysate was incubated for 1 hour at 4 0 C.
- the resin was loaded on a column, washed with 10 ml_ NTA binding buffer followed by 10 ml_ NTA wash buffer (150 mM NaCI, 50 mM Tris, 20 mM Imidazole, pH 7.9).
- the proteins were eluted in 1 ml_ fractions with 10 ml_ of NTA elution buffer (150 mM NaCI, 50 mM Tris, 250 mM Imidazole, pH 7.9). Fractions containing protein were pooled and the amount of protein was determined using the Bradford assay.
- Isolated procaspase-3 was diluted to 50 ng/mL in caspase assay buffer (50 mM HEPES, 100 mM NaCI, 10 mM DTT, 0.1 mM EDTA, 0.1 % CHAPS and 10% glycerol, pH 7.4). 45 ⁇ L of the procaspase-3 solution was added to each well of a Nunc 384-well flat bottom microtiter plate. Approximately 20,000 compounds were screened. About 6,000 of the compounds were collected from various sources within the department of chemistry at the University of Illinois; their structures are available at: http://www.scs.uiuc.edu/ ⁇ phgroup/comcollections.html. The other approximately 14,000 compounds were purchased from Chembridge Corporation (San Diego, California). PAC-1 was a member of the compounds purchased from Chembridge Corporation.
- procaspase-3 activators The dose dependence of procaspase-3 activators was determined by adding various concentrations of compound to 90 ⁇ l_ of a 50 ng/mL procaspase-3, active caspase-3, procaspase-7 or active caspase-7 in caspase assay buffer in a 96-well plate. The plate was then incubated for 12 hours at 37 0 C. 10 ⁇ L of a 2 mM solution of Ac-DEVD-pNA in caspase assay buffer was then added to each well. The plate was read every 2 minutes at 405 nm for 2 hours in a Spectra Max Plus 384 well plate reader. The slope of the linear portion for each well was determined and the fold increase in activation from non-treated control wells was calculated.
- Procaspase-3 was expressed and isolated exactly as above. Procaspase-3 was diluted to about 50 ⁇ g/mL in caspase assay buffer. The procaspase-3 was then incubated in the presence or absence of 100 ⁇ M PAC-1 for varying times at 37 0 C. After this incubation, an equal volume of load buffer (150 mM NaCI, 50 mM Tris, 2% SDS, 20% glycerol, pH 8.0) was added to each procaspase-3 sample. All samples were then stored at -8O 0 C until the time-course was completed. All samples were then incubated at 95 0 C for 5 minutes and run on a 12% SDS- PAGE gel.
- load buffer 150 mM NaCI, 50 mM Tris, 2% SDS, 20% glycerol, pH 8.0
- Proteins were then transferred to nitrocellulose paper overnight. Blots were washed in TTBS (150 mM NaCI, 50 mM Tris, 0.1 % Tween-20, pH 7.4) and blocked with a 10% milk solution for 2 hours. Blots were then incubated in a 1 :5000 dilution of anti-Penta His Alexa Fluor 647 antibody for 2 hours. The blot was then washed with TTBS and scanned on a Typhoon fluorescence scanner (Amersham Biosciences, SunnyVale CA).
- the ability of PAC-1 to activate each procaspase-3 mutant was determined by adding various concentrations of PAC-1 to 90 ⁇ l_ of a 50 ng/mL wild-type procaspase-3 and mutant procaspase-3 in caspase assay buffer in a 96-well plate. The plate was then incubated for 12 hours at 37 0 C. 10 ⁇ L of a 2 mM solution of Ac-DEVD-pNA in caspase assay buffer was then added to each well. The plate was read every 2 minutes at 405 nm for 2 hours in a Spectra Max Plus 384 well plate reader. The slope of the linear portion for each well was determined and the fold increase in activity for each mutant was calculated.
- the plate was then incubated for 12 hours at 37 0 C. 10 ⁇ L of a 2 mM solution of Ac- DEVD-pNA in caspase assay buffer was then added to each well. The plate was read every 2 minutes at 405 nm for 2 hours in a Spectra Max Plus 384 plate reader (Molecular Devices, Sunnyvale CA). The slope of the linear portion for each well was determined and the fold increase in activation for each pH value was calculated.
- Annexin V staining 500 ⁇ L of media containing 200 ⁇ M PAC-1 or only DMSO as a control was added to the wells of a 24-well plate. 500 ⁇ L HL-60 cells at a concentration of 2 x 10 6 cells/mL were then added to the 24-well plate. The plate was incubated for 20 hours at 37 0 C. Cells were harvested by centrifugation and washed twice in PBS. The cells were then washed in AnnexinV binding buffer (10 mM HEPES, 140 mM NaCI, 2.5 mM CaCI2, pH 7.4) and resuspended in 100 ⁇ l_ of Annexin V binding buffer.
- AnnexinV binding buffer 10 mM HEPES, 140 mM NaCI, 2.5 mM CaCI2, pH 7.4
- the fluorescent intensity of each cell was determined by flow cytometry at 525 nm (green channel) and 675 nm (red channel). 50,000 cells were analyzed in each experiment. The shift in the red channel was then used to determine the amount of mitochondrial membrane depolarization.
- caspase-3 like activity In vivo determination of caspase-3 like activity.
- the amount of caspase-3 like protease activity was determined by the amount of Ac-DEVD-pNA (N-acetyl- ASP-Glu-Val-Asp-p-nitroanilide) cleaved per minute by cell lysates.
- 50 ⁇ l_ of media containing varying concentrations of PAC-1 was added to the wells of a 96-well plate.
- 50 ⁇ l_ of HL-60 cells at a concentration of 5 x 10 6 cells/mL were added to the plate and incubated for various times. After the incubation period, the plate was spun at 1000 x g for 5 minutes to pellet the cells.
- the cells were then washed with 100 ⁇ l_ of PBS and resuspended in 150 ⁇ l_ of ice cold Caspase Assay Buffer. Each well was then sonicated to lyse the cells. 90 ⁇ l_ of cell lysate was transferred from each well into a new plate. Ac-DEVD-pNA was added into each well to give a final concentration of 200 ⁇ M. The plate was then read every 2 minutes at 405 nm for 2 hours in a Spectra Max Plus 384 plate reader (Molecular Devices, Sunnyvale CA). The slope of the linear portion for each well was determined and the amount of Ac-DEVD-pNA cleaved per minute was calculated.
- the amount of PARP cleavage was determined by using an in vivo PARP activity assay. To accomplish this, 50 ⁇ l_ of media containing 200 ⁇ M NAD + was added to the control wells of a 96-well plate. 50 ⁇ l_ of media containing 200 ⁇ M PAC-1 and 200 ⁇ M NAD + was then added to the experimental wells. 25 ⁇ l_ of HL-60 cells at a concentration of 5 x 10 6 cells/mL were then added to each well. The cells were incubated for various times and then spun at 1000 x g for 5 minutes.
- the cell media was removed and replaced with 50 ⁇ l_ Lysing PARP Buffer (50 mM Tris, 10 mM MgCI2, pH 8.0, 1 % Triton X-100) containing 25 mM H 2 O 2 .
- the plate was then incubated for 60 minutes at 37 0 C.
- 20 ⁇ l_ of 2 M KOH and 20 ⁇ l_ of a 20% (v/v) acetophenone (in ethanol) solution was added to each well of the 96-well plate.
- the plate was then incubated for 10 minutes at 4 0 C. 90 ⁇ l_ of an 88% (v/v) formic acid solution was added to each well of the 96-well plate.
- the plate was then incubated for 5 min. in an oven set to 11 O 0 C.
- the plate was allowed to cool and then read on a Criterion Analyst AD (Molecular Devices, Sunnyvale, CA) with an excitation of 360 nm, an emission of 445 nm and a 400 nm cutoff dichroic mirror.
- the fluorophore was excited using a 1000 W continuous lamp for 1.6 x 10 5 ⁇ s with 5 reads performed per well.
- the number of moles of NAD + cleaved per minute was then calculated and the remaining PARP activity as compared to control wells was determined.
- the cells were then resuspended in 1 ml_ of a 1 :10,000 dilution of anti-mouse Ab Cy3 labeled antibody for 2 hours at room temperature protected from light.
- the cells were washed five times with PBS and resuspended in 500 ⁇ l_ of PBS.
- the fluorescent intensity of each cell was determined by flow cytometry at 675 nm (red channel). At least 20,000 cells were analyzed in each experiment. The median of the population was used to determine the relative concentration of procaspase-3 in each cell line.
- IC50 values in various cell lines 50 ⁇ l_ of media containing various concentrations of PAC-1 or etoposide was added to each well of a 96-well plate except control wells, which contained only DMSO.
- U-937, HL-60 and human bone marrow cells were harvested by centrifugation, while all other cell lines were first trypsinized before centrifugation. Cells were then resuspended in media and diluted to either 1 x 10 6 cells/mL for U-937, HL-60 and human bone marrow cells or 50,000 cells/mL for all other cell lines.
- PAC-1 and other compounds are prepared according to the following schemes, e.g., Scheme 1 and/or Scheme 2. Further variations are prepared according to methods known in the art.
- PAC- 1 is prepared according to Scheme 2:
- Analog compounds of PAC-1 were prepared and assessed for the capability to directly activate purified procaspase-3 in vitro. Table 2. Activity of PAC-1 and analog compounds.
- the attending physician would know how to and when to terminate, interrupt, or adjust administration due to toxicity, or to organ dysfunctions, etc. Conversely, the attending physician would also know to adjust treatment to higher levels if the clinical response were not adequate (in light of or precluding toxicity aspects).
- the magnitude of an administered dose in the management of the disorder of interest can vary with the severity of the condition to be treated and to the route of administration. The severity of the condition may, for example, be evaluated, in part, by standard prognostic evaluation methods. Further, the dose and perhaps dose frequency, can also vary according to circumstances, e.g. the age, body weight, and response of the individual patient. A program comparable to that discussed above also may be used in veterinary medicine.
- Suitable agents may be formulated and administered systemically or locally. Techniques for formulation and administration may be found in Alfonso and Gennaro (1995) and elsewhere in the art. Suitable routes may include, for example, oral, rectal, transdermal, vaginal, transmucosal, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, or intramedullary injections, as well as intraocular, intrathecal, intravenous, or intraperitoneal administration.
- agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, water for injection, physiological saline buffer, or other solution.
- physiologically compatible buffers such as Hanks' solution, Ringer's solution, water for injection, physiological saline buffer, or other solution.
- penetrants appropriate to the barrier to be permeated can be used in the formulation. Such penetrants are generally known in the art.
- compositions of the present invention may be administered parenterally, such as by intravenous injection, or other routes.
- Appropriate compounds can be formulated readily using pharmaceutically acceptable carriers well known in the art into dosages suitable for oral administration.
- Such carriers enable the compounds of the invention to be formulated as tablets, pills, capsules, liquids, gels, syrups, slurries, elixirs, solutions, suspensions and the like, e.g. for oral ingestion by a patient to be treated.
- formulations can be prepared for creams, ointments, lotions, and the like.
- Agents intended to be administered intracellular ⁇ may be administered using techniques well known to those of ordinary skill in the art. For example, such agents may be encapsulated into liposomes, other membrane translocation facilitating moieties, or other targeting moieties; then administered as described above.
- Liposomes can include spherical lipid bilayers with aqueous interiors. All molecules present in an aqueous solution at the time of liposome formation can be incorporated into the aqueous interior. The liposomal contents are both protected from the external microenvironment and, because liposomes fuse with cell membranes, are efficiently delivered into the cell cytoplasm. Additionally, due to hydrophobicity attributes, small organic molecules may be directly administered intracellular ⁇ .
- compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. Determination of the effective amounts is well within the capability of those skilled in the art, especially in light of the disclosure provided herein and other information in the art.
- these pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically.
- suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically.
- the preparations formulated for oral administration may be in the form of tablets, dragees, capsules, or solutions, including those formulated for delayed release or only to be released when the pharmaceutical reaches the small or large intestine.
- compositions of the present invention may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, suspending, granulating, dragee-making, levitating, emulsifying, encapsulating, entrapping, lyophilizing, and other processes.
- Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.
- Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
- the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
- compositions for oral use can be obtained by combining the active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
- suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP).
- disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
- Dragee cores are optionally provided with suitable coatings.
- suitable coatings may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
- Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
- compositions which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
- the push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
- the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
- stabilizers may be added.
- EXAMPLE 5 Direct Induction of Apoptosis in Cancer Cells with a Small Molecule Activator of Procaspase-3.
- ABSTRACT Mutation or aberrant expression of proteins in the apoptotic cascade is a hallmark of cancer. These changes prevent proapoptotic signals from being transmitted to the executioner caspases, thus preventing apoptotic cell death and allowing cellular proliferation.
- Caspase-3 and caspase-7 are the key executioner caspases, existing as inactive zymogens that are activated by upstream signals. Importantly, levels of procaspase-3 are significantly higher in certain cancerous cells relative to non-cancerous controls.
- Cancerous cells isolated from primary colon tumors are considerably more sensitive to apoptotic induction by PAC-1 than the cells from adjacent non-cancerous tissue from the same patient; these cancerous cells contain on average about 7-fold more procaspase-3 than the cells from the adjacent non-cancerous primary tissue.
- the sensitivity to PAC-1 of the primary cells from the colon cancer tumors strongly correlates with the level of the procaspase-3 target.
- PAC-1 as a single entity was shown as active to retard the growth of tumors in three different mouse models, including two models where PAC-1 was administered orally.
- PAC-1 directly activates procaspase-3 to caspase-3 in vivo, thereby allowing this compound to induce apoptosis even in cells that have defective apoptotic machinery.
- PAC-1 is the first small molecule known to directly activate procaspase-3; the direct activation of executioner caspases is an anti-cancer strategy that may prove beneficial in the many cancers in which procaspase-3 levels are elevated.
- procaspase-3 results in the generation of the active "executioner” caspase that subsequently catalyzes the hydrolysis of a multitude of protein substrates.
- Active caspase-3 is a homodimer of heterodimers and is produced by proteolysis of procaspase-3. In vivo, this proteolytic activation typically occurs through the action of caspase-8 or caspase-9. To ensure that this zymogen is not prematurely activated, procaspase-3 has a tri-aspartic acid "safety catch" that blocks access to the IETD site of proteolysis. This safety catch enables procaspase-3 to resist autocatalytic activation and proteolysis by caspase-9.
- the position of the safety catch is sensitive to pH; thus, upon cellular acidification (as occurs during apoptosis) the safety catch is thought to allow access to the site of proteolysis, and active caspase-3 can be produced either by the action of caspase-9 or through an autoactivation mechanism.
- procaspase-3 Cells from certain types of cancerous tissue have elevated levels of procaspase-3.
- procaspase-3 levels are elevated in certain neuroblastomas, lymphomas, and liver cancers.
- a systematic evaluation of procaspase-3 levels in the 60 cell-line panel used by the NCI revealed that particular lung, melanoma, renal, and breast cancers show greatly enhanced levels of procaspase-3.
- Procaspase-3 was expressed and purified in E. coli according to standard procedures. Procaspase-3 was added to the wells of a 384-well plate, and the compounds were added to a final concentration of about 40 ⁇ M (the final concentration of procaspase-3 was 50 ng/mL). Each plate was then incubated for two hours at 37 0 C, after which the caspase-3 peptidic substrate Ac-Asp-Glu-Val-Asp-p-nitroanilide (Ac-DEVD-pNa) was added to a concentration of 200 ⁇ M.
- Ac-DEVD-pNa Ac-DEVD-pNa
- Procaspase-3 consists of a N-terminal pro domain (residues 1 -28), followed by a large subunit (17 kDa) and a small subunit (12 kDa) that are separated by an intersubunit linker. 22 In vivo, two procaspase-3 monomers assemble to form a homodimer that can be activated by cleavage at D175 in the intersubunit linker. The precise role of the pro domain is unclear, and it has been shown that cleavage in the intersubunit region alone is sufficient for full catalytic activity.
- procaspase-3 Although procaspase-3 has enough catalytic activity to drive its own proteolytic maturation, it is highly resistant to this autoactivation due to the presence of the three amino acid safety catch. However, when the safety catch is mutated significant autoactivation of procaspase-3 is observed.
- the procaspase-3 protein was incubated with 100 ⁇ M of PAC-1 for time points ranging from one to five hours. As shown by the Western blot in Figure 1 B, PAC-1 induces the cleavage of procaspase-3 in a time-dependant fashion, with >50% processing observed after 4 hours. In contrast, procaspase-3 incubated in buffer shows virtually no autoactivation over that same time span. PAC-1 was also effective in this assay at a concentration of 5 ⁇ M.
- Procaspase-7 is also predicted to have a similar safety catch region, although it has only two aspartic acids in the key triad (Asp-Thr-Asp), instead of three.
- PAC-1 can also activate procaspase-7, although in a less efficient manner than its activation of procaspase-3 (EC50 of 4.5 ⁇ M versus 0.22 ⁇ M for procaspase-3 activation).
- the effect of PAC-1 is abolished at low pH values where procaspase-3 undergoes rapid autoactivation (Figure 2C).
- PAC-1 was found to induce apoptosis in a variety of cancer cell lines.
- addition of PAC-1 leads to considerable phosphatidylsehne exposure on the cell membrane accompanied by significant chromatin condensation ( Figures 3A, 3B).
- the compound induces cleavage of the caspase substrate PARP-1 (as assessed by an in vivo PARP activity assay) and causes mitochondrial membrane depolarization (see below).
- Significant cellular blebbing of PAC-1 treated cells was also observed by microscopy.
- the toxicity of PAC-1 could be abolished in the presence of the caspase inhibitor z-VAD-fmk.
- PAC-1 is indeed inducing apoptosis via direct activation of procaspase-3, then the time course of apoptotic events should be altered relative to that observed with standard proapoptotic agents.
- Etoposide is well known to induce apoptosis through the intrinsic pathway; thus, mitochondrial membrane depolarization is followed by procaspase-3 activation in etoposide-treated cells. Indeed, in HL-60 cells treated with 10 ⁇ M etoposide, mitochondrial membrane depolarization is observed, followed by detection of caspase-3-like activity ( Figure 4A). In contrast, treatment of cells with PAC-1 gives a markedly different result.
- PAC-1 is most potent versus the lung cancer cell line NCI-H226, with an IC50 of 0.35 ⁇ M.
- PAC-1 is most potent versus the lung cancer cell line NCI-H226, with an IC50 of 0.35 ⁇ M.
- MCF-7 cancer cell line
- PAC-1 has virtually no effect on MCF-7 cells, inducing death with an ICso>75 ⁇ M.
- etoposide showed no such correlation between potency in cell culture and cellular levels of procaspase-3.
- etoposide was ineffective (IC50>50 ⁇ M) in inducing death in three of the melanoma cell lines (UACC-62, CRL- 1872, and B16-F10), the breast cancer cell line (Hs 578t), and the lung cancer cell line (NCI-H226); these cell lines have procaspase-3 levels of 1.0, 2.4, 1.9, 3.7, and 5.3, respectively.
- Etoposide was effective (IC 50 ⁇ 1 ⁇ M) versus HL-60, U-937, SK-N- SH and PC-12, which have procaspase-3 levels of 4.3, 4.0, 4.7, and 4.4, respectively. Thus, overall there is no correlation between procaspase-3 levels and IC50 for etoposide.
- PAC-1 induced cell death in the primary cancerous cells with IC 50 values from 0.007-1.41 ⁇ M
- PAC-1 induced cell death in the adjacent non-cancerous tissue with IC 50 values from 5.02-9.98 ⁇ M
- the cancerous tissue that had elevated levels of procaspase-3 was extremely sensitive to PAC-1.
- PAC-1 induced death in the cancer cells from patient 17 with an IC50 of 7 nM, and these cells were over 700-fold more sensitive to PAC-1 than cells from the adjacent normal tissue.
- Figure 6A showing relative procaspase-3 concentrations in normal and cancerous samples from Patients 1 , 2, and 3 over a period of time of about 54 days;
- Figure 6B illustrates that cells in cancerous tissue can be greater than about 80-fold more sensitive to PAC-1 in comparison with normal tissue.
- PAC-1 was also evaluated against four other non-cancerous cell types: white blood cells isolated from the bone marrow of a healthy donor, Hs888Lu (lung fibroblast cells), MCF-10A (breast fibroblast cells), and Hs578Bst (breast epithelial cells).
- the non-cancerous cell types are among those with the lowest amount of procaspase-3, and PAC-1 is comparatively less able to induce death in these cells, with IC 50 values of 3.2 - 8.5 ⁇ M ( Figure 5B, green diamonds).
- PAC-1 induces death in a wide variety of cell types (non-cancerous cell lines, non-cancerous primary cells, cancerous cell lines, primary cancerous cells) in a manner directly related to the level of procaspase-3.
- the elevation of procaspase- 3 in cancerous cells allows PAC-1 to selectively induce death in these cell types.
- PAC-1 was evaluated in a mouse xenograft model using a slow release mode of drug delivery. In this model, subcutaneous tumors were formed in ovariectomized female athymic BALB/c (nude) mice using the ACHN (renal cancer) cell line.
- PAC-1 was evaluated in a second mouse xenograft model, this one using oral administration as the drug delivery mode.
- subcutaneous xenograft tumors were formed in male athymic BALB/c-nu/nu mice (5 weeks old, SLC, Hamamaysu, Japan) using the NCI-H226 (lung cancer) cell line, eight mice per group, three tumors per mouse.
- the mice were treated with PAC-1 via oral gavage once a day for 21 days at a concentration of 0, 50, or 100 mg/kg and sacrificed 1 week later.
- oral administration of PAC-1 significantly retards tumor growth in a dose-dependent manner.
- PAC-1 was evaluated in a mouse model where the NCI-H226 cells were injected into male athymic BALB/c-nu/nu mice via tail vein injection. The total experiment lasted 28 days; the mice were treated once a day with PAC-1 (100 mg/kg) via oral gavage on days 1 -4 and 7-11. On other days the mice did not receive PAC-1. A second group of mice received only vehicle. After 28 days the mice were sacrificed, and their lungs were examined. As shown in Figure 5E, there is a clear difference between the lung of the control mouse (with obvious gray tumor mass) and the lung of the PAC-1 treated mouse. Results are also shown in a panel from an animal treated with gefitinib (IressaTM; AstraZeneca).
- Cancerous cells typically have a reduced sensitivity to proapoptotic signals due to the mutation or aberrant expression of an assortment of proteins in the apoptotic cascade. As such, many types of cancer are notoriously resistant to not only the endogenous signals for apoptotic cell death, but also to chemotherapeutic agents that act through similar mechanisms.
- the paradoxical elevation of procaspase-3 levels in certain cancers provides an opportunity to use this existing intracellular pool of protein to directly induce apoptosis, thus bypassing the often non-functional upstream portion of the cascade.
- PAC-1 induces the autoactivation of procaspase-3 in vitro. In cell culture, PAC-1 treatment induces rapid caspase-3- like activity.
- PAC-1 caspase-3 mediated cleavage of anti-apoptotic proteins (Bcl-2, BcI-XL, etc.) then induces depolarization of the mitochondrial membrane and amplifies apoptosis.
- the potency of PAC-1 toward a variety of cancerous and non-cancerous cell types is proportional to the concentration of procaspase-3 in the cell. As the primary cancerous cells isolated from resected colon tumors have elevated levels of procaspase-3, these cells are considerably more sensitive to PAC-1 than cells from adjacent non-cancerous tissue.
- PAC-1 is effective in three different mouse models of cancer, including two where PAC-1 is administered orally.
- procaspase-3 activating compounds can be exceedingly effective against a variety of common cancers in which procaspase-3 levels are aberrantly high.
- Assessment of procaspase-3 levels in cancer biopsies is simple and rapid; as such, the potential effectiveness of a compound such as PAC-1 can be assessed a priori with a high degree of accuracy.
- Such personalized medicine strategies can be preferential to therapies that rely on general cytotoxins and can be valuable in anti-cancer therapy.
- Fig. 1 B Cleavage of procaspase-3 to active caspase-3 as induced by PAC-1. Procaspase-3 was recombinantly expressed in E. coli with an N-terminal His-6 tag and purified, lmmunoblotting was performed with an anti-His-6 antibody. In the absence of PAC-1 no maturation of procaspase-3 is observed.
- PAC-1 In the presence of 100 ⁇ M PAC-1 , cleavage to generate the p19 fragment is observed within 1 h, and >50% cleavage is observed after 4 h. PAC-1 is also effective at 5 ⁇ M in this assay.
- Fig. 2A Activation of mutants in the "safety catch" region of procaspase-3 by PAC-1.
- PAC-1 has an EC 50 for activation of 0.22 ⁇ M on wild type procaspase-3 (DDD), and corresponding EC 50 values of 2.77 ⁇ M (DAD), 113 ⁇ M (DDA), and 131 ⁇ M (ADD) for the mutants.
- Fig. 2B PAC-1 activates procaspase-7 with an EC 50 of 4.5 ⁇ M.
- Fig. 2C Dependence of PAC-1 activation of procaspase-3 on pH. At low pH the safety catch is off and procaspase-3 is essentially maximally activated. Error bars represent standard deviations from the
- FIG. 3A Phosphatidylserine exposure (as measured by Annexin-V staining) after a 20 h treatment with 100 ⁇ M PAC-1. PAC-1 is also effective at 5 ⁇ M in this assay (see Supporting Figure 2).
- Fig. 3B Chromatin condensation as visualized by Hoescht staining after a 20 h treatment with 100 ⁇ M PAC-1.
- Fig. 4A Mitochondrial membrane depolarization (MMP) and caspase-3 like activity in HL-60 cells treated with 10 ⁇ M etoposide.
- MMP Mitochondrial membrane depolarization
- PAC-1 Mitochondrial membrane depolarization (MMP) and caspase-3 like activity in HL-60 cells treated with 100 ⁇ M PAC-1.
- Fig. 4C PAC-1 treatment (100 ⁇ M) induces a rapid decrease in cellular PARP activity in HL-60 cells, consistent with an immediate activation of cellular caspase-3/-7.
- etoposide (10 ⁇ M) treated cells show a decrease in PARP activity at much later time points.
- Fig. 4D and Fig. 4E PAC-1 induces cell death in a procaspase-3 dependant manner.
- the procaspase-3 levels were determined (by flow cytometry with an antibody to procaspase-3) and the IC 50 of PAC-1 was measured (through a 72 h treatment with a range of PAC-1 concentrations and quantitation using the MTS assay).
- FIG. 5A Procaspase-3 levels are elevated in cells derived from freshly resected colon cancer tissue. Freshly resected primary colon tumors (together with adjacent non-cancerous tissue) were obtained from 18 different patients, the cancerous and non-cancerous tissue were separated, and the procaspase-3 levels were measured for each using an antibody to procaspase-3 and flow cytometry. On average, cells from the cancerous tissue have a 7.6-fold elevation in procaspase-3 as compared to the cells derived from the adjacent noncancerous tissue from the same patient.
- Fig. 5B PAC-1 induces cell death in a manner proportional to the cellular level of procaspase-3.
- the red circles represent the primary cancerous cells from the 18 colon tumors.
- the black triangles represent the same cancer cell lines depicted in Figure 4D.
- the green diamonds are four noncancerous cell types: Hs888Lu (lung fibroblast cells), MCF-10A (breast fibroblast cells), Hs578Bst (breast epithelial cells), and white blood cells isolated from the bone marrow of a healthy donor.
- the blue squares are the primary non-cancerous cells isolated from the tumor margins of the 18 patients.
- Table 4 Cells derived from primary colon cancer tissue are considerably more sensitive to death induction by PAC-1 than are cells derived from adjacent non-cancerous tissue from the same patient. Fig.
- PAC-1 reduces the growth of tumors in a xenograft model of cancer. Tumors were formed with the ACHN (renal cancer) cell line by subcutaneous injection, with six mice in each group, and four tumors per mouse. Once the tumors grew to about 30 mm 2 , PAC-1 was implanted as a cholesterol pellet. Error bars represent standard error from the mean. Fig. 5D) Oral administration of PAC-1 significantly retards tumor growth in a mouse xenograft model. Tumors were formed using the NCI-H226 (lung cancer) cell line by subcutaneous injection, eight mice in each group, and three tumors per mouse. PAC-1 or vehicle was administered once a day by oral gavage on days 1 -21.
- ACHN renal cancer
- Fig. 5E Oral administration of PAC-1 significantly retards tumor growth in an i.v. injection model. Mice were injected i.v. with the NCI-H226 (lung cancer) cell line. The mice were treated with PAC-1 (100 mg/kg) via oral gavage following the protocol as described in the text. Images show the lungs of the mice that did not receive PAC-1 and have a large amount of gray tumor mass on the lung. In contrast, the mice that did receive PAC-1 have almost no visible gray matter.
- EXAMPLE 6 Testing of PAC-1 in mouse model of lung cancer.
- a xenograft model was employed using NCI-H226 (lung cancer) cells.
- PAC-1 was given intraperitoneal ⁇ (i.p.) at 10 mg/kg.
- a comparison of efficacy was performed with gefitinib (IressaTM; AstraZeneca, Wilmington, Delaware) at 40 mg/kg using 5 mice per group. Results are shown in Figure 7, indicating that PAC-1 was associated with reducing growth in tumor volume.
- EXAMPLE 7 Combinatorial derivatives, synthesis, and therapeutic use.
- a number of compounds are prepared as derivatives of the PAC-1 structure.
- a hydrazide group is reacted with an aldehyde group to yield a combinatorial library of derivative compounds.
- Any one of hydrazide precursor groups (AX) designated L1 -L20 are used to generate hydrazides which are reacted with any one of aldehyde groups (BX) designated 1 -28, thus yielding 560 PAC-1 derivative compounds.
- a derivative compound is synthesized using methods as described herein and according to knowledge available in the art. See the scheme and component structures below in addition to Figure 8A and 8B.
- such derivative compounds are further modified, e.g. to alter a property such as activity, solubility, toxicity, stability, and/or other properties in connection with pharmaceutical applications.
- the derivative compounds are used as anti-cancer agents.
- Compounds are validated as capable of having antineoplastic activity, apoptosis regulation, and/or procaspase-3 activation.
- primary isolates of freshly removed colon cancer are used to assess procaspase-3 levels and sensitivity of cells to test compound levels, where a test compound is PAC-1 or a derivative compound.
- Compounds are classified regarding a propensity to induce cell death in cancerous cells versus normal cells.
- EXAMPLE 8 Activity of certain derivatives relative to PAC-1.
- PAC-1 and certain derivatives were tested in the HL-60 cell line and IC50 values were determined. The results are indicated in Table 5 (where L- and R-- designations refer to structures shown in the AX and BX series above, respectively). Several of the PAC-1 derivatives exhibited an activity level that was generally about one order of magnitude greater than that of the PAC-1 compound.
- DX1 -17 Additional compounds were synthesized and tested for activity. These compounds are designated DX1 -17 herein. Structures for these compounds are shown in Figure 11. It is noted that compound DX1 is PAC-1 and that compound DX3 is de-allyl PAC-1.
- FIG. 13A indicates substantial activity levels for compounds PAC-1 (alias DX1 ), DX3, and DX11 relative to the control levels (for lanes indicated with letter "C").
- Figure 13B also illustrates results of testing for activity of compounds DX1 , DX12, DX13, DX15, and DX17; the arrow indicates the location of procaspase-3.
- Experimental conditions included compound concentrations of 50 micromolar, procaspase-3 levels of about 35 nanomolar, and treatment periods of 8 hr.
- a DX compound herein is capable of inducing or selectively inducing apoptosis in a cancer cell.
- a compound is used as an anti-cancer drug.
- a compound is used as a pro- apoptotic agent.
- a preferred DX compound is DX6, DX7, DX8, DX9, DX10, DX11 , DX12, or DX15.
- Fig. 15 illustrates results from activity testing of compounds including such in the series DX, FX, and GX. Test conditions used 2.5 ⁇ M procaspase-3 (D 3 A) with the indicated test compound at 100 ⁇ M (filled columns); and further with 10 ⁇ M zinc (open columns).
- Fig. 16 illustrates results from activity testing of compounds in the series DX and FX, plotted as percent activity versus compound concentration.
- the ability of the compounds to activate procaspase-3 (D3A) was monitored by the use of 100 ⁇ M Ac-DEVD-pNA substrate, and the absorbance was monitored at 405nm. An amount of 10 ⁇ M zinc is sufficient to fully inhibit 2.5 ⁇ M Procaspase-3 (D3A).
- This experiment revealed four classes of compounds: Activators, Inhibitors, Dual mode, and Non-effectors. Compounds that were capable of relieving the inhibitory affect of zinc are considered activators. Compounds that inhibit procaspase-3 (D3A) activity even in the absence of zinc are considered inhibitors. Some compounds exhibit the characteristics of both an activator and an inhibitor, and some compounds had no effect in this assay.
- FLIP FLICE inhibitory protein
- NCBI National Center for Biotechnology Information
- Hergenrother PJ Obtaining and screening compound collections: a user's guide and a call to chemists. Curr Opin Chem Biol. 2006
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed in connection with modification of procaspases such as procaspase-3. In embodiments, compositions are capable of activation of procaspase-3.
Description
COMPOSITIONS AND METHODS INCLUDING CELL DEATH INDUCERS AND
PROCASPASE ACTIVATION
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. provisional application 60/914,592, filed April 27, 2007, which is incorporated by reference in its entirety herein.
STATEMENT ON FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0002] Not applicable
BACKGROUND OF THE INVENTION
[0003] Apoptosis, or programmed cell death, plays a central role in the development and homeostasis of all multicellular organisms (Shi Y, 2002, Molecular Cell 9:459-470). A frequent hallmark of cancer is resistance to natural apoptotic signals. Depending on the cancer type, this resistance is typically due to up- or down-regulation of key proteins in the apoptotic cascade or to mutations in genes encoding these proteins. Such changes occur in both the intrinsic apoptotic pathway, which funnels through the mitochondria and caspase-9, and the extrinsic apoptotic pathway, which involves the action of death receptors and caspase-8. For example, alterations in proper levels of proteins such as p53, Bim, Bax, Apaf-1 , FLIP and many others have been observed in cancers. The alterations can lead to a defective apoptotic cascade, one in which the upstream pro-apoptotic signal is not adequately transmitted to activate the executioner caspases, caspase-3 and caspase-7.
[0004] As most apoptotic pathways ultimately involve the activation of procaspase- 3, upstream genetic abnormalities are effectively "breaks" in the apoptotic circuitry, and as a result such cells proliferate atypically. Given the central role of apoptosis in
cancer, efforts have been made to develop therapeutics that target specific proteins in the apoptotic cascade. For instance, peptidic or small molecule binders to cascade members such as p53 and proteins in the BcI family or to the inhibitor of apoptosis (IAP) family of proteins have pro-apoptotic activity, as do compounds that promote the oligomerization of Apaf-1. However, because such compounds target early (or intermediate to high) positions on the apoptotic cascade, cancers with mutations in proteins downstream of those members can still be resistant to the possible beneficial effects of those compounds.
[0005] For therapeutic purposes it would be advantageous to identify a small molecule that directly activates a proapoptotic protein far downstream in the apoptotic cascade. The approach to our invention involves such a relatively low position in the cascade, thus enabling the killing of even those cells that have mutations in their upstream apoptotic machinery. Moreover, the therapeutic strategies disclosed herein can have a higher likelihood of success if that proapoptotic protein were upregulated in cancer cells. In the present invention, our efforts to identify small molecules began with targeting the significant downstream effector protein of apoptosis, procaspase-3.
[0006] The conversion or activation of procaspase-3 to caspase-3 results in the generation of the active "executioner" caspase form that subsequently catalyzes the hydrolysis of a multitude of protein substrates. Active caspase-3 is a homodimer of heterodimers and is produced by proteolysis of procaspase-3. In vivo, this proteolytic activation typically occurs through the action of caspase-8 or caspase-9. To ensure that the proenzyme or zymogen is not prematurely activated, procaspase- 3 has a 12 amino acid "safety catch" that blocks access to the IETD site (amino acid sequence, ile-glu-thr-asp) of proteolysis. See Roy, S. et al.; Maintenance of caspase-3 proenzyme dormancy by an intrinsic "safety catch" regulatory thpeptide, Proc. Natl. Acad. Sci. 98, 6132-6137 (2001 ).
[0007] This safety catch enables procaspase-3 to resist autocatalytic activation and proteolysis by caspase-9. Mutagenic studies indicate that three consecutive aspartic acid residues appear to be the critical components of the safety catch. The position of the safety catch is sensitive to pH; thus, upon cellular acidification (as occurs during apoptosis) the safety catch is thought to allow access to the site of
proteolysis, and active caspase-3 can be produced either by the action of caspase-9 or through an autoactivation mechanism.
[0008] In particular cancers, the expression of procaspase-3 is upregulated. A study of primary isolates from 20 colon cancer patients revealed that on average, procaspase-3 was upregulated six-fold in such isolates relative to adjacent noncancerous tissue (Roy et al., 2001 ). In addition, procaspase-3 is upregulated in certain neuroblastomas, lymphomas, and liver cancers (Nakagawara, A. et al., 1997, Cancer Res. 57:4578-4584; Izban, K. F. et al., Am. J. Pathol. 154:1439-1447; Persad, R. et al., Modern Patholo. 17:861 -867). Furthermore, a systematic evaluation was performed of procaspase-3 levels in the 60 cell-line panel used for cancer screening by the National Cancer Institute (NCI) Developmental Therapeutics Program. The evaluation revealed that certain lung, melanoma, renal, and breast cancers show greatly enhanced levels of procaspase-3 expression (Svingen, P.A. et al., Clin. Cancer Res. 10:6807-6820).
[0009] Due to the role of active caspase-3 in achieving apoptosis, the relatively high expression levels of procaspase-3 in certain cancerous cell types, and the intriguing safety catch-mediated suppression of its autoactivation, we reasoned that small molecules that directly modify procaspase-3 could be identified and that such molecules could have great applicability in targeted cancer therapy.
[0010] Herein we disclose, inter alia, compositions and methods including small molecules capable of inducing cell death. In embodiments, compositions and methods involve compounds which can interact directly or indirectly with programmed cell death pathway members such as procaspase-3.
[0011] U.S. Provisional Application Serial 60/684,807 filed May 26, 2005; U.S. Provisional Application Serial 60743878 filed March 28, 2006; US Patent Application Serial 11/420,425 filed May 25, 2006 (published as US 20070049602, March 1 , 2007); PCT International Application Serial PCT/US 06/020910 filed May 26, 2006 (published as WO2006/128173, 30 November 2006), which are incorporated by reference herein, relate to the subject matter of the present application.
SUMMARY OF THE INVENTION
[0012] The invention broadly provides compounds, methods of therapeutic treatment, methods of screening for compounds, and methods of screening for cell and patient suitability for treatment in connection with modifiers of procaspases. In an embodiment, the modifiers are inhibitors. In an embodiment, the modifiers are activators. In an embodiment, the invention provides such compounds and methods in connection with activators of procaspase-3 and procaspase-7. In embodiments, the inventions are applicable in the context of a variety of cancer diseases and cancer cell types such as breast, lymphoma, adrenal, renal, melanoma, leukemia, neuroblastoma, lung, brain, and others known in the art.
[0013] As a further introduction, compounds capable of activating an enzyme that is often overexpressed in its inactive form in cancer cells have been discovered. The compound induces programmed cell death (apoptosis) in cancer cells, including those that have upregulated procaspase-3. Many cancers resist standard chemotherapy. Compounds of the invention can take advantage of a biological target that may be upregulated in cancer cells and thus can prove effective even in cells with defects in their apoptotic machinery. These compounds can also be successful in targeted cancer therapy, where there can be advantages of selectivity in the killing of cancer cells with comparably reduced toxicity to non-cancerous cells having lower levels of procaspase-3.
[0014] Without wishing to be bound by a particular theory, it is believed that embodiments of compounds and methods of the invention may act via the mechanism of modulation of apoptosis or programmed cell death to be effective in the treatment of cancer cells. In a preferred embodiment, the modulation of apoptosis is by induction of apoptosis. In another embodiment, the modulation of apoptosis is by inhibition of apoptosis.
[0015] In an embodiment, the invention provides a method of selectively inducing apoptosis in a cancer cell, comprising: (a) administering to said cancer cell an effective amount of a compound capable of modifying a procaspase-3 molecule of said cancer cell; and (b) modifying said procaspase-3 molecule so as to induce apoptosis. In an embodiment, said cancer cell is in a patient in need of treatment.
[0016] In an embodiment, compounds and methods may act indirectly in connection with a programmed cell death pathway member, e.g., procaspase-3, such as by chelating or otherwise interacting directly or indirectly with a molecule which is necessary for the pathway member. In an embodiment the molecule is a metal such as zinc.
[0017] In an embodiment, said compound is of formula Z:
and salts thereof,
wherein n = 0, 1 or 2;
each R, independently of other R, is selected from hydrogen, halogen, alkyl, alkoxy or alkenyl;
R2X is a halogen or X is O, S, NR7, CO, OCO, or OCS, when X is O or S, R2 = hydrogen, alkyl, aryl, R8CO-, R8OCO-, R8SCO, R8OCS- or a moiety that is removable under physiological conditions, where R8 is alkyl or aryl, when X is NR7, R2 and R7, independently, are selected from hydrogen, alkyl, aryl, R8CO-, R8OCO-, or a moiety that is removable under physiological conditions; when X is CO, OCO or OCS, R2 is hydrogen, alkyl, aryl, or a moiety that is removable under physiological conditions;
R3 is selected from hydrogen, halogen, alkyl, haloalkyl, alkenyl, alkenol, alkanol, or haloalkenyl;
R4 and R5 are both N; R4 is N and R5 is CH; R4 is CH and R5 is N or R4 and R5 are both CH;
R6 is hydrogen or alkyl;
A = oxygen or sulfur; and
B is aryl, heteroaryl or R9-O-CO-, where Rg is alkyl or aryl.
[0018] In a more specific embodiment of formula Z, R3 is allyl. In another embodiment of formula Z, R2X is OH. In another embodiment of formula Z, R2X is NH2. In specific embodiments, aryl groups are phenyl groups substituted with one or more R groups as defined above. In specific embodiments, alkyl groups are C1 -C6 alkyl groups or C1 -C3 alkyl groups. In specific embodiments, alkenyl groups are C2- C6 alkenyl groups or C2-C4 alkenyl groups. In specific embodiments, alkenyl groups are allyl groups. In specific embodiments of formula Z, B is a R9-O-CO-. In specific embodiments of formula Z, B is a phenyl substituted with one or more R substituents. In specific embodiments of formula Z, R9 is a t-butyl group. In specific embodiments, R6 is hydrogen or methyl. In specific embodiments, n is O and B is R9- O-CO-. In specific embodiments, n is 1 or 2 and B is aryl. In a specific embodiment, A is O. In a specific embodiment, R is hydrogen. In a specific embodiment of formula Z, at least one R or R3 is a substituent other than hydrogen. In a specific embodiment of formula Z, at least one R is a substituent other than hydrogen. In a specific embodiment of formula Z, R2X is OH and R3 is allyl. In a specific embodiment of formula Z, n is 1 and B is pyridinyl. In a specific embodiment of formula Z, n is 1 and B is 2-pyridinyl. In a specific embodiment of formula Z, n is 1 and B is 3-pyridinyl. In a specific embodiment of formula Z, n is 1 and B is 4- pyridinyl. In specific embodiments of formula Z, n is O and B is R9-OCO- and R9 is alkyl. In specific embodiments of formula Z, n is O and B is R9-OCO- and R9 is t- butyl.
and salts thereof;
wherein each R, independently of other R, is selected from hydrogen, halogen, alkyl, or alkenyl;
R2X is a halogen or X is O, S, NR7, CO, OCO, or OCS, when X is O or S, R2 = hydrogen, alkyl, aryl, R8CO-, R8OCO-, R8SCO, R8OCS- or a moiety that is removable under physiological conditions, where R8 is alkyl or aryl, when X is NR7, R2 and R7, independently, are selected from hydrogen, alkyl, aryl, R8CO-, R8OCO-, or a moiety that is removable under physiological conditions; when X is CO, OCO or OCS, R2 is hydrogen, alkyl, aryl, or a moiety that is removable under physiological conditions;
R3 is selected from hydrogen, halogen, alkyl, haloalkyl, alkenyl, alkenol, alkanol, or haloalkenyl;
R4 and R5 are both N; R4 is N and R5 is CH; R4 is CH and R5 is N or R4 and R5 are both CH;
Re is hydrogen or alkyl;
A = oxygen or sulfur; and
R9 is alkyl or aryl.
[0020] In a more specific embodiment of formula ZA, R3 is allyl. In specific embodiments of formula ZA, R9 is an alkyl group. In specific embodiments of formula ZA, R9 is an C1 -C6 alkyl group. In specific embodiments, R9 is a t-butyl group. In another embodiment of formula ZA, R2X is OH. In another embodiment of formula ZA, R2X is NH2. In specific embodiments of formula ZA, aryl groups are
phenyl groups substituted with one or more R groups as defined above. In specific embodiments of formula ZA, alkyl groups are C1 -C6 alkyl groups or C1 -C3 alkyl groups. In specific embodiments of formula ZA, alkenyl groups are C2-C6 alkenyl groups or C2-C4 alkenyl groups. In specific embodiments of formula ZA, alkenyl groups are allyl groups. In specific embodiments of formula ZA, R6 is hydrogen or methyl. In a specific embodiment of formula ZA, A is O. In a specific embodiment of formula ZA, R is hydrogen. In a specific embodiment of formula ZA, at least one R or R3 is a substituent other than hydrogen. In a specific embodiment of formula ZA, at least one R is a substituent other than hydrogen. In a specific embodiment of formula ZA, R2X is OH and R3 is allyl.
[0021] In an embodiment, said compound is of formula ZZ:
and salts thereof,
wherein n = 1 or 2; Ra, Rb, Rc, Rd, and Re are independently selected from hydrogen, halogen, alkyl, alkenyl, alkoxy, and aryl and other variables are as defined in formula Z.
[0022] In a specific embodiment of formula ZZ, n is 1. In a specific embodiment of formula ZZ, R2X is OH. In a specific embodiment of formula ZZ, R2X is NH2. In a specific embodiment of formula ZZ, A is O. In a specific embodiment of formula ZZ, R3 is allyl. In a specific embodiment of formula ZZ, R6 is hydrogen. In a specific embodiment of formula ZZ, R is hydrogen. In a specific embodiment of formula ZZ, one or two of Ra, Rb, Rc, Rd and Re are C1 -C3 alkyl, C1-C3 alkoxy or halogens and the remaining groups are hydrogens. In a specific embodiment, Rc is a C1 -C3 alkyl or a C1 -C3 alkoxy and Ra, Rb, Rd, and Re are all hydrogens. In a specific embodiment, all of Ra, Rb, Rc, Rd and Re are hydrogens. In a specific embodiment,
Rc is fluorine and Ra, Rb, Rc, Rd and Re are all hydrogens. In a specific embodiment, R2X is chlorine. In a specific embodiment, R2X is OH. In a specific embodiment, R2X is SH. In a specific embodiment, R2X is CH3S. . In a specific embodiment, R2X is HO-CO-. . In a specific embodiment, R2X is CH3O-CO-.
[0023] In additional embodiments of formula ZZ, R4 and R5 are both N, A is oxygen, and other variable groups are as defined above. In an embodiment of formula ZZ, R4 and R5 are both N, A is oxygen, R2 is hydrogen, and other variable groups are as defined above. In an embodiment of formula ZZ, R4 and R5 and both N, A is oxygen, R2 is hydrogen, R3 is allyl, and other variable groups are as defined above. In an embodiment of ZZ, one of R is a fluorine. In a specific embodiment of formula ZZ, at least one R or R3 is a substituent other than hydrogen. In a specific embodiment of formula ZZ, at least one R is a substituent other than hydrogen. In a specific embodiment of formula ZZ, R2X is OH and R3 is allyl. In a specific embodiment of formula ZZ, at least one of Ra-Re is a substituent other than hydrogen. In a specific embodiment of formula ZZ, at least one R or R3 is a substituent other than hydrogen, and at least one of Ra-Re is a substituent other than hydrogen.
[0024] In an embodiment, the invention provides compounds of formula ZB:
or salts thereof,
where m is 1 -4 and other variables are as defined for formula Z. In specific embodiments of formula ZB, m is 2. In additional embodiments of formula ZB, R4 and R5 are both N. In an embodiment of formula ZB, R3 is allyl. In specific embodiments of formula ZB, B is aryl. In specific embodiments of formula ZB, B is Rg-O-CO-. In another embodiment of formula ZB, R2X is OH. In another embodiment of formula ZB, R2X is NH2. In specific embodiments of formula ZB, aryl
groups are phenyl groups substituted with one or more R groups as defined above. In specific embodiments of formula ZB, alkyl groups are C1 -C6 alkyl groups or C1 - C3 alkyl groups. In specific embodiments of formula ZB, alkenyl groups are C2-C6 alkenyl groups or C2-C4 alkenyl groups. In specific embodiments of formula ZB, alkenyl groups are allyl groups. In specific embodiments of formula ZB, R9 is a t- butyl group. In specific embodiments of formula ZB, R6 is hydrogen or methyl. In specific embodiments of formula ZB, n is 0 and B is Rg-O-CO-. In specific embodiments, n is 1 or 2 and B is aryl. In a specific embodiment of formula ZB, R is hydrogen. In a specific embodiment of formula ZB, at least one R or R3 is a substituent other than hydrogen. In a specific embodiment of formula ZB, at least one R is a substituent other than hydrogen. In a specific embodiment of formula ZB, R2X is OH and R3 is allyl.
[0025] In an embodiment, the invention provides compounds of formula ZC:
and salts thereof,
where q is 1 or 2 and other variables are as defined for formula Z.
[0026] In a specific embodiment of formula ZC, q is 2. In a specific embodiment of formula ZC, R3 is allyl. In another embodiment of formula ZC, R2X is OH. In another embodiment of formula ZC, R2X is NH2. In specific embodiments of formula ZC, aryl groups are phenyl groups substituted with one or more R groups as defined above. In specific embodiments of formula ZC, alkyl groups are C1 -C6 alkyl groups or C1 - C3 alkyl groups. In specific embodiments of formula ZC, alkenyl groups are C2-C6 alkenyl groups or C2-C4 alkenyl groups. In specific embodiments of formula ZC, alkenyl groups are allyl groups. In specific embodiments of formula ZC, B is a R9-O- CO-. In specific embodiments of formula ZC, B is a phenyl substituted with one or more R substituents. In specific embodiments of formula ZC, Rg is a t-butyl group. In
specific embodiments, R6 is hydrogen or methyl. In specific embodiments of formula ZC, n is 0 and B is R9-O-CO-. In specific embodiments of formula ZC, n is 1 or 2 and B is aryl. In a specific embodiment of formula ZC, A is O. In a specific embodiment of formula ZC, R is hydrogen. In a specific embodiment of formula ZC, at least one R or R3 is a substituent other than hydrogen. In a specific embodiment of formula ZC, at least one R is a substituent other than hydrogen. In a specific embodiment of formula ZC, R2X is OH and R3 is allyl.
[0027] In an embodiment, the invention provides compounds of formula ZD:
and salts thereof,
where each of R6 and R'6 is independently selected from hydrogen or alkyl and other variables are as defined in formula Z.
[0028] In specific embodiments of formula ZD, R6 is hydrogen or methyl and R'6 is hydrogen. In specific embodiments of formula ZD, R'6 is hydrogen. In specific embodiments of formula ZD, n is 1 and B is aryl. In specific embodiments of formula ZD, n is 1 and B is phenyl substituted with one or more R groups as defined above. In specific embodiments of formula ZD, A is O.
[0029] In an embodiment, the invention provides compounds of formula ZY:
where Y is selected from any one of :
Y1 = -CH2-CO-NR6-N=CH- Y2 = -CH2-CO-N R6-N RVCH2-
Y3 = -CH2-CH2-NR6-N=CH- Y4 = -CH2-CH2-NR6-NRyCH2-
Y5 = -CH2-CO-NH-CH2-CH2-, or Y6 = -CH2-CO-NH-CH2-
R5 is CH or N and other variables are as defined in above formulas.
[0030] In specific embodiments of formula ZX, n is 1 and B is aryl or heteroaryl. In specific embodiments of formula ZX, n is 1 and B is phenyl, R-substituted phenyl or pyridinyl. In specific embodiments of formula ZX, Y is Y2, Y3, or Y4. In specific embodiments of formula ZX, Y is Y5 or Y6. in specific embodiments, R5 is CH or N. IN specific embodiments, R5 is N. In specific embodiments, Y is Y1 , n is O and B is R9-O-CO-. In specific embodiments, n is 0 and B is B is R9-O-CO-. In specific embodiments R2 X is OH. In specific embodiments, R2 X is -NH2. In specific embodiments R2 X is OH and R3 is allyl. In specific embodiments, R2 X is -NH2 and R3 is allyl. In specific embodiments, at least one of R is a non-hydrogen substituent. In specific embodiments, Re is hydrogen or methyl. In specific embodiments, R'β is hydrogen.
and salts thereof,
where variables are as defined above. In specific embodiments Y is Y1. In other specific embodiments, Y is Y1 and B is aryl. In other specific embodiments R5 is N. In other specific embodiments, R and R3 are all hydrogens. In other specific embodiments, B is aryl. In other specific embodiments, n is 1 or 2. In other specific embodiments, B is phenyl and RA represents substitution with hydrogens on the phenyl ring. IN other embodiments, Y is Y1 , A is O and R6 is hydrogen. In other specific embodiments, Y is Y1 , n is 1 , B is optionally substituted phenyl. In other embodiments, B is R9-COO-. In other embodiments Rg is C1 -C6 alkyl and more specifically is t-butyl. In other specific embodiments, Y is Y1 , R5 is N, n is 0 and B is optionally substituted phenyl. In other specific embodiments, Y is Y1 , R5 is N, n is 0 and B is Rg-COO-. In specific embodiments Y is Y2 or Y4. In other specific embodiments, Y is Y1 or Y3. In other specific embodiments, Y is Y5 or Y6.
[0032] In an embodiment, a compound is provided wherein B is a phenyl with at least one substituent other than hydrogen. In an embodiment, a compound is provided wherein the aromatic ring shown on the right side of compound ZY (or its analogous equivalent in other compounds described herein) has at least one substituent other than hydrogen. In an embodiment, a compound is provided wherein both rings have at least one substituent other than hydrogen.
[0033] In an embodiment, the method further comprises the step of assessing a procaspase-3 or caspase-3 parameter in a cancer cell; wherein said parameter is
one or more of a semi-quantitative or quantitative amount, a functional amount, and an activity level of said procaspase-3 or caspase-3.
[0034] In an embodiment, the invention provides a method of direct in vitro screening for a compound capable of modifying a procaspase-3 molecule, comprising: (a) providing a test compound; (b) providing a purified procaspase-3; (c) exposing the test compound to the purified procaspase-3; (d) measuring a procaspase-3 activity following exposure to the test compound; (e) identifying a modifying compound by comparing a test activity upon the exposure to the test compound with an unmodified activity in the absence of exposure to the test compound; thereby screening for a compound capable of modifying a procaspase-3 molecule. In an embodiment, the method further comprises comparing said modified activity or said unmodified activity with a reference activity; wherein said reference activity is due to exposure of procaspase-3 to a compound selected from the group consisting of structural formula Z, ZA, ZB, ZC, ZD, ZZ, PAC-1 or Compound 5.
[0035] In an embodiment, the invention provides a method of screening for a compound capable of activating procaspase-3 comprising: a) providing procaspase- 3; providing a test compound, preferably a small molecule; b) reacting the procaspase-3 with the test compound, thereby putatively generating caspase-3; and c) measuring caspase-3 activity. In a particular embodiment, the measuring caspase-3 activity employs a substrate, Ac-DEVD-pNA. In a particular embodiment, the measuring uses a wavelength readout parameter of about 410 nm. In a particular embodiment, the screening is carried out in parallel using multiple test compounds.
[0036] In an embodiment, the invention provides a method of screening which uses the detection of a subunit of procaspase-3 as an indicator that the full length
(inactive) procaspase-3 is processed to caspase-3. In a particular embodiment, the subunit has a molecular weight of about 19kD as measured by a protein gel migration technique, for example in a Western blot.
[0037] In an embodiment, the invention provides a method of in cellular screening for a compound capable of modifying a procaspase-3 molecule, comprising: (a) providing a test compound; (b) providing a cell, wherein the cell putatively expresses
procaspase-3; (c) exposing the cell to the test compound; (d) measuring a cell parameter following exposure to the test compound; wherein said parameter comprises one or more of cell viability, apoptotic indicator, and other parameters; (e) identifying a modifying compound by comparing a tested cell parameter upon the exposure to the test compound with an unmodified cell parameter in the absence of exposure to the test compound; thereby screening for a compound capable of modifying a procaspase-3 molecule. In an embodiment, the method further comprises comparing said modified activity or said unmodified activity with a reference activity; wherein said reference activity is due to exposure to a compound selected from the group consisting of formula Z, ZA, ZB, ZC, ZD, or ZZ or subsets of compounds of such formula, PAC-1 , and Compound 5.
[0038] In an embodiment, the invention provides a method of identifying or diagnosing a potential susceptibility to treatment for a cancer cell with a procaspase activator compound, comprising (a) assessing a procaspase parameter in said cancer cell; and (b) determining if said parameter allows an increased susceptibility to activation of a procaspase. In an embodiment, said procaspase parameter is a procaspase-3 level and said procaspase is procaspase-3. In an embodiment, said procaspase parameter is a procaspase-7 level and said procaspase is procaspase- 7. A level can be a semi-quantitative or quantitative amount, or functional amount (e.g. an activity-based amount, e.g. a standardized unit or international unit).
[0039] In an embodiment, the invention provides a method of treating a cancer cell, comprising (a) identifying a potential susceptibility to treatment of a cancer cell with a procaspase activator compound; and (b) exposing said cancer cell to an effective amount of the procaspase activator compound. In an embodiment, the procaspase activator compound is selected from the group consisting of formula ZZ or subsets of compounds of such formula, PAC-1 , and Structure 5. In an embodiment, the method of claim 16 wherein said procaspase activator compound is capable of activating procaspase-3, procaspase-7, or both procaspase-3 and procaspase-7.
[0040] In an embodiment, the invention provides a method of synthesizing PAC-1 , comprising the steps of Scheme 1. In an embodiment, the invention provides a method of synthesizing Compound 5, comprising the steps of Scheme 1 with appropriate modification. In an embodiment, the invention provides a method of
synthesizing compounds of the formula Z as disclosed herein and as would be understood in the art.
[0041 ] In an embodiment, the invention provides compounds of the formula Z1 , ZA1. ZC1 or ZZV.
and salts thereof where variables are as defined above.
[0042] In specific embodiments of formulas Z1 , ZA1 , ZC1 and ZZ1 , R2X is OH. In specific embodiments of formulas Z1 and ZA1 , both R4 and R5 are N. In specific embodiments of formulas Z1 , ZA1 , ZC1 and ZZ1 , R6 is hydrogen. In specific embodiments of formulas Z1 , ZA1 , ZC1 and ZZ1 , R3 is allyl. In a specific embodiment of formulas Z1 , ZA1 , ZC1 and ZZ1 , at least one R or R3 is a substituent other than hydrogen. In a specific embodiment of formulas Z1 , ZA1 , ZC1 and ZZ1 , at least one R is a substituent other than hydrogen. In a specific embodiment of formulas Z1 , ZA1 , ZC1 and ZZ1 , R2X is OH and R3 is allyl. In specific embodiments of formulas Z1 , ZA1 , ZC1 and ZZ1 , one or two of Ra, Rb, Rc, Rd or Re are halogens, C1 -C3 alkyl or C1 -C3 alkoxy groups and the remaining groups are hydrogens. In specific embodiments of formulas Z1 , ZA1 , ZC1 and ZZ1 , all of Ra, Rb, Rc, Rd, and Re are hydrogens.
[0043] In specific embodiments of GXX1 , R3 and R are all hydrogens. In specific embodiments of GXX1 , Ra, Rb, Rc, Rd, and Re are all hydrogens. In specific embodiments of GXX1 , n is 1. In specific embodiments of GXX1 , R6 is hydrogen.
[0044] In specific embodiments, the invention provides compounds of formula DX1 , DX2, DX3, DX4, DX5, DX6, DX7, DX8, DX9, DX10, DX11 , DX12, DX13, DX14, DX15, DX16, or DX17.
[0045] In specific embodiments, the invention provides compounds of formulas illustrated in Figure 12.
[0046] In specific embodiments, the invention provides compounds of formulas FX1 , FX2, FX3, FX4, FX5, FX6, FX7, FX8, and FX9.
[0047] In specific embodiments, the invention provides a compound of formula GX1.
[0048] In an embodiment, the invention provides a therapeutic composition comprising one or more compounds of any of the formulas herein and for each compound a pharmaceutically acceptable salt or ester thereof; wherein the compounds are present in the composition in an amount or in a combined amount effective for obtaining the desired therapeutic benefit. The therapeutic compositions of this invention optionally further comprise one or more pharmaceutically acceptable components, for example carriers and excipients as known in the art.
[0049] In an embodiment, the invention provides a method of screening a candidate cancer patient for possible treatment with a procaspase activator by identifying an elevated level of a procaspase in the candidate, comprising obtaining a cell or tissue test sample from the candidate, assessing the procaspase level in the test sample, and determining whether the procaspase level is elevated in the test sample relative to a reference level, thereby screening a candidate cancer patient for possible treatment with a procaspase activator. In an embodiment, the procaspase is selected from the group consisting of procaspase-2, -3, -6-, -7, -8, and -9. In a particular embodiment, the procaspase is procaspase-3.
[0050] In an embodiment, an elevated level of the test sample is at least about 2- fold greater than the reference level. In an embodiment, an elevated level of the test sample is at least about 4-fold greater than the reference level. In an embodiment, the reference level is from a second test sample from the same patient. In an embodiment, the reference level is from a normal cell or tissue sample. The reference level can be from a cell line, such as a cancer cell line or a normal cell line. In an embodiment, the reference level is an absolute threshold amount. See Svingen, P.A. et al., Clin. Cancer Res. 10:6807-6820 which describes various amounts of levels of procaspases including numbers of molecules per cell.
[0051] In an embodiment, the invention provides a method of inducing apoptosis in a cell, comprising administering to said cell a compound of the invention. In an
embodiment, the cell is a cancer cell. In an embodiment, the compound has structural formula Z, ZA, ZB, ZC, ZD or ZZ.
[0052] In an embodiment, the invention provides a method of inducing death in a cancer cell, comprising administering to said cancer cell a compound capable of activating a procaspase molecule of said cancer cell. In an embodiment the procaspase is one or more of procasepas-3 and procaspase-7. In a preferred embodiment the procaspase is procaspase 3. In an embodiment, the compound has structural formula Z, ZA, ZB, ZC, ZD or ZZ.
[0053] In an embodiment, the invention provides a medicament comprising one or more compounds of formulas Z, ZA, ZB, ZC, ZD, or ZZ as well as a method for making a medicament comprising such compounds. More specifically, the medicament further comprising a pharmaceutically acceptable carrier suitable for a selected means of administration of the medicament. In a more specific method of making the medicament, one or more compounds of the recited formulas are combined with the selected pharmaceutically acceptable carrier.
[0054] In an embodiment, the invention provides compositions and methods where a compound of the composition or method is not a compound disclosed in: U.S. Provisional Application Serial 60/684,807 filed May 26, 2005; U.S. Provisional Application Serial 60743878 filed March 28, 2006; US Patent Application Serial 11/420,425 filed May 25, 2006 (published as US 20070049602, March 1 , 2007); PCT International Application Serial PCT/US 06/020910 filed May 26, 2006 (published as WO2006/128173, 30 November 2006). In an embodiment herein, said compound is not a compound of formula is of formula ZZX;
[0055] wherein n = 1 or 2; R, independently of other R, is hydrogen, halogen, allyl, or short alkyl; R2 = hydrogen, short alkyl, ester, or other moiety that is removable under physiological conditions; R3 = hydrogen, halogen, alkyl, haloalkyl, allyl,
alkenyl, alkenol, alkanol, or haloalkenyl; R4 and R5 are N; or R4=N and R5=C; or R4 and R5 = C; and A = oxygen or sulfur.
BRIEF DESCRIPTION OF THE FIGURES
[0056] Figure 1. A) In vitro activation of procaspase-3 and active caspase-3 by PAC-1. PAC-1 activates procaspase-3 with an EC50 = 0.22 μM. Error bars represent standard deviations from the mean. B) Cleavage of procaspase-3 to active caspase-3 as induced by PAC-1. Procaspase-3 was recombinantly expressed in E. coli with an N-terminal His-6 tag and purified, lmmunoblotting was performed with an anti-His-6 antibody. In the absence of PAC-1 , no maturation of procaspase-3 is observed. In the presence of 100 μM PAC-1 , cleavage to generate the p19 fragment is observed within 1 hour, and >50% cleavage is observed after 4 hours.
[0057] Figure 2. A) Activation of mutants in the "safety catch" region of procaspase-3 by PAC-1. PAC-1 has an EC50 for activation of 0.22 μM on wild type procaspase-3 (DDD), and corresponding EC5O values of 2.77 μM (DAD), 113 μM (DDA), and 131 μM (ADD) for certain mutants. B) PAC-1 activates procaspase-7 with an EC5O of 4.5 μM. C) Dependence of PAC-1 activation of procaspase-3 on pH. At low pH the safety catch is "off", and procaspase-3 is essentially maximally activated. Error bars represent standard deviations from the mean.
[0058] Figure 3. PAC-1 induces apoptosis in HL-60 cells. A) Phosphatidylserine exposure (as measured by Annexin-V staining) after a 20 hour treatment with 100 μM PAC-1. B) Chromatin condensation as visualized by Hoescht staining after a 20 hour treatment with 100 μM PAC-1.
[0059] Figure 4. A) Mitochondrial membrane depolarization (MMP) and caspase-3 like activity in HL-60 cells treated with 10 μM etoposide. B) Mitochondrial membrane depolarization (MMP) and caspase-3 like activity in HL-60 cells treated with 100 μM PAC-1. C) PAC-1 treatment (100 μM) induces a rapid decrease in cellular PARP activity in HL-60 cells, consistent with an immediate activation of cellular caspase-3/- 7. In contrast, etoposide (10 μM) treated cells show a decrease in PARP activity at much later time points. D) PAC-1 induces cell death in a procaspase-3 dependent manner. For a number of diverse cancer cell lines, the procaspase-3 levels were
determined (by flow cytometry) and the IC50 of PAC-1 was measured (R2=0.9822). PAC-1 is quite potent (IC50=O.35 μM) in the NCI-H226 lung cancer cell line known to have high levels of procaspase-3, but markedly less potent in normal white blood cells derived from the bone marrow of a healthy human donor.
[0060] Fig. 5A illustrates relative procaspase-3 levels in normal and cancerous cells from several patients.
[0061] Fig. 5B illustrates IC50 levels for PAC-1 in a variety of cell types having a range of relative procaspase-3 levels.
[0062] Fig. 5C illustrates the effect of treating animals with PAC-1 on outcomes of tumor growth.
[0063] Fig. 5D illustrates the effect of oral treatment of animals with PAC-1 on outcomes of tumor growth.
[0064] Fig. 5E illustrates results of progression of cancer in a lung cancer model for control, PAC-1 , and gefitinib (Iressa™; AstraZeneca) treatment groups. Tumor cells were injected into mice by i.v. administration; Iressa and PAC-1 were given orally at 100 mg/kg.
[0065] Fig. 6A illustrates relative procaspase-3 levels in normal and cancerous cells of three patients.
[0066] Fig. 6B illustrates the sensitivity of normal and cancerous cells from Patient 3 to treatment with PAC-1.
[0067] Fig. 7 illustrates results of administering PAC-1 intraperitoneal^ in the context of a mouse model of lung cancer.
[0068] Fig. 8A and 8B illustrate structures for compounds of PAC-1 derivatives and a combinatorial library.
[0069] Fig. 9 illustrates a nucleotide sequence for Homo sapiens caspase 3, apoptosis-related cysteine peptidase (CASP3), transcript variant alpha, mRNA (Accession No. NM_004346; 2689 bp mRNA linear; obtained from http://www.ncbi.nlm.nih.gov/entrez).
[0070] Fig. 10 illustrates a nucleotide sequence for Homo sapiens caspase 7, apoptosis-related cysteine peptidase (CASP7), transcript variant alpha, mRNA (Accession No. NM_001227; 2605 bp; mRNA linear; obtained from http://www.ncbi.nlm.nih.gov/entrez).
[0071] Fig. 11 illustrates structures for compounds designated DX1 -DX17 (see, e.g., Examples 9 and 10).
[0072] Fig. 12 illustrates activity levels (IC50 values) next to structures of compounds DX1 -17 from apoptosis induction assays using HL-60 cells.
[0073] Fig. 13 illustrates results of testing certain compounds for the ability to effect activation of procaspase-3.
[0074] Fig. 14 illustrates the structures of certain compounds including FX1 -FX9 and GXL
[0075] Fig. 15 illustrates results from activity testing of compounds including such in the series DX, FX, and GX. Test conditions used 2.5 μM procaspase-3 (D3A) with the indicated test compound at 100 μM (filled columns); and further with 10 μM zinc (open columns).
[0076] Fig. 16 illustrates results from activity testing of compounds in the series DX and FX, plotted as percent activity versus compound concentration.
DETAILED DESCRIPTION OF THE INVENTION
[0077] In general, the terms and phrases used herein have their art-recognized meaning, which can be found by reference to standard texts, journal references and contexts known to those skilled in the art.
[0078] The following abbreviations are applicable. IAP, inhibitor of apoptosis; PAC-1 , procaspase activating compound 1 ; PARP, Poly(ADP-ribose) polymerase.
[0079] The following definitions are provided to clarify their specific use in the context of the invention.
[0080] When used herein, the term "chemotherapeutic agent" refers to any substance capable of reducing or preventing the growth, proliferation, or spread of a cancer cell, a population of cancer cells, tumor, or other malignant tissue. The term is intended also to encompass any antitumor or anticancer agent.
[0081] When used herein, the term "effective amount" is intended to encompass contexts such as a pharmaceutically effective amount or therapeutically effective amount. For example, in embodiments the amount is capable of achieving a beneficial state, beneficial outcome, functional activity in a screening assay, or improvement of a clinical condition.
[0082] When used herein, the term "cancer cell" is intended to encompass definitions as broadly understood in the art. In an embodiment, the term refers to an abnormally regulated cell that can contribute to a clinical condition of cancer in a human or animal. In an embodiment, the term can refer to a cultured cell line or a cell within or derived from a human or animal body. A cancer cell can be of a wide variety of differentiated cell, tissue, or organ types as is understood in the art.
[0083] The term "alkyl" refers to a monoradical branched or unbranched saturated hydrocarbon chain preferably having from 1 to 22 carbon atoms and to cycloalkyl groups having one or more rings having 3 to 22 carbon atoms. Short alkyl groups are those having 1 to 6 carbon atoms including methyl, ethyl, propyl, butyl, pentyl and hexyl groups, including all isomers thereof. Long alkyl groups are those having 8-22 carbon atoms and preferably those having 12-22 carbon atoms as well as those having 12-20 and those having 16-18 carbon atoms.
[0084] The term "cycloalkyl" refers to cyclic alkyl groups of from 3 to 22 carbon atoms having a single cyclic ring or multiple condensed rings. Cycloalkyl grouos include those having 3-8 member rings and those having 5 and 6 member rings. Cycloalkyl groups include, by way of example, single ring structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl, and the like, or multiple ring structures such as adamantanyl, and the like.
[0085] The term "alkenyl" refers to a monoradical of a branched or unbranched unsaturated hydrocarbon group preferably having from 2 to 22 carbon atoms and to cycloalkenyl groups having one or more rings having 3 to 22 carbon atoms wherein
at least one ring contains a double bond. Alkenyl groups may contain one or more double bonds (C=C) which may be conjugated. Preferred alkenyl groups are those having 1 or 2 double bonds. Short alkenyl groups are those having 2 to 6 carbon atoms including ethylene (vinyl) propylene, butylene, pentylene and hexylene groups, including all isomers thereof. Long alkenyl groups are those having 8-22 carbon atoms and preferably those having 12-22 carbon atoms as well as those having 12-20 carbon atoms and those having 16-18 carbon atoms. The term "cycloalkenyl" refers to cyclic alkenyl groups of from 3 to 22 carbon atoms having a single cyclic ring or multiple condensed rings in which at least one ring contains a double bond (C=C). Cycloalkenyl groups include, by way of example, single ring structures such as cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclooctenyl, cylcooctadienyl and cyclooctathenyl. The term allyl refers to the alkenyl group - CH2-CH=CH2.
[0086] The term "alkynyl" refers to a monoradical of an unsaturated hydrocarbon preferably having from 2 to 22 carbon atoms and having one or more triple bonds (CDC). Alkynyl groups include ethynyl, propargyl, and the like. Short alkynyl groups are those having 2 to 6 carbon atoms, including all isomers thereof. Long alkynyl groups are those having 8-22 carbon atoms and preferably those having 12-22 carbon atoms as well as those having 12-20 carbon atoms and those having 16-18 carbon atoms.
[0087] The term "aryl" refers to a group containing an unsaturated aromatic carbocyclic group of from 6 to 22 carbon atoms having a single ring (e.g., phenyl), one or more rings (e.g., biphenyl)or multiple condensed (fused) rings, wherein at least one ring is aromatic (e.g., naphthyl, dihydrophenanthrenyl, fluorenyl, or anthryl). Aryls include phenyl, naphthyl and the like. Aryl groups may contain portions that are alkyl, alkenyl or akynyl in addition to the the unsaturated aromatic ring(s). The term "alkaryl" refers to the aryl groups containing alkyl portions, i.e., -alkylene-aryl and -substituted alkylene-aryly. Such alkaryl groups are exemplified by benzyl (- CH2-phenyl), phenethyl and the like.
[0088] Alkyl, alkenyl, alkynyl and aryl groups are optionally substituted as described herein (the term(s) can include substituted variations) and may contain 1 -8 non-hydrogen substituents dependent upon the number of carbon atoms in the
group and the degree of unsaturation of the group. All such variable as described herein can be unsubstituted (in which any variables groups that can be hydrogen are hydrogen) or substituted with one or more non-hydrogen substituents selected from halogen, including fluorine, chlorine, bromine or iodine, C1 -C3 haloalkyl, hydroxyl (OH), thiol (HS-), C1 -C6 alkyl, C1 -C3 alkyl, C1 -C6 alkoxy, C1 -C3 alkoxy, phenyl, benzyl, alkenyl, C2-C4 alkenyl, alkynyl, C2-C4 alkynyl, -NH2, -NR1H, -NR1R", R1CO-, R1R11NCO-, R1CO-NH-, or R1CO-NR1-, where R1 and R" are C1 -C6 alkyl, C1 -C3 alkyl or phenyl.
[0089] The term "amino" refers to the group -NH2 or to the group -NR1R" where each R1 and R" is independently selected from the group consisting of hydrogen, alkyl or aryl groups.
[0090] Haloalkyl" refers to alkyl as defined herein substituted by one or more halo groups as defined herein, which may be the same or different. Representative haloalkyl groups include, by way of example, trifluoromethyl, 3-fluorododecyl, 12,12,12-trifluorododecyl, 2-bromooctyl, 3-bromo-6-chloroheptyl, and the like.
[0091] The term "heteroaryl" refers to an aromatic group of from 2 to 22carbon atoms having 1 to 4 heteroatoms selected from oxygen, nitrogen and sulfur within at least one ring (if there is more than one ring). Heteroaryl groups may be optionally substituted. Heteroaryl grouos include among others those having 5 and 6-member rings and those having one or two nitrogens in the ring, those having one or two oxygens in the ring as well as those having one or two sulfurs in the ring.
[0092] The term "heterocycle" or "heterocyclic" refers to a monoradical saturated or unsaturated group having a single ring or multiple condensed rings, from 2-22 carbon atoms and from 1 to 6 hetero atoms, preferably 1 to 4 heteroatoms, selected from nitrogen, sulfur, phosphorus, and/or oxygen within at least one ring.
Heterocyclic groups may be substituted. Rings preferably have 3-10 members and more specifically have 5 or 6 members.
[0093] The term "ester" refers to chemical entities as understood in the art and in particular can include groups of the form (RCO-).
[0094] As to any of the above groups which contain one or more substituents, it is understood, that such groups do not contain any substitution or substitution patterns which are sterically impractical and/or synthetically non-feasible. The compounds of this invention include all novel stereochemical isomers arising from the substitution of disclosed compounds.
[0095] In an embodiment, the invention provides compounds of the formula Z excluding PAC-1 , wherein the structure of PAC-1 is:
[0096] In an embodiment, the invention provides a compound of compound 5, which is:
[0097] In an embodiment, the invention provides a compound of formula Z other than compound 5.
[0098] In an embodiment, the invention provides a compound having the formula Z2:
wherein Ri and R2 independently represent substitution on the indicated rings with one or more hydrogen, halogen, alkyl, allyl, haloalkyl, alkenyl, alkenol, alkanol, or haloalkenyl. In an embodiment, Ri and R2 independently represent substitution on the indicated rings with one or more hydrogen, halogen, allyl, or C1 -C3 alkyl.
[0099] In an embodiment, the invention provides a compound selected from the group consisting of a PAC-1 derivative combinatorial library comprising a hydrazide
compound combined with an aldehyde compound. In an embodiment, the hydrazide compound is selected from the group consisting of hydrazides generated from AX compounds described herein.
[00100] In an embodiment, the aldehyde compound is selected from the group consisting of BX compounds described herein. In an embodiment, the hydrazide compound is selected from the group consisting of AX compounds described herein and the aldehyde compound is selected from the group consisting of BX compounds described herein.
[00101] In an embodiment, the invention provides a method of synthesizing a PAC-1 derivative compound comprising providing a hydrazide compound, providing an aldehyde compound, and reacting the hydrazide compound with the aldehyde compound, thereby synthesizing a PAC-1 derivative compound.
[00102] In an embodiment, the hydrazide compound has the formula ZZ3:
where Ri represents substitution on the indicated ring of one or more R groups as defined in formula Z.
where R2 represents substitution on the indicated ring of one or more R3 or R groups as defined in formula Z.
[00104] In an embodiment, the hydrazide compound has the formula ZZ3 and the aldehyde compound has the formula ZZ4.
[00105] In an embodiment, the invention provides a compound selected from the group consisting of: L01 R06, L02R03, L02R06, L08R06, L09R03, L09R06, and L09R08.
[00106] In an embodiment, a composition of the invention is a chemotherapeutic agent.
[00107] In an embodiment, the invention provides compounds and methods involving effective concentrations preferably from about 10 nM to about 100 μM of the disclosed structural formulas. In another preferred embodiment, the effective concentrations are from about 200 nM to about 5 μM. In an embodiment, the effective concentration is considered to be a value such as a 50% activity concentration in a direct procaspase activation assay, in a cell apoptosis induction assay, or in an animal clinical therapeutic assessment. In a preferred embodiment, such value is less than about 200 μM. In a preferred embodiment, the value is less than about 10 μM.
[00108] Compounds of the invention and compounds useful in the methods of this invention include those of the disclosed formulas and salts and esters of those compounds, including preferably pharmaceutically-acceptable salts and esters.
[00109] In an embodiment, the invention provides prodrug forms of compositions. Prodrugs of the compounds of the invention are useful in the methods of this invention. Any compound that will be converted in vivo to provide a biologically, pharmaceutically or therapeutically active form of a compound of the invention is a prodrug. Various examples and forms of prodrugs are well known in the art. A biomolecule such as a precursor protein or precursor nucleic acid can be a prodrug. Examples of prodrugs are found, inter alia, in Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985), Methods in Enzymology, Vol. 42, at pp. 309-396, edited by K. Widder, et. al. (Academic Press, 1985); A Textbook of Drug Design and Development, edited by Krosgaard-Larsen and H. Bundgaard, Chapter 5, "Design and Application of Prodrugs," by H. Bundgaard, at pp. 113-191 , 1991 ); H.
Bundgaard, Advanced Drug Delivery Reviews, Vol. 8, p. 1 -38 (1992); H. Bundgaard, et al., Journal of Pharmaceutical Sciences, Vol. 77, p. 285 (1988); and Nogrady (1985) Medicinal Chemistry A Biochemical Approach, Oxford University Press, New York, pages 388-392).
[00110] In an embodiment, a composition of the invention is in a form that is isolated or purified.
[00111] It is recognized that regardless of the ultimate correctness of any mechanistic explanation or hypothesis believed or disclosed herein, an embodiment of the invention can nonetheless be operative and useful.
[00112] When a group of substituents is disclosed herein, it is understood that all individual members of that group and all subgroups, including any isomers and enantiomers of the group members, are disclosed separately. When a Markush group or other grouping is used herein, all individual members of the group and all combinations and subcombinations possible of the group are intended to be individually included in the disclosure. It is intended that any one or more members of any Makush group or listing provided in the specification can be excluded from the invention if desired. When a compound is described herein such that a particular isomer or enantiomer of the compound is not specified, for example, in a formula or in a chemical name, that description is intended to include each isomers and enantiomer of the compound described individual or in any combination. Additionally, unless otherwise specified, all isotopic variants of compounds disclosed herein are intended to be encompassed by the disclosure. For example, it will be understood that any one or more hydrogens in a molecule disclosed can be replaced with deuterium or tritium. Isotopic variants of a molecule are generally useful as standards in assays for the molecule and in chemical and biological research related to the molecule or its use. Specific names of compounds are intended to be exemplary, as it is known that one of ordinary skill in the art can name the same compounds differently.
[00113] Molecules disclosed herein may contain one or more ionizable groups [groups from which a proton can be removed (e.g., -OH, -COOH, etc.) or added (e.g., amines) or which can be quaternized (e.g., amines)]. All possible ionic forms of such molecules and salts thereof are intended to be included individually in the disclosure herein. With regard to salts of the compounds herein, one of ordinary skill in the art can select from among a wide variety of available counterions those that are appropriate for preparation of salts of this invention for a given application. For example, in general any anions can be employed in the formation of salts of compounds herein; e.g. halide, sulfate, carboxylate, acetate, phosphate, nitrate, trifluoroacetate, glycolate, pyruvate, oxalate, malate, succinate, fumarate, tartarate,
citrate, benzoate, methanesulfonate, ethanesulfonate, p-toluenesulfonate, salicylate and others.
[00114] Compounds of the present invention, and salts or esters thereof, may exist in their tautomeric form, in which hydrogen atoms are transposed to other parts of the molecules and the chemical bonds between the atoms of the molecules are consequently rearranged. It should be understood that all tautomeric forms, insofar as they may exist, are included within the invention. Additionally, the compounds may have trans and cis isomers and may contain one or more chiral centers, therefore existing in enantiomeric and diastereomeric forms. The invention can encompass all such isomers, individual enantiomers, as well as mixtures of cis and trans isomers, mixtures of diastereomers; non-racemic and racemic mixtures of enantiomers (optical isomers); and the foregoing mixtures enriched for one or more forms; except as stated otherwise herein. When no specific mention is made of the configuration (cis, trans or R or S) of a compound (or of an asymmetric carbon), then any one of the isomers or a mixture of more than one isomer is intended. The processes for preparation can use racemates, enantiomers, or diastereomers as starting materials. When enantiomeric or diastereomeric products are prepared, they can be separated by conventional methods, for example, by chromatographic or fractional crystallization. The inventive compounds may be in the free or hydrate form.
[00115] Every formulation or combination of components described or exemplified herein can be used to practice the invention, unless otherwise stated.
[00116] Whenever a range is described in the present application, for example, a temperature range, a time range, or a composition or concentration range, all intermediate ranges and subranges, as well as all individual values included in the ranges given are intended to be included in the disclosure.
[00117] Information in any references disclosed herein can in some cases indicate the state of the art, for example for patent documents as of their effective filing dates; it is intended that such information can be employed herein, if needed, to exclude specific embodiments that are actually found to be in the prior art. For example, when a compound is disclosed and/or claimed, it should be understood that
compounds qualifying as prior art with regard to the present invention, including compounds for which an enabling disclosure is provided in the references, are not intended to be included in the composition of matter claims herein.
[00118] Some references provided herein are incorporated by reference to provide details concerning sources of starting materials, additional starting materials, additional reagents, additional methods of synthesis, additional methods of analysis, and additional uses of the invention. One of ordinary skill in the art will appreciate that starting materials, reagents, solid substrates, synthetic methods, purification methods, and analytical methods other than those specifically exemplified can be employed in the practice of the invention based on knowledge in the art and without resort to undue experimentation.
[00119] The invention may be further understood by the following non-limiting examples.
EXAMPLE 1. Procaspase activating compounds.
[00120] Mutation or aberrant expression of proteins in the apoptotic cascade is a frequent hallmark of cancer. These changes can prevent proapoptotic signals from being transmitted to the executioner caspases, thus preventing apoptotic cell death and allowing cellular proliferation. Caspase-3 and caspase-7 are key executioner caspases, existing as inactive zymogens that are activated by upstream signals. Importantly, expression levels of procaspase-3 are significantly higher in certain cancerous cells relative to non-cancerous controls. Here we report the identification of small molecules that directly activate procaspase-3 to active caspase-3. A particular compound, PAC-1 , effects activation in vitro with an EC50 on the order of 220 nanomolar and induces apoptosis in a multitude of cancerous cell lines.
[00121] In contrast to many known anti-cancer drugs, cells treated with PAC-1 show an immediate activation of procaspase-3, and the toxicity of PAC-1 is shown to be directly proportional to the amount of procaspase-3 contained in a cell. Thus PAC-1 directly activates procaspase-3 to caspase-3 in vivo, allowing this compound to induce apoptosis even in cells that have defective apoptotic machinery. PAC-1 is the first small molecule known to directly activate procaspase-3; the direct activation of executioner caspases is a novel anti-cancer strategy that may prove beneficial in
a variety of cancers, including the many cancers in which procaspase-3 is u p regulated.
[00122] A collection of about 20,000 structurally diverse small molecules was screened for the ability to activate procaspase-3 in vitro. Procaspase-3 was expressed and purified in E. coli (Roy et al., 2001 ). Procaspase-3 (at a concentration of 50 ng/mL) was added to the wells of a 384-well plate, and the compounds were added to a final concentration of approximately 40 μM. Each plate was then incubated for two hours at 370C, after which the caspase-3 peptidic substrate Ac-Asp-Glu-Val-Asp-p-nitroanilide (Ac-DEVD-pNa) was added to a concentration of 200 μM. The formation of the p-nitroaniline chromophore was followed at 405 nm over the course of two hours.
[00123] Of the compounds evaluated, four induced a significant increase over background in the hydrolysis of the peptidic caspase-3 substrate. Of those four, one showed a strong dose-dependent effect on in vitro procaspase-3 activation. As shown in Figure 1A, this first procaspase activating compound (PAC-1 ) gives half- maximal activation of procaspase-3 at a concentration of 0.22 μM. This compound is not simply increasing the activity of caspase-3 itself, as it has no effect on the catalytic activity of the fully processed caspase-3 enzyme (Figure 1A).
[00124] Procaspase-3 has an N-terminal pro domain (residues 1 -28), followed by a large subunit (17 kDa) and a small subunit (12 kDa) that are separated by an intersubunit linker (Pop et al., 2003). In vivo, two procaspase-3 monomers assemble to form a catalytically inactive homodimer that can be activated by cleavage at D175 in the intersubunit linker. The precise role of the pro domain is unclear, and it has been shown that cleavage in the intersubunit region alone is sufficient for full catalytic activity (Stennicke, H. R. et al., 1998). Although procaspase-3 is catalytically competent, it is highly resistant to autoactivation due to the presence of the 12 amino acid safety catch; however, when the safety catch is mutated significant autoactivation of procaspase-3 is observed (Roy et al., 2001 ). Compounds that interact with this important regulatory region or at other positions can allow the autoactivation of procaspase-3.
[00125] To directly assess the ability of PAC-1 to catalyze the autoactivation of procaspase-3, the procaspase-3 protein was incubated with 100 μM of PAC-1 for time points ranging from one to five hours. As shown by the Western blot in Figure 1 B, PAC-1 induces the cleavage of procaspase-3 in a time- dependent fashion, with >50% processing observed after 4 hours. In contrast, procaspase-3 incubated in buffer shows virtually no autoactivation over that same time span. In an attempt to pinpoint the region of procaspase-3 with which PAC-1 is interacting, alanine substitutions were made in the key aspartic acid triad in the safety catch region, residues Asp179, Asp180 and Asp181. Mutations at these positions all dramatically decreased the ability of PAC-1 to activate procaspase-3, with certain mutations more detrimental to activation of procaspase-3 by PAC-1 (Figure 2A).
[00126] Like caspase-3, caspase-7 also exists as an inactive zymogen that is activated by proteolysis. Caspase-3 and caspase-7 are both executioner caspases and have considerable sequence and structural homology (Denault, J. -B. et al., 2003). Procaspase-7 may also have a similar safety catch region, although it has only two aspartic acids in the key triad (Asp-Thr-Asp), instead of three. As indicated by the data in Figure 2B, PAC-1 can also activate procaspase-7, although in a less efficient manner than its activation of procaspase-3 (EC50 of 4.5 μM versus 0.22 μM for procaspase-3 activation). The potency of procaspase-7 activation by PAC-1 is similar to its effect on the Asp-Ala-Asp mutant of procaspase-3 (EC50 = 2.77 μM). The effect of PAC-1 is abolished at low pH values where procaspase-3 undergoes rapid autoactivation (Figure 2C).
[00127] The ability for a small molecule that activates procaspase-3 to induce apoptosis in human cell lines was tested, and PAC-1 was found to induce apoptosis in a variety of cancer cell lines. In HL-60 cells addition of PAC-1 leads to considerable phosphatidylserine exposure on the cell membrane accompanied by significant chromatin condensation (Figures 3A and B). In addition, the compound induces cleavage of PARP-1 (as assessed by an in vivo PARP activity assay; Putt KS et al., 2005) and causes mitochondrial membrane depolarization (see below). Significant cellular blebbing was also observed by microscopy. Furthermore, the toxicity of PAC-1 could be abolished in the presence of the caspase inhibitor z-VAD- fmk (data not shown; see Slee et al., 1996).
[00128] If PAC-1 is indeed inducing apoptosis via direct activation of procaspase-3, the time course of apoptotic events should be altered relative to that observed with standard proapoptotic agents. Etoposide is well known to induce apoptosis through the intrinsic pathway; thus, mitochondrial membrane depolarization is followed by procaspase-3 activation in etoposide-treated cells. Indeed, in HL-60 cells treated with 10 μM etoposide, mitochondrial membrane depolarization is observed, followed by detection of caspase-3-like activity (Figure 4A). In contrast, treatment of cells with PAC-1 gives a markedly different result. With PAC-1 , the first observed biochemical hallmark of apoptosis is caspase-3-like enzymatic activity. This activity is noted within minutes of compound addition, and 50% activation takes place in just over 2 hours and well before any significant mitochondrial membrane depolarization (Figure 4B). In addition, PARP activity is rapidly reduced in cells treated with PAC-1 , whereas this reduction is observed at later time points in etoposide treated cells (Figure 4C). Control experiments show that PAC-1 does not directly inhibit enzymatic activity of PARP-1. In the typical sequence of apoptotic events, the mitochondrial membrane depolarizes, caspases are activated, and caspase substrates (such as PARP-1 ) are cleaved. The observation that cells treated with PAC-1 show a rapid activation of caspase-3/-7 (before mitochondrial membrane depolarization) and a rapid cleavage of a caspase substrate is indicative of this compound exerting its cellular toxicity through the direct activation of procaspase-3.
[00129] To further define the potency of PAC-1 , the ability of this compound to induce cell death in cancer cell lines with varying levels of procaspase-3 was assessed. A determination was made of the amount of procaspase-3 present in multiple cancer cell lines (leukemia, lymphoma, melanoma, neuroblastoma, breast cancer, lung cancer and renal cancer) and in the white blood cells isolated from the bone marrow of a healthy donor. The IC50 values for cell death induction were obtained for PAC-1 in these cell lines. The combined data shows a strong correlation between cellular concentration of procaspase-3 and sensitivity to PAC-1 (Figure 4D). Notably, the white blood cells derived from the bone marrow of a healthy human donor are among those with the lowest amount of procaspase-3, and PAC-1 is comparatively less toxic to these cells. PAC-1 is most potent versus the lung cancer cell line NCI-H226, with an IC50 of 0.35 μM. In accordance with data in
the literature (Svingen et al., 2004), we found this cell line to have a concentration of procaspase-3 that is greater than five times that of the non-cancerous control.
[00130] In contrast to these experiments with PAC-1 , etoposide showed no such correlation between potency in cell culture and cellular levels of procaspase-3. For instance, etoposide was ineffective (IC50 >50 μM) in inducing death in three of the melanoma cell lines (UACC-62, CRL-1872, and B16-F10), the breast cancer cell line (Hs 578t), and the lung cancer cell line (NCI-H226); these cell lines have procaspase-3 levels of 1.0, 2.4, 1.9, 3.7, and 5.3, respectively. Etoposide was effective (IC50 <1 μM) versus HL-60, U-937, SK-N-SH and PC-12, which have procaspase-3 levels of 4.3, 4.0, 4.7, and 4.4, respectively. Thus, overall there is no correlation between procaspase-3 levels and IC50 for etoposide.
[00131] Cancerous cells typically have a reduced sensitivity to proapoptotic signals due to the mutation or aberrant expression of an assortment of proteins in the apoptotic cascade. As such, many types of cancer are notoriously resistant to not only the endogenous signals for apoptotic cell death, but also to chemotherapeutic agents that act through similar mechanisms. The paradoxical upregulation of procaspase-3 expression levels in certain cancers provides an opportunity to use this existing intracellular pool of protein to directly induce apoptosis, thus bypassing the often non-functional or compromised upstream portion of the cascade. Although procaspase-3 is notorious for its relative inability to undergo autoactivation, it is dependent upon a 12 amino acid safety catch to keep itself in the inactive state. PAC-1 induces the autoactivation of procaspase-3 in vitro, and this activation is greatly diminished by mutation of the key tri-aspartate region of the safety catch. This data is consistent with the notion that PAC-1 is directly interfering with the ability of the safety catch to maintain procaspase-3 dormancy.
[00132] In cell culture, PAC-1 treatment induces rapid caspase-3-like activity. It is likely that the caspase-3 mediated cleavage of anti-apoptotic proteins (Bcl-2, BcI-XL, etc.) then induces depolarization of the mitochondrial membrane and amplifies apoptosis. Further, the potency of PAC-1 toward a variety of cancer cell lines is directly proportional to the concentration of procaspase-3 in the cell. It is worth noting that several of the cell lines that PAC-1 is effective against have faulty apoptotic pathways that make them resistant to apoptosis; for instance, Apaf-1
expression is dramatically decreased in SK-MEL-5 cells, and Bcl-2 is overexpressed in the NCI-H226 lung cancer cell line.
[00133] Data presented herein fully support the notion that procaspase-3 activating compounds can be exceedingly effective against common cancers. The effectiveness can be enhanced for situations in which procaspase-3 levels are aberrantly high.
[00134] Assessment of procaspase-3 levels in cancer biopsies can be simple and rapid; as such, the potential effectiveness of a compound such as PAC-1 can be assessed a priori with a high degree of accuracy. Procaspase-3 activators and methods herein thus provide personalized medicine strategies that can be preferential to therapies that rely on general cytotoxins in the realm of anti-cancer treatments.
MATERIALS AND METHODS
[00135] Materials: Ni-NTA resin and anti-Penta His Alexa Fluor 647 antibody was purchased from Qiagen (Valencia, CA). Bradford dye was purchased from Bio-Rad (Hercules, CA). Pin transfer devices were purchased from V & P Scientific (San Diego, CA). The reagent z-vad-fmk was purchased from Calbiochem (San Diego, CA). Rosetta E. coli was purchased from Novagen (Madison, Wl). Anti-caspase-3 antibody was purchased from Sigma (St. Louis, MO). Annexin V Alexa Fluor 488 conjugate, JC-9, and propidium iodide were purchased from Molecular Probes (Eugene, OR). IPTG and MTS/PMS CellTiter 96 Cell Proliferation Assay reagent were purchased from Promega (Madison, Wl). Fetal Bovine Serum was purchased from Biomeda (Foster City, CA). 96 and 384-well microtiter plates, microscope slides, microscope coverslips, horse serum and all other reagents were purchased from Fisher (Chicago, IL).
[00136] Methods: Cell Culture Conditions. U-937, HL-60, CRL-1872, ACHN, NCI- H226, SK-MEL-5 and UACC-62 cells were grown in RPMI 1640 media supplemented with 10% FBS. SK-N-SH, B16-F10 and Hs 578t cells were grown in Eagle's minimal essential medium with Earle's BSS, 1.5 g/L sodium bicarbonate and supplemented with 10% FBS. PC-12 cells were grown in RPMI 1640 media supplemented with 5% FBS and 10% horse serum. Human bone marrow was grown
in IDMEM supplemented with 40% FBS. All cell lines were incubated at 370C in a 5% CO2, 95% air atmosphere. U-937 and HL-60 cells were split every two to three days as needed. Human bone marrow was thawed from frozen stock and immediately diluted and used for experiments. All other cells were split when they reached approximately 80% confluency.
[00137] Protein Expression and Purification. 1 ml_ of an overnight culture of Rosetta E. coli containing the procaspase-3 or procaspase-7 expression plasmid was seeded into 1 L of LB media containing proper antibiotic. Cells were induced with 1 mM IPTG for 30 minutes. Cells were then spun down and re-suspended in NTA binding buffer (150 mM NaCI, 50 mM Tris, 10 mM Imidazole, pH 7.9). The cells were lysed by passing twice through a French press. The cell lysate was then spun at 14,000 x g for 30 min. The supernatant was decanted and 1 ml_ of nickel-NTA resin was added. The cell lysate was incubated for 1 hour at 40C. The resin was loaded on a column, washed with 10 ml_ NTA binding buffer followed by 10 ml_ NTA wash buffer (150 mM NaCI, 50 mM Tris, 20 mM Imidazole, pH 7.9). The proteins were eluted in 1 ml_ fractions with 10 ml_ of NTA elution buffer (150 mM NaCI, 50 mM Tris, 250 mM Imidazole, pH 7.9). Fractions containing protein were pooled and the amount of protein was determined using the Bradford assay.
[00138] Library Screen. Isolated procaspase-3 was diluted to 50 ng/mL in caspase assay buffer (50 mM HEPES, 100 mM NaCI, 10 mM DTT, 0.1 mM EDTA, 0.1 % CHAPS and 10% glycerol, pH 7.4). 45 μL of the procaspase-3 solution was added to each well of a Nunc 384-well flat bottom microtiter plate. Approximately 20,000 compounds were screened. About 6,000 of the compounds were collected from various sources within the department of chemistry at the University of Illinois; their structures are available at: http://www.scs.uiuc.edu/~phgroup/comcollections.html. The other approximately 14,000 compounds were purchased from Chembridge Corporation (San Diego, California). PAC-1 was a member of the compounds purchased from Chembridge Corporation.
[00139] The compounds, made up as 10 mM stock solutions in DMSO, were transferred into the wells using a 384-pin transfer apparatus that transfers 0.2 μL of compound. This yielded a final compound concentration of about 40 μM. Controls were performed in which only DMSO (containing no compound) was pin-transferred.
The plates were then incubated for 2 hours at 370C. 5 μl_ of a 2 mM solution of Ac- DEVD-pNA (N-acetyl-ASP-Glu-Val-Asp-p-nitroanilide) in caspase assay buffer was added to each well. The plate was then read every 2 minutes at 405 nm for 2 hours in a Spectra Max Plus 384 plate reader (Molecular Devices, Sunnyvale CA). The slope of the linear portion for each well was used to determine the activity of caspase-3.
[00140] Activation curves. The dose dependence of procaspase-3 activators was determined by adding various concentrations of compound to 90 μl_ of a 50 ng/mL procaspase-3, active caspase-3, procaspase-7 or active caspase-7 in caspase assay buffer in a 96-well plate. The plate was then incubated for 12 hours at 370C. 10 μL of a 2 mM solution of Ac-DEVD-pNA in caspase assay buffer was then added to each well. The plate was read every 2 minutes at 405 nm for 2 hours in a Spectra Max Plus 384 well plate reader. The slope of the linear portion for each well was determined and the fold increase in activation from non-treated control wells was calculated.
[00141] PAC-1 activation gel. Procaspase-3 was expressed and isolated exactly as above. Procaspase-3 was diluted to about 50 μg/mL in caspase assay buffer. The procaspase-3 was then incubated in the presence or absence of 100 μM PAC-1 for varying times at 370C. After this incubation, an equal volume of load buffer (150 mM NaCI, 50 mM Tris, 2% SDS, 20% glycerol, pH 8.0) was added to each procaspase-3 sample. All samples were then stored at -8O0C until the time-course was completed. All samples were then incubated at 950C for 5 minutes and run on a 12% SDS- PAGE gel. Proteins were then transferred to nitrocellulose paper overnight. Blots were washed in TTBS (150 mM NaCI, 50 mM Tris, 0.1 % Tween-20, pH 7.4) and blocked with a 10% milk solution for 2 hours. Blots were then incubated in a 1 :5000 dilution of anti-Penta His Alexa Fluor 647 antibody for 2 hours. The blot was then washed with TTBS and scanned on a Typhoon fluorescence scanner (Amersham Biosciences, SunnyVale CA).
[00142] Safety catch mutations. The DDD procaspase-3 safety catch (SEQ ID NO:1 ; SEQ ID NO:2; SEQ ID NO:9) was mutated to ADD (SEQ ID NO:3, SEQ ID
NO:4, SEQ ID NO:10), DAD (SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:11 ) and DDA
(SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:12) using the quickchange strategy with the following primers, gacagacagtggtgttgCGgatgacatggcgtgtcataaaatacc
(SEQ ID NO:13), gacagacagtggtgttgatgCtgacatggcgtgtcataaaatacc (SEQ ID NO:14) and gacagacagtggtgttgatgatgCcatggcgtgtcataaaatacc (SEQ ID NO: 15) respectively. See also Figure 9 and Figure 10. Mutated bases are underlined and capitalized. All mutant plasmids were sequenced to ensure proper sequence throughout the gene. All mutant plasmids were expressed exactly as wild- type procaspase-3 as described above. The ability of PAC-1 to activate each procaspase-3 mutant was determined by adding various concentrations of PAC-1 to 90 μl_ of a 50 ng/mL wild-type procaspase-3 and mutant procaspase-3 in caspase assay buffer in a 96-well plate. The plate was then incubated for 12 hours at 370C. 10 μL of a 2 mM solution of Ac-DEVD-pNA in caspase assay buffer was then added to each well. The plate was read every 2 minutes at 405 nm for 2 hours in a Spectra Max Plus 384 well plate reader. The slope of the linear portion for each well was determined and the fold increase in activity for each mutant was calculated.
[00143] Effect of pH on PAC-1 activation of procaspase-3. The effect of pH on procaspase-3 activation by PAC-1 was determined by diluting procaspase-3 in pH caspase assay buffer (25 mM MES, 25 mM Tris, 25 mM HEPES, 25 mM PIPES, 100 mM NaCI, 10 mM DTT, 0.1 mM EDTA, 0.1 % CHAPS and 10% glycerol) to a concentration of 50 ng/mL. The buffer was then changed to various pH values and 90 μL was added to each well of a 96-well plate. PAC-1 was added to a concentration of 100 μM or DMSO was added as a control for each pH value. The plate was then incubated for 12 hours at 370C. 10 μL of a 2 mM solution of Ac- DEVD-pNA in caspase assay buffer was then added to each well. The plate was read every 2 minutes at 405 nm for 2 hours in a Spectra Max Plus 384 plate reader (Molecular Devices, Sunnyvale CA). The slope of the linear portion for each well was determined and the fold increase in activation for each pH value was calculated.
[00144] Annexin V staining. 500 μL of media containing 200 μM PAC-1 or only DMSO as a control was added to the wells of a 24-well plate. 500 μL HL-60 cells at a concentration of 2 x 106 cells/mL were then added to the 24-well plate. The plate was incubated for 20 hours at 370C. Cells were harvested by centrifugation and washed twice in PBS. The cells were then washed in AnnexinV binding buffer (10
mM HEPES, 140 mM NaCI, 2.5 mM CaCI2, pH 7.4) and resuspended in 100 μl_ of Annexin V binding buffer. 5 μl_ of annexin V, Alexa Fluor 488 conjugate was added and the tubes were incubated at room temperature for 15 minutes protected from light. 400 μl_ of Annexin V binding buffer was then added, followed by the addition of 1 μl_ of a 1 mg/mL solution of propidium iodide. The fluorescent intensity of each cell was determined by flow cytometry at 525 nm (green channel) and 675 nm (red channel). At least 50,000 cells were analyzed in each experiment.
[00145] Condensed chromatin staining. 500 μl_ of media containing 200 μM PAC-1 or only DMSO as a control was added to the wells of a 24-well plate. 500 μl_ HL-60 cells at a concentration of 2 x 106 cells/mL were then added to the 24-well plate. The cells were incubated for 20 hours and harvested by centrifugation. The cells were then washed in PBS buffer followed by the addition of ice-cold 100% ethanol. The cells were fixed overnight at 40C. Fixed cells were incubated with 2 μg/mL Hoechst- 33258 for 30 minutes at room temperature. A drop of cells was then added to a microscope slide and covered with a No. 1 thickness coverslip. Condensed chromatin was observed at 40Ox magnification on a Zeiss Axiovert 100 microscope.
[00146] Cell death inhibition by z-vad-fmk. 100 μl_ HL-60 cells at a concentration of 5 x 105 cells/mL were added to the wells of a 96-well plate. The cells were then incubated for 1 hour in the presence or absence of 100 μM z-vad-fmk, a cell- permeable pan caspase inhibitor. PAC-1 was then added at various concentrations, and the cells were incubated for an additional 24 hours. Cell death was quantitated by the addition of 20 μl_ of the MTS/PMS CellTiter 96 Cell Proliferation Assay reagent to each well. The plates were incubated at 370C for approximately 45 minutes until the colored product formed. The absorbance was then measured at 490 nm in a Spectra Max Plus 384 plate reader (Molecular Devices, Sunnyvale CA).
[00147] In vivo determination of mitochondrial membrane potential. 1 ml_ of HL-60 cells at a concentration of 1 x 106 cells/mL were added to the wells of a 24-well plate. PAC-1 was then added to a concentration of 100 μM or only DMSO was added as a control. The cells were incubated for various times, and the cells then were harvested by centrifugation. The cells were washed in PBS and resuspended in 1 mL of PBS. 10 μg of the JC-9 dye was added and the cells were incubated at room temperature for 10 minutes protected from light. The cells were then washed two
times with PBS and brought up in 500 μl_ PBS. The fluorescent intensity of each cell was determined by flow cytometry at 525 nm (green channel) and 675 nm (red channel). 50,000 cells were analyzed in each experiment. The shift in the red channel was then used to determine the amount of mitochondrial membrane depolarization.
[00148] In vivo determination of caspase-3 like activity. The amount of caspase-3 like protease activity was determined by the amount of Ac-DEVD-pNA (N-acetyl- ASP-Glu-Val-Asp-p-nitroanilide) cleaved per minute by cell lysates. To accomplish this, 50 μl_ of media containing varying concentrations of PAC-1 was added to the wells of a 96-well plate. 50 μl_ of HL-60 cells at a concentration of 5 x 106 cells/mL were added to the plate and incubated for various times. After the incubation period, the plate was spun at 1000 x g for 5 minutes to pellet the cells. The cells were then washed with 100 μl_ of PBS and resuspended in 150 μl_ of ice cold Caspase Assay Buffer. Each well was then sonicated to lyse the cells. 90 μl_ of cell lysate was transferred from each well into a new plate. Ac-DEVD-pNA was added into each well to give a final concentration of 200 μM. The plate was then read every 2 minutes at 405 nm for 2 hours in a Spectra Max Plus 384 plate reader (Molecular Devices, Sunnyvale CA). The slope of the linear portion for each well was determined and the amount of Ac-DEVD-pNA cleaved per minute was calculated.
[00149] In vivo determination of PARP cleavage. The amount of PARP cleavage was determined by using an in vivo PARP activity assay. To accomplish this, 50 μl_ of media containing 200 μM NAD+ was added to the control wells of a 96-well plate. 50 μl_ of media containing 200 μM PAC-1 and 200 μM NAD+ was then added to the experimental wells. 25 μl_ of HL-60 cells at a concentration of 5 x 106 cells/mL were then added to each well. The cells were incubated for various times and then spun at 1000 x g for 5 minutes. The cell media was removed and replaced with 50 μl_ Lysing PARP Buffer (50 mM Tris, 10 mM MgCI2, pH 8.0, 1 % Triton X-100) containing 25 mM H2O2. The plate was then incubated for 60 minutes at 370C. To determine the amount of NAD+ still present, 20 μl_ of 2 M KOH and 20 μl_ of a 20% (v/v) acetophenone (in ethanol) solution was added to each well of the 96-well plate. The plate was then incubated for 10 minutes at 40C. 90 μl_ of an 88% (v/v) formic acid solution was added to each well of the 96-well plate. The plate was then
incubated for 5 min. in an oven set to 11 O0C. The plate was allowed to cool and then read on a Criterion Analyst AD (Molecular Devices, Sunnyvale, CA) with an excitation of 360 nm, an emission of 445 nm and a 400 nm cutoff dichroic mirror. The fluorophore was excited using a 1000 W continuous lamp for 1.6 x 105 μs with 5 reads performed per well. The number of moles of NAD+ cleaved per minute was then calculated and the remaining PARP activity as compared to control wells was determined.
[00150] Relative concentration of procaspase-3 in various cell lines. U-937, HL-60 and human bone marrow cells were harvested by centhfugation while all other cell lines were first trypsinized to release the cells and then harvested by centrifugation. All cells were washed in PBS and resusupended in 1 ml_ of ice-cold 100% ethanol. Cells were fixed overnight at 40C. The cells were spun at 1000 x g for 5 minutes, washed with PBS and 100 μl_ of a 1 :100 dilution of anti-caspase-3 antibody in PBS was then added. The cells were incubated for 2 hours at room temperature followed by five PBS washes. The cells were then resuspended in 1 ml_ of a 1 :10,000 dilution of anti-mouse Ab Cy3 labeled antibody for 2 hours at room temperature protected from light. The cells were washed five times with PBS and resuspended in 500 μl_ of PBS. The fluorescent intensity of each cell was determined by flow cytometry at 675 nm (red channel). At least 20,000 cells were analyzed in each experiment. The median of the population was used to determine the relative concentration of procaspase-3 in each cell line.
[00151] Determination of IC50 values in various cell lines. 50 μl_ of media containing various concentrations of PAC-1 or etoposide was added to each well of a 96-well plate except control wells, which contained only DMSO. U-937, HL-60 and human bone marrow cells were harvested by centrifugation, while all other cell lines were first trypsinized before centrifugation. Cells were then resuspended in media and diluted to either 1 x 106 cells/mL for U-937, HL-60 and human bone marrow cells or 50,000 cells/mL for all other cell lines. 50 μL of the cell solutions were then added to each well and the plates were incubated for either 24 or 72 hours for etoposide and PAC-1 respectively. Cell death was quantitated by the addition of 20 μL of the MTS/PMS CellTiter 96 Cell Proliferation Assay reagent to each well. The plates were then incubated at 370C for approximately one hour until the colored product
formed. The absorbance was measured at 490 nm in a Spectra Max Plus 384 plate reader (Molecular Devices, Sunnyvale CA).
[00152] Data Analysis: The data from all flow cytometry experiments was analyzed using Summit Software (Cytomation, Fort Collins CO). All graphs were analyzed using Table Curve 2D.
[00153] Professor Ronald Hoffman (University of Illinois-Chicago Cancer Center) provided human bone marrow. Professor Guy Salvesen (Burnham Institute) provided the procaspase-3 and procaspase-7 expression vectors.
REFERENCE TO SEQUENCE LISTING - Appendix A. The separately accompanying sequence listing information, designated Appendix A, is to be considered and incorporated as part of the specification herewith.
Table 1. Overview of Sequence Listing information.
EXAMPLE 2. Synthesis of procaspase activating compounds.
[00154] PAC-1 and other compounds are prepared according to the following schemes, e.g., Scheme 1 and/or Scheme 2. Further variations are prepared according to methods known in the art.
Scheme 1
[00155] In a particular example, PAC- 1 is prepared according to Scheme 2:
EXAMPLE 3. Analogs of PAC-1.
[00156] Analog compounds of PAC-1 were prepared and assessed for the capability to directly activate purified procaspase-3 in vitro.
Table 2. Activity of PAC-1 and analog compounds.
EXAMPLE 4. Pharmaceutical embodiments.
[00157] The following describes information relevant to pharmaceutical and pharmacological embodiments and is further supplemented by information in the art available to one of ordinary skill. The exact formulation, route of administration and dosage can be chosen by an individual physician in view of a patient's condition (see e.g. Fingl et. al., in The Pharmacological Basis of Therapeutics, 1975, Ch. 1 p. 1 ).
[00158] It should be noted that the attending physician would know how to and when to terminate, interrupt, or adjust administration due to toxicity, or to organ
dysfunctions, etc. Conversely, the attending physician would also know to adjust treatment to higher levels if the clinical response were not adequate (in light of or precluding toxicity aspects). The magnitude of an administered dose in the management of the disorder of interest can vary with the severity of the condition to be treated and to the route of administration. The severity of the condition may, for example, be evaluated, in part, by standard prognostic evaluation methods. Further, the dose and perhaps dose frequency, can also vary according to circumstances, e.g. the age, body weight, and response of the individual patient. A program comparable to that discussed above also may be used in veterinary medicine.
[00159] Depending on the specific conditions being treated and the targeting method selected, such agents may be formulated and administered systemically or locally. Techniques for formulation and administration may be found in Alfonso and Gennaro (1995) and elsewhere in the art. Suitable routes may include, for example, oral, rectal, transdermal, vaginal, transmucosal, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, or intramedullary injections, as well as intraocular, intrathecal, intravenous, or intraperitoneal administration.
[00160] For injection or other routes, agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, water for injection, physiological saline buffer, or other solution. For transmucosal administration, penetrants appropriate to the barrier to be permeated can be used in the formulation. Such penetrants are generally known in the art.
[00161] Use of pharmaceutically acceptable carriers to formulate the compounds herein disclosed for the practice of the invention into dosages suitable for systemic or other administration is within the scope of the invention. With proper choice of carrier and suitable manufacturing practice, the compositions of the present invention, in particular those formulated as solutions, may be administered parenterally, such as by intravenous injection, or other routes. Appropriate compounds can be formulated readily using pharmaceutically acceptable carriers well known in the art into dosages suitable for oral administration. Such carriers enable the compounds of the invention to be formulated as tablets, pills, capsules,
liquids, gels, syrups, slurries, elixirs, solutions, suspensions and the like, e.g. for oral ingestion by a patient to be treated. For other routes, formulations can be prepared for creams, ointments, lotions, and the like.
[00162] Agents intended to be administered intracellular^ may be administered using techniques well known to those of ordinary skill in the art. For example, such agents may be encapsulated into liposomes, other membrane translocation facilitating moieties, or other targeting moieties; then administered as described above. Liposomes can include spherical lipid bilayers with aqueous interiors. All molecules present in an aqueous solution at the time of liposome formation can be incorporated into the aqueous interior. The liposomal contents are both protected from the external microenvironment and, because liposomes fuse with cell membranes, are efficiently delivered into the cell cytoplasm. Additionally, due to hydrophobicity attributes, small organic molecules may be directly administered intracellular^.
[00163] Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. Determination of the effective amounts is well within the capability of those skilled in the art, especially in light of the disclosure provided herein and other information in the art.
[00164] In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. The preparations formulated for oral administration may be in the form of tablets, dragees, capsules, or solutions, including those formulated for delayed release or only to be released when the pharmaceutical reaches the small or large intestine.
[00165] The pharmaceutical compositions of the present invention may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, suspending, granulating, dragee-making, levitating, emulsifying, encapsulating, entrapping, lyophilizing, and other processes.
[00166] Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.
Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
[00167] Pharmaceutical preparations for oral use can be obtained by combining the active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
[00168] Dragee cores are optionally provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
[00169] Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids,
such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added.
EXAMPLE 5. Direct Induction of Apoptosis in Cancer Cells with a Small Molecule Activator of Procaspase-3.
[00170] ABSTRACT: Mutation or aberrant expression of proteins in the apoptotic cascade is a hallmark of cancer. These changes prevent proapoptotic signals from being transmitted to the executioner caspases, thus preventing apoptotic cell death and allowing cellular proliferation. Caspase-3 and caspase-7 are the key executioner caspases, existing as inactive zymogens that are activated by upstream signals. Importantly, levels of procaspase-3 are significantly higher in certain cancerous cells relative to non-cancerous controls. Here we report the identification of a small molecule (PAC-1 ) that directly activates procaspase-3 to active caspase-3 in vitro with an EC50 of 220 nanomolar, and induces apoptosis in a variety of cancer cell lines. In contrast to many known anti-cancer drugs, cells treated with PAC-1 show an immediate activation of procaspase-3, and the efficacy of PAC-1 is shown to be proportional to the amount of procaspase-3 contained in a cell. Derivatives of PAC-1 that do not activate procaspase-3 in vitro also have no proapoptotic activity. Cancerous cells isolated from primary colon tumors are considerably more sensitive to apoptotic induction by PAC-1 than the cells from adjacent non-cancerous tissue from the same patient; these cancerous cells contain on average about 7-fold more procaspase-3 than the cells from the adjacent non-cancerous primary tissue. In addition, the sensitivity to PAC-1 of the primary cells from the colon cancer tumors strongly correlates with the level of the procaspase-3 target. Finally, PAC-1 as a single entity was shown as active to retard the growth of tumors in three different mouse models, including two models where PAC-1 was administered orally. Thus PAC-1 directly activates procaspase-3 to caspase-3 in vivo, thereby allowing this compound to induce apoptosis even in cells that have defective apoptotic machinery. PAC-1 is the first small molecule known to directly activate procaspase-3; the direct activation of executioner caspases is an anti-cancer strategy that may prove beneficial in the many cancers in which procaspase-3 levels are elevated.
[00171] INTRODUCTION. A hallmark of cancer is its resistance to natural apoptotic signals. Depending on the cancer type, this resistance is typically due to either up-
or down-regulation of key proteins in the apoptotic cascade, or to mutations in genes encoding these proteins. Such changes occur in both the intrinsic apoptotic pathway, which funnels through the mitochondria and caspase-9, and the extrinsic apoptotic pathway, which involves the action of death receptors and caspase-8. For example, alterations in proper levels of p53, Bim, Bax, Apaf-1 , FLIP and many others have been observed in cancers and lead to a defective apoptotic cascade, one in which the upstream pro-apoptotic signal is not properly transmitted to activate the executioner caspases, caspase-3 and caspase-7. As most apoptotic pathways ultimately involve the activation of procaspase-3, these genetic abnormalities are effectively "breaks" in the apoptotic circuitry, and as a result such cells proliferate uncontrolled.
[00172] Given the central role of apoptosis in cancer, efforts have been made to develop therapeutics that target specific proteins in the apoptotic cascade. For instance, peptidic or small molecule binders to p53, proteins in the BcI family, or to the IAPs have pro-apoptotic activity, as do compounds that promote the oligomehzation of Apaf-1. However, because many of these compounds target early or intermediate positions on the apoptotic cascade, cancers with mutations in downstream proteins will likely be resistant to their effects. For therapeutic purposes it would be ideal to identify a small molecule that directly activates a proapoptotic protein far downstream in the apoptotic cascade. In addition, such a therapeutic strategy would have a higher likelihood of success if levels of that proapoptotic protein were elevated in cancer cells.
[00173] The conversion of procaspase-3 to caspase-3 results in the generation of the active "executioner" caspase that subsequently catalyzes the hydrolysis of a multitude of protein substrates. Active caspase-3 is a homodimer of heterodimers and is produced by proteolysis of procaspase-3. In vivo, this proteolytic activation typically occurs through the action of caspase-8 or caspase-9. To ensure that this zymogen is not prematurely activated, procaspase-3 has a tri-aspartic acid "safety catch" that blocks access to the IETD site of proteolysis. This safety catch enables procaspase-3 to resist autocatalytic activation and proteolysis by caspase-9. The position of the safety catch is sensitive to pH; thus, upon cellular acidification (as occurs during apoptosis) the safety catch is thought to allow access to the site of
proteolysis, and active caspase-3 can be produced either by the action of caspase-9 or through an autoactivation mechanism.
[00174] Cells from certain types of cancerous tissue have elevated levels of procaspase-3. A study of primary isolates from 20 colon cancer patients revealed that on average procaspase-3 was elevated six-fold in such isolates relative to adjacent non-cancerous tissue. In addition, procaspase-3 levels are elevated in certain neuroblastomas, lymphomas, and liver cancers. In fact, a systematic evaluation of procaspase-3 levels in the 60 cell-line panel used by the NCI revealed that particular lung, melanoma, renal, and breast cancers show greatly enhanced levels of procaspase-3. Given the central importance of active caspase-3 to successful apoptosis, the high levels of procaspase-3 in certain cancerous cell types, and the intriguing safety catch-mediated suppression of its autoactivation, we reasoned that small molecules that directly activate procaspase-3 could be identified and that such molecules could have great potential in targeted cancer therapy. In this manuscript we report the in vitro identification of a small molecule activator of procaspase-3, PAC-1. PAC-1 is powerfully proapoptotic in cancer cell lines in a manner proportional to procaspase-3 levels, its proapoptotic effect is due to its direct and immediate activation of procaspase-3, and it is effective against primary colon cancer isolates and in three different mouse models of cancer.
[00175] Approximately 20,500 structurally diverse small molecules were screened for the ability to activate procaspase-3 in vitro. Procaspase-3 was expressed and purified in E. coli according to standard procedures. Procaspase-3 was added to the wells of a 384-well plate, and the compounds were added to a final concentration of about 40 μM (the final concentration of procaspase-3 was 50 ng/mL). Each plate was then incubated for two hours at 370C, after which the caspase-3 peptidic substrate Ac-Asp-Glu-Val-Asp-p-nitroanilide (Ac-DEVD-pNa) was added to a concentration of 200 μM. The formation of the p-nitroaniline chromophore was followed at 405 nm over the course of two hours. Of the -20,500 compounds evaluated, four induced a significant increase over background in the hydrolysis of the peptidic caspase-3 substrate. Of those four, one showed a strong dose dependent effect on in vitro procaspase-3 activation. As shown in Figure 1A, this first procaspase-activating compound (PAC-1 ) gives half-maximal activation of
procaspase-3 at a concentration of 0.22 μM. This compound is not simply increasing the activity of caspase-3 itself, as it has no effect on the catalytic activity of the fully processed caspase-3 enzyme (Figure 1A).
[00176] Procaspase-3 consists of a N-terminal pro domain (residues 1 -28), followed by a large subunit (17 kDa) and a small subunit (12 kDa) that are separated by an intersubunit linker.22 In vivo, two procaspase-3 monomers assemble to form a homodimer that can be activated by cleavage at D175 in the intersubunit linker. The precise role of the pro domain is unclear, and it has been shown that cleavage in the intersubunit region alone is sufficient for full catalytic activity. Although procaspase-3 has enough catalytic activity to drive its own proteolytic maturation, it is highly resistant to this autoactivation due to the presence of the three amino acid safety catch. However, when the safety catch is mutated significant autoactivation of procaspase-3 is observed. To directly assess the ability of PAC-1 to catalyze the maturation of procaspase-3 to the active caspase-3, the procaspase-3 protein was incubated with 100 μM of PAC-1 for time points ranging from one to five hours. As shown by the Western blot in Figure 1 B, PAC-1 induces the cleavage of procaspase-3 in a time-dependant fashion, with >50% processing observed after 4 hours. In contrast, procaspase-3 incubated in buffer shows virtually no autoactivation over that same time span. PAC-1 was also effective in this assay at a concentration of 5 μM.
[00177] Alanine substitutions were then made in the key aspartic acid triad in the safety catch region of procaspase-3, residues Asp179, Asp180 and Asp181. Mutations at these positions all dramatically decreased the ability of PAC-1 to activate procaspase-3, with certain mutations more detrimental to activation of procaspase-3 by PAC-1 (Figure 2A). Like caspase-3, caspase-7 also exists as an inactive zymogen that is activated by proteolysis. Caspase-3 and caspase-7 are both executioner caspases and have considerable structural homology. Procaspase-7 is also predicted to have a similar safety catch region, although it has only two aspartic acids in the key triad (Asp-Thr-Asp), instead of three. As indicated by the data in Figure 2B, PAC-1 can also activate procaspase-7, although in a less efficient manner than its activation of procaspase-3 (EC50 of 4.5 μM versus 0.22 μM for procaspase-3 activation). The potency of procaspase-7 activation by PAC-1 is
similar to its effect on the Asp-Ala-Asp mutant of procaspase-3 (EC50 = 2.77 μM). As expected, the effect of PAC-1 is abolished at low pH values where procaspase-3 undergoes rapid autoactivation (Figure 2C).
[00178] PAC-1 was found to induce apoptosis in a variety of cancer cell lines. In HL-60 cells addition of PAC-1 leads to considerable phosphatidylsehne exposure on the cell membrane accompanied by significant chromatin condensation (Figures 3A, 3B). In addition, the compound induces cleavage of the caspase substrate PARP-1 (as assessed by an in vivo PARP activity assay) and causes mitochondrial membrane depolarization (see below). Significant cellular blebbing of PAC-1 treated cells was also observed by microscopy. Furthermore, the toxicity of PAC-1 could be abolished in the presence of the caspase inhibitor z-VAD-fmk.
[00179] If PAC-1 is indeed inducing apoptosis via direct activation of procaspase-3, then the time course of apoptotic events should be altered relative to that observed with standard proapoptotic agents. Etoposide is well known to induce apoptosis through the intrinsic pathway; thus, mitochondrial membrane depolarization is followed by procaspase-3 activation in etoposide-treated cells. Indeed, in HL-60 cells treated with 10 μM etoposide, mitochondrial membrane depolarization is observed, followed by detection of caspase-3-like activity (Figure 4A). In contrast, treatment of cells with PAC-1 gives a markedly different result. With this compound, the first observed biochemical hallmark of apoptosis is caspase-3-like enzymatic activity, with activity noted within minutes of PAC-1 addition and 50% activation taking place in just over 2 hours and well before any significant mitochondrial membrane depolarization (Figure 4B). In addition, PARP-1 activity is rapidly reduced in cells treated with PAC-1 , whereas this reduction is observed at later time points in etoposide treated cells (Figure 4C); control experiments show that PAC-1 does not directly inhibit enzymatic activity of PARP-1. In the typical sequence of apoptotic events the mitochondrial membrane depolarizes, caspases are activated, and caspase substrates (such as PARP-1 ) are cleaved. The observation that cells treated with PAC-1 show a rapid activation of caspase-3/-7 (before mitochondrial membrane depolarization) and a rapid cleavage of a caspase substrate (PARP-1 ) is indicative of PAC-1 exerting its cellular toxicity through the direct activation of procaspase-3.
[00180] To further define the potency of PAC-1 , the ability of this compound to induce cell death in cancer cell lines with varying levels of procaspase-3 was assessed. A determination was first made of the levels of procaspase-3 present in multiple cancer cell lines (leukemia, lymphoma, melanoma, neuroblastoma, breast cancer, lung cancer, adrenal cancer and renal cancer). The IC50 values for cell death induction were obtained for PAC-1 versus these cell lines. The combined data shows a strong correlation between cellular concentration of procaspase-3 and sensitivity to PAC-1 (Figure 4D, Figure 4E). PAC-1 is most potent versus the lung cancer cell line NCI-H226, with an IC50 of 0.35 μM. We found this cell line to have a concentration of procaspase-3 that is greater than five times that of baseline levels. Importantly, there is one cancer cell line (MCF-7, breast cancer cells) that is known to have no expression of procaspase-3. PAC-1 has virtually no effect on MCF-7 cells, inducing death with an ICso>75 μM.
[00181] In contrast, etoposide showed no such correlation between potency in cell culture and cellular levels of procaspase-3. For instance, etoposide was ineffective (IC50>50 μM) in inducing death in three of the melanoma cell lines (UACC-62, CRL- 1872, and B16-F10), the breast cancer cell line (Hs 578t), and the lung cancer cell line (NCI-H226); these cell lines have procaspase-3 levels of 1.0, 2.4, 1.9, 3.7, and 5.3, respectively. Etoposide was effective (IC50<1 μM) versus HL-60, U-937, SK-N- SH and PC-12, which have procaspase-3 levels of 4.3, 4.0, 4.7, and 4.4, respectively. Thus, overall there is no correlation between procaspase-3 levels and IC50 for etoposide.
[00182] Several derivatives of PAC-1 were synthesized and evaluated for both their procaspase-3 activating properties and their effects on cancer cells in cell culture (Table 3). The PAC-1 derivative that lacks the allyl group (de-allyl PAC-1 ) is able to induce procaspase-3 activation and cell death at levels similar to PAC-1. However, all other derivatives showed no activity in either assay. Thus, while it appears the allyl group is dispensable for biological activity, the phenolic hydroxyl and aromatic rings are all critical for PAC-1 activity. This data is also consistent with the proposed mechanism of action of PAC-1 ; compounds that do not activate procaspase-3 in vitro have no proapoptotic effect on cancer cells in culture.
[00183] To test this direct, small molecule-mediated procaspase-3 activation strategy in clinical isolates of cancer, we obtained freshly resected colon tumors (together with adjacent non-cancerous tissue) from 18 patients from Carle Foundation Hospital (Urbana, IL). The cancerous and non-cancerous tissue was separated, and the cells derived from these were evaluated for their levels of procaspase-3 and their sensitivity to PAC-1. As shown in Figure 5A, in all cases the cancerous cells had elevated levels (1.7- to 17.2-fold, with an average of 7.6-fold elevation) of procaspase-3 relative to the cells from the adjacent non-cancerous tissue from the same patient. Further, these cancerous cells were quite susceptible to death induction by PAC-1. PAC-1 induced cell death in the primary cancerous cells with IC50 values from 0.007-1.41 μM, while PAC-1 induced cell death in the adjacent non-cancerous tissue with IC50 values from 5.02-9.98 μM (Figure 5B and Table 4). The cancerous tissue that had elevated levels of procaspase-3 was extremely sensitive to PAC-1. For example, PAC-1 induced death in the cancer cells from patient 17 with an IC50 of 7 nM, and these cells were over 700-fold more sensitive to PAC-1 than cells from the adjacent normal tissue. See also Figure 6A showing relative procaspase-3 concentrations in normal and cancerous samples from Patients 1 , 2, and 3 over a period of time of about 54 days; Figure 6B illustrates that cells in cancerous tissue can be greater than about 80-fold more sensitive to PAC-1 in comparison with normal tissue.
[00184] In addition to cells from the non-cancerous tissue of the 18 patients, PAC-1 was also evaluated against four other non-cancerous cell types: white blood cells isolated from the bone marrow of a healthy donor, Hs888Lu (lung fibroblast cells), MCF-10A (breast fibroblast cells), and Hs578Bst (breast epithelial cells). Notably, the non-cancerous cell types are among those with the lowest amount of procaspase-3, and PAC-1 is comparatively less able to induce death in these cells, with IC50 values of 3.2 - 8.5 μM (Figure 5B, green diamonds). As is apparent from Figure 5B, PAC-1 induces death in a wide variety of cell types (non-cancerous cell lines, non-cancerous primary cells, cancerous cell lines, primary cancerous cells) in a manner directly related to the level of procaspase-3. The elevation of procaspase- 3 in cancerous cells allows PAC-1 to selectively induce death in these cell types.
[00185] PAC-1 was evaluated in a mouse xenograft model using a slow release mode of drug delivery. In this model, subcutaneous tumors were formed in ovariectomized female athymic BALB/c (nude) mice using the ACHN (renal cancer) cell line. Once the tumors were measured to be greater than about 30 mm2, drug was administered via the implantation of a pellet of PAC-1 and cholesterol, providing for slow and steady levels of compound release. Three groups of mice were used, with pellets containing 0 mg, 1 mg, and 5 mg of PAC-1 , six mice per group, with four tumors per mouse. Tumor sizes were monitored for about 8 weeks. As shown in Figure 5C, tumor growth is significantly retarded in the mice that were implanted with the pellet containing 5 mg of PAC-1. Food intake evaluation in the last week of the experiment showed no difference in food consumption between the three groups of mice. After the mice were sacrificed, plasma samples were taken from each mouse, and the PAC-1 content of each was analyzed. For mice that received a 5 mg pellet of PAC-1 , this analysis revealed PAC-1 to be present at a concentration of 5 nM in the plasma after the 54 day experiment.
[00186] PAC-1 was evaluated in a second mouse xenograft model, this one using oral administration as the drug delivery mode. In this model, subcutaneous xenograft tumors were formed in male athymic BALB/c-nu/nu mice (5 weeks old, SLC, Hamamaysu, Japan) using the NCI-H226 (lung cancer) cell line, eight mice per group, three tumors per mouse. After formation of the tumors in the mice, the mice were treated with PAC-1 via oral gavage once a day for 21 days at a concentration of 0, 50, or 100 mg/kg and sacrificed 1 week later. As clearly indicated by the graph in Figure 5D, oral administration of PAC-1 significantly retards tumor growth in a dose-dependent manner.
[00187] Finally, PAC-1 was evaluated in a mouse model where the NCI-H226 cells were injected into male athymic BALB/c-nu/nu mice via tail vein injection. The total experiment lasted 28 days; the mice were treated once a day with PAC-1 (100 mg/kg) via oral gavage on days 1 -4 and 7-11. On other days the mice did not receive PAC-1. A second group of mice received only vehicle. After 28 days the mice were sacrificed, and their lungs were examined. As shown in Figure 5E, there is a clear difference between the lung of the control mouse (with obvious gray tumor
mass) and the lung of the PAC-1 treated mouse. Results are also shown in a panel from an animal treated with gefitinib (Iressa™; AstraZeneca).
[00188] Cancerous cells typically have a reduced sensitivity to proapoptotic signals due to the mutation or aberrant expression of an assortment of proteins in the apoptotic cascade. As such, many types of cancer are notoriously resistant to not only the endogenous signals for apoptotic cell death, but also to chemotherapeutic agents that act through similar mechanisms. The paradoxical elevation of procaspase-3 levels in certain cancers provides an opportunity to use this existing intracellular pool of protein to directly induce apoptosis, thus bypassing the often non-functional upstream portion of the cascade. PAC-1 induces the autoactivation of procaspase-3 in vitro. In cell culture, PAC-1 treatment induces rapid caspase-3- like activity. It is likely that the caspase-3 mediated cleavage of anti-apoptotic proteins (Bcl-2, BcI-XL, etc.) then induces depolarization of the mitochondrial membrane and amplifies apoptosis. Further, the potency of PAC-1 toward a variety of cancerous and non-cancerous cell types is proportional to the concentration of procaspase-3 in the cell. As the primary cancerous cells isolated from resected colon tumors have elevated levels of procaspase-3, these cells are considerably more sensitive to PAC-1 than cells from adjacent non-cancerous tissue. It is worth noting that several of the cell lines against which PAC-1 is effective have faulty apoptotic pathways that make them resistant to apoptosis; for instance, Apaf-1 expression is dramatically decreased in SK-MEL-5 cells, and Bcl-2 is overexpressed in the NCI-H226 lung cancer cell line. Finally, PAC-1 is effective in three different mouse models of cancer, including two where PAC-1 is administered orally.
[00189] Data presented herein support the notion that procaspase-3 activating compounds can be exceedingly effective against a variety of common cancers in which procaspase-3 levels are aberrantly high. Assessment of procaspase-3 levels in cancer biopsies is simple and rapid; as such, the potential effectiveness of a compound such as PAC-1 can be assessed a priori with a high degree of accuracy. Such personalized medicine strategies can be preferential to therapies that rely on general cytotoxins and can be valuable in anti-cancer therapy.
[00190] Professor Guy Salvesen (Burnham Institute) provided the procaspase-3 and procaspase-7 expression vectors.
FIGURE LEGENDS
[00191] Figures 1 and 2. The structure of PAC-1 is shown elsewhere in the specification. Fig. 1A) In vitro activation of procaspase-3 and active caspase-3 by PAC-1. PAC-1 activates procaspase-3 with an EC5O = 0.22 μM. Fig. 1 B) Cleavage of procaspase-3 to active caspase-3 as induced by PAC-1. Procaspase-3 was recombinantly expressed in E. coli with an N-terminal His-6 tag and purified, lmmunoblotting was performed with an anti-His-6 antibody. In the absence of PAC-1 no maturation of procaspase-3 is observed. In the presence of 100 μM PAC-1 , cleavage to generate the p19 fragment is observed within 1 h, and >50% cleavage is observed after 4 h. PAC-1 is also effective at 5 μM in this assay. Fig. 2A) Activation of mutants in the "safety catch" region of procaspase-3 by PAC-1. PAC-1 has an EC50 for activation of 0.22 μM on wild type procaspase-3 (DDD), and corresponding EC50 values of 2.77 μM (DAD), 113 μM (DDA), and 131 μM (ADD) for the mutants. Fig. 2B) PAC-1 activates procaspase-7 with an EC50 of 4.5 μM. Fig. 2C) Dependence of PAC-1 activation of procaspase-3 on pH. At low pH the safety catch is off and procaspase-3 is essentially maximally activated. Error bars represent standard deviations from the mean.
[00192] Figures 3 and 4. PAC-1 induces apoptosis in HL-60 cells. Fig. 3A) Phosphatidylserine exposure (as measured by Annexin-V staining) after a 20 h treatment with 100 μM PAC-1. PAC-1 is also effective at 5 μM in this assay (see Supporting Figure 2). Fig. 3B) Chromatin condensation as visualized by Hoescht staining after a 20 h treatment with 100 μM PAC-1. Fig. 4A) Mitochondrial membrane depolarization (MMP) and caspase-3 like activity in HL-60 cells treated with 10 μM etoposide. Fig. 4B) Mitochondrial membrane depolarization (MMP) and caspase-3 like activity in HL-60 cells treated with 100 μM PAC-1. Fig. 4C) PAC-1 treatment (100 μM) induces a rapid decrease in cellular PARP activity in HL-60 cells, consistent with an immediate activation of cellular caspase-3/-7. In contrast, etoposide (10 μM) treated cells show a decrease in PARP activity at much later time points. Fig. 4D and Fig. 4E) PAC-1 induces cell death in a procaspase-3 dependant manner. For a number of diverse cancerous cell lines, the procaspase-3 levels were determined (by flow cytometry with an antibody to procaspase-3) and the IC50 of PAC-1 was measured (through a 72 h treatment with a range of PAC-1
concentrations and quantitation using the MTS assay). PAC-1 is quite potent (IC5o=O.35 μM) in the NCI-H226 lung cancer cell line known to have high levels of procaspase-3. Error bars represent standard deviations from the mean.
[00193] Table 3. PAC-1 and de-allyl PAC-1 activate procaspase-3 in vitro and induce death in cancer cells in cell culture, but other structural analogues have no procaspase-3 activating effect in vitro and give no induction of death in cell culture.
[00194] Figure 5. Fig. 5A) Procaspase-3 levels are elevated in cells derived from freshly resected colon cancer tissue. Freshly resected primary colon tumors (together with adjacent non-cancerous tissue) were obtained from 18 different patients, the cancerous and non-cancerous tissue were separated, and the procaspase-3 levels were measured for each using an antibody to procaspase-3 and flow cytometry. On average, cells from the cancerous tissue have a 7.6-fold elevation in procaspase-3 as compared to the cells derived from the adjacent noncancerous tissue from the same patient. Fig. 5B) PAC-1 induces cell death in a manner proportional to the cellular level of procaspase-3. The red circles represent the primary cancerous cells from the 18 colon tumors. The black triangles represent the same cancer cell lines depicted in Figure 4D. The green diamonds are four noncancerous cell types: Hs888Lu (lung fibroblast cells), MCF-10A (breast fibroblast cells), Hs578Bst (breast epithelial cells), and white blood cells isolated from the bone marrow of a healthy donor. The blue squares are the primary non-cancerous cells isolated from the tumor margins of the 18 patients. Table 4) Cells derived from primary colon cancer tissue are considerably more sensitive to death induction by PAC-1 than are cells derived from adjacent non-cancerous tissue from the same patient. Fig. 5C) PAC-1 reduces the growth of tumors in a xenograft model of cancer. Tumors were formed with the ACHN (renal cancer) cell line by subcutaneous injection, with six mice in each group, and four tumors per mouse. Once the tumors grew to about 30 mm2, PAC-1 was implanted as a cholesterol pellet. Error bars represent standard error from the mean. Fig. 5D) Oral administration of PAC-1 significantly retards tumor growth in a mouse xenograft model. Tumors were formed using the NCI-H226 (lung cancer) cell line by subcutaneous injection, eight mice in each group, and three tumors per mouse. PAC-1 or vehicle was administered once a day by oral gavage on days 1 -21. Error
bars represent standard error from the mean. Fig. 5E) Oral administration of PAC-1 significantly retards tumor growth in an i.v. injection model. Mice were injected i.v. with the NCI-H226 (lung cancer) cell line. The mice were treated with PAC-1 (100 mg/kg) via oral gavage following the protocol as described in the text. Images show the lungs of the mice that did not receive PAC-1 and have a large amount of gray tumor mass on the lung. In contrast, the mice that did receive PAC-1 have almost no visible gray matter.
Table 3. Selected compounds indicating activity levels.
EC50 (μM) for IC50 (μM) for Compound procaspase-3 death induction activation in HL-60 cells
HCL
^N^ O 0.43 1.74
H de-allyl PAC-1
HCL
HN'^V| O >50 >100
N H
-N-^ O >50 >100
^N^ O >50 >100
EXAMPLE 6. Testing of PAC-1 in mouse model of lung cancer.
[00195] A xenograft model was employed using NCI-H226 (lung cancer) cells. PAC-1 was given intraperitoneal^ (i.p.) at 10 mg/kg. A comparison of efficacy was performed with gefitinib (Iressa™; AstraZeneca, Wilmington, Delaware) at 40 mg/kg using 5 mice per group. Results are shown in Figure 7, indicating that PAC-1 was associated with reducing growth in tumor volume.
EXAMPLE 7. Combinatorial derivatives, synthesis, and therapeutic use.
[00196] A number of compounds are prepared as derivatives of the PAC-1 structure. A hydrazide group is reacted with an aldehyde group to yield a combinatorial library of derivative compounds.
[00197] Any one of hydrazide precursor groups (AX) designated L1 -L20 are used to generate hydrazides which are reacted with any one of aldehyde groups (BX) designated 1 -28, thus yielding 560 PAC-1 derivative compounds. A derivative
compound is synthesized using methods as described herein and according to knowledge available in the art. See the scheme and component structures below in addition to Figure 8A and 8B.
AX
L20
L15
L5 L10
BX
[00198] In an embodiment, such derivative compounds are further modified, e.g. to alter a property such as activity, solubility, toxicity, stability, and/or other properties in connection with pharmaceutical applications.
[00199] The derivative compounds are used as anti-cancer agents. Compounds are validated as capable of having antineoplastic activity, apoptosis regulation, and/or procaspase-3 activation. For example, primary isolates of freshly removed colon cancer are used to assess procaspase-3 levels and sensitivity of cells to test compound levels, where a test compound is PAC-1 or a derivative compound. Compounds are classified regarding a propensity to induce cell death in cancerous cells versus normal cells.
[00200] In further assessing a derivative compound, in vitro and in vivo testing is performed. Stability in connection with exposure to liver microsomes is evaluated.
EXAMPLE 8. Activity of certain derivatives relative to PAC-1.
[00201] PAC-1 and certain derivatives were tested in the HL-60 cell line and IC50 values were determined. The results are indicated in Table 5 (where L- and R-- designations refer to structures shown in the AX and BX series above, respectively). Several of the PAC-1 derivatives exhibited an activity level that was generally about one order of magnitude greater than that of the PAC-1 compound.
Table 5.
[00202] Additional compounds were synthesized and tested for activity. These compounds are designated DX1 -17 herein. Structures for these compounds are shown in Figure 11. It is noted that compound DX1 is PAC-1 and that compound DX3 is de-allyl PAC-1.
[00203] Compounds DX1 -DX17 were tested using the HL-60 cell line for the ability to effect apoptosis, and IC50 values were determined. Activity levels of compounds from assays of 72 hrs duration with HL-60 cells are shown in Table 6 and along with structures in Figure 12.
Table 6. Results for compounds DX1 -17 in HL-60 cells.
[00204] Certain compounds were also tested for the ability to effect in vitro activation of procaspase-3. Results of Western blots are shown in Figure 13. Figure 13A indicates substantial activity levels for compounds PAC-1 (alias DX1 ), DX3, and DX11 relative to the control levels (for lanes indicated with letter "C"). Figure 13B also illustrates results of testing for activity of compounds DX1 , DX12, DX13, DX15, and DX17; the arrow indicates the location of procaspase-3. Experimental
conditions included compound concentrations of 50 micromolar, procaspase-3 levels of about 35 nanomolar, and treatment periods of 8 hr.
[00205] In an embodiment, a DX compound herein is capable of inducing or selectively inducing apoptosis in a cancer cell. In an embodiment, a compound is used as an anti-cancer drug. In an embodiment, a compound is used as a pro- apoptotic agent. In an embodiment, a preferred DX compound is DX6, DX7, DX8, DX9, DX10, DX11 , DX12, or DX15.
EXAMPLE 10. Synthetic schemes for certain compounds and methods.
[00206] Schemes for synthesis of compounds including DX1 -DX17 are shown herein.
[00207] Scheme for DX1
PAC-1 (1)
[00211] Scheme for DX5
[00212] Scheme for DX6
[00214] Scheme for DX8
8 [00215] Scheme for DX9
[00216] Scheme for DX10
10
[00217] Scheme for DX11
11
12
14
15
[00222] Scheme for DX16
57% 17
EXAMPLE 11. Synthetic schemes for certain compounds and methods.
[00224] Schemes for synthesis of further compounds including FX1 -FX9 and GX1 are shown herein.
[00225] Scheme for FX1 :
83% FX1
[00226] Scheme for FX2:
100 81 % FX2
FX3
80%
88% microwave: 1 050C, 200W 60 min
82%
39% 102
FX4
[00229] Scheme for FX5:
102 80% FX5
[00230] Scheme for FX6:
1 02 88% FX6
[00232] Scheme for FX8:
102 84%
FX8
[00233] Scheme for FX9 and GX1:
GX1 : 63%
EXAMPLE 12. Activity of certain compounds.
[00234] Certain compounds were tested for activity. Results are indicated in Figures 15 and 16. Fig. 15 illustrates results from activity testing of compounds including such in the series DX, FX, and GX. Test conditions used 2.5 μM procaspase-3 (D3A) with the indicated test compound at 100 μM (filled columns); and further with 10 μM zinc (open columns). Fig. 16 illustrates results from activity testing of compounds in the series DX and FX, plotted as percent activity versus compound concentration.
[00235] Assay description - Materials and methods. Compounds were tested in an in vitro activity assay. In this assay, an "uncleavable" or cleavage-resistant form of procaspase-3 was used. In this protein, the cleavage sites have been mutated from aspartic acid residues to alanine residues (D3A). This form of procaspase-3 generally cannot be cleaved through autoactivation or by another protease. As such, the activity of the compounds on the zymogen can be monitored independent of proteolytic processing. In these experiments, 2.5 μM Procaspase-3 (D3A) was incubated for 1 hour in the presence and absence of 10 μM zinc and the presence and absence of compounds. The ability of the compounds to activate procaspase-3 (D3A) was monitored by the use of 100 μM Ac-DEVD-pNA substrate, and the
absorbance was monitored at 405nm. An amount of 10 μM zinc is sufficient to fully inhibit 2.5 μM Procaspase-3 (D3A). This experiment revealed four classes of compounds: Activators, Inhibitors, Dual mode, and Non-effectors. Compounds that were capable of relieving the inhibitory affect of zinc are considered activators. Compounds that inhibit procaspase-3 (D3A) activity even in the absence of zinc are considered inhibitors. Some compounds exhibit the characteristics of both an activator and an inhibitor, and some compounds had no effect in this assay.
[00236] Compounds that were activators or had dual activity were further tested in a dose response experiment. In this experiment, 2.5 μM Procaspase-3 (D3A) was incubated with 10 μM zinc and various concentrations of each compound. After incubation for 1 hour, 200 μM Ac-DEVD-pNA was added to each sample and the absorbance was monitored at 405 nm. In this experiment we find that the compounds are able to activate procaspase-3 in the presence of zinc to varying degrees. Additionally, some of these compounds show inhibition at higher concentrations.
STATEMENTS REGARDING INCORPORATION BY REFERENCE AND VARIATIONS
[00237] All references throughout this application, for example patent documents including issued or granted patents or equivalents; patent application publications; unpublished patent applications; and non-patent literature documents or other source material; are hereby incorporated by reference herein in their entireties, as though individually incorporated by reference, to the extent each reference is at least partially not inconsistent with the disclosure in this application (for example, a reference that is partially inconsistent is incorporated by reference except for the partially inconsistent portion of the reference).
[00238] Any appendix or appendices hereto are incorporated by reference as part of the specification and/or drawings.
[00239] Where the terms "comprise", "comprises", "comprised", or "comprising" are used herein, they are to be interpreted as specifying the presence of the stated features, integers, steps, or components referred to, but not to preclude the presence or addition of one or more other feature, integer, step, component, or
group thereof. Separate embodiments of the invention are also intended to be encompassed wherein the terms "comprising" or "comprise(s)" or "comprised" are optionally replaced with the terms, analogous in grammar, e.g.; "consisting/consist(s)" or "consisting essentially of/consist(s) essentially of" to thereby describe further embodiments that are not necessarily coextensive. For clarification, as used herein "comprising" is synonymous with "having," "including," "containing," or "characterized by," and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. As used herein, "consisting of" excludes any element, step, component, or ingredient not specified in the claim element. As used herein, "consisting essentially of" does not exclude materials or steps that do not materially affect the basic and novel characteristics of the claim (e.g., not affecting an active ingredient). In each instance herein any of the terms "comprising", "consisting essentially of and "consisting of may be replaced with either of the other two terms. The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein.
[00240] The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention. It will be appreciated by one of ordinary skill in the art that compositions, methods, devices, device elements, materials, optional features, procedures and techniques other than those specifically described herein can be applied to the practice of the invention as broadly disclosed herein without resort to undue experimentation. All art-known functional equivalents of compositions, methods, devices, device elements, materials, procedures and techniques described herein; and portions thereof; are intended to be encompassed by this invention. Whenever a range is disclosed, all subranges and individual values are intended to be encompassed. This invention is not to be limited by the embodiments disclosed, including any shown in the drawings or exemplified in the specification, which are given by way of example or illustration and not of limitation. The scope of the invention shall be limited only by the claims.
REFERENCES
[00241] These applications are particularly incorporated by reference in entirety: U.S. Provisional Patent Application No. 60/516556 by Hergenrother et al., filed October 30, 2003; U.S. Provisional Patent Application No. 60/603246 by Hergenrother et al., filed August 20, 2004; U.S. 10/976,186 by Hergenrother et al., filed October 27, 2004.
U.S. Provisional Application Serial 60/684,807 filed May 26, 2005; U.S. Provisional Application Serial 60743878 filed March 28, 2006; US Patent Application Serial 11/420,425 filed May 25, 2006; PCT International Application Serial PCT/US 06/020910 filed May 26, 2006; US Provisional Application Serial 60/914,592 filed April 27, 2007.
[00242] US 6,762,045 Membrane derived caspase-3, compositions comprising the same and methods of use therefore; US 6,534,267 Polynucleotides encoding activators of caspases; US 6,403,765 Truncated Apaf-1 and methods of use thereof; US 6,303,329; 6,878,743 by Choong, et al. issued April 12, 2005; US 20040077542 by Wang, Xiaodong; et al., published April 22, 2004; US 20040180828 by Shi, Yigong, published September 16, 2004.
[00243] Slee EA et al., Benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethylketone (Z-VAD. FMK) inhibits apoptosis by blocking the processing of CPP32, Biochem J. 1996 Apr 1 ;315 ( Pt 1 ):21 -4.
[00244] 1. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
[00245] 2. Okada, H. & Mak, T. W. Pathways of apoptotic and non-apoptotic death in tumour cells. Nature Rev. Cancer 4, 592-603 (2004).
[00246] 3. Roy, S. et al. Maintenance of caspase-3 proenzyme dormancy by an intrinsic "safety catch" regulatory tripeptide. Proc. Natl. Acad. Sci. 98, 6132-6137 (2001 ).
[00247] 4. Svingen, P. A. et al. Components of the cell death machine and drug sensitivity of the National Cancer Institute Cell Line Panel. Clin. Cancer Res. 10, 6807-6820 (2004).
[00248] 5. Lowe, S. W., Cepero, E. & Evan, G. Intrinsic tumor suppression. Nature 432, 307-315 (2004).
[00249] 6. Vogelstein, B. & Kinzler, K. W. Achilles' heel of cancer. Nature 412, 865- 866 (2001 ).
[00250] 7. Traven, A., Huang, D. C. & Lithgow, T. Protein hijacking: key proteins held captive against their will. Cancer Cell 5, 107-108 (2004).
[00251] 8. Soengas, M. S. et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409, 207-211 (2001 ).
[00252] 9. Wajant, H. Targeting the FLICE inhibitory protein (FLIP) in cancer therapy. MoI. Interv. 3, 124-127 (2003).
[00253] 10. Denicourt, C. & Dowdy, S. F. Targeting apoptotic pathways in cancer cells. Science 305, 1411 -1413 (2004).
[00254] 11. Vassilev, L. T. et al. In vivo activation of the p53 pathway by small- molecule antagonists of MDM2. Science 303, 844-848 (2004).
[00255] 12. Degterev, A. et al. Identification of small-molecule inhibitors of interaction between the BH3 domain and BcI-XL. Nature Cell Biol. 3, 173-182 (2001 ).
[00256] 13. Becattini, B. et al. Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting BcI-XL. Chem. Biol. 11 , 389-395 (2004).
[00257] 14. Wang, J. -L. et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Natl. Acad. Sci. 97, 7124-7129 (2000).
[00258] 15. Li, L. et al. A small molecule Smac mimic potentiates TRAIL- and TNFa- mediated cell death. Science 305, 1471 -1474 (2004).
[00259] 16. Nguyen, J. T. & Wells, J. A. Direct activation of the apoptosis machinery as a mechanism to target cancer cells. Proc. Natl. Acad. Sci. U.S.A. 100, 7533-7538 (2003).
[00260] 17. Jiang, X. et al. Distincitive roles of PHAP proteins and prothymosin-α in a death regulatory pathway. Science 299, 223-226 (2003).
[00261] 18. Boatright, K. M. & Salvesen, G. S. Mechanisms of caspase activation. Curr. Opin. Cell. Biol. 15, 725-731 (2003).
[00262] 19. Nakagawara, A. et al. High levels of expression and nuclear localization of interleukin-1 β converting enzyme (ICE) and CPP32 in favorable human neuroblastomas. Cancer Res. 57, 4578-4584 (1997).
[00263] 20. Izban, K. F. et al. Characterization of the interleukin-1 β-converting enzyme/Ced-3-family protease, caspase-3/CPP32, in Hodgkin's disease. Am. J. Pathol. 154, 1439-1447 (1999).
[00264] 21. Persad, R. et al. Overexpression of caspase-3 in hepatocellular carcinomas. Modern Patholo. 17, 861 -867 (2004).
[00265] 22. Pop, C, Feeney, B., Tripathy, A. & Clark, A. C. Mutations in the procaspase-3 dimer interface affect the activity of the zymogen. Biochemistry 42, 12311 -12320 (2003).
[00266] 23. Stennicke, H. R. et al. J. Biol. Chem. 273, 27084-27090 (1998).
[00267] 24. Denault, J.-B. & Salvesen, G. S. Human caspase-7 activity and regulation by its N-terminal peptide. J. Biol. Chem. 278, 34042-24050 (2003).
[00268] 25. Putt, K. S., Beilman, G. J. & Hergenrother, P. J. Direct quantitation of Poly(ADP-ribose) polymerase (PARP) activity as a means to distinguish necrotic and apoptotic death in cell and tissue samples. ChemBioChem 6, 53-55 (2005).
[00269] 26. Liang, Y., Nylander, K. D., Yan, C. & Schor, N. F. Role of caspase 3- dependent Bcl-2 cleavage in potentiation of apoptosis by Bcl-2. MoI. Pharmacol. 61 , 142-149 (2002).
[00270] 27. Fujita, N., Nagahshi, A., Nagashima, K., Rokudai, S. & Tsuruo, T. Acceleration of apoptotic cell death after the cleavage of BcI-XL protein by caspase- 3-like proteases. Oncogene 17, 1295-1304 (1998).
[00271] 28. Earnshaw, W. C, Martins, L. M. & Kaufmann, S. H. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu. Rev. Biochem. 68, 383-424 (1999).
[00272] 29. Koty, P. P., Zhang, H. & Levitt, M. L. Antisense bcl-2 treatment increases programmed cell death in non-small cell lung cancer cell lines. Lung Cancer 23, 115-127 (1999).
[00273] National Center for Biotechnology Information (NCBI) Database of the National Library of Medicine / National Institutes of Health (NIH) website: http://www.ncbi.nlm.nih.gov/ using the Gene database to search for CASP3 (caspase 3, apoptosis-related cysteine protease [Homo sapiens] GenelD: 836 Locus tag: HGNC:1504; MIM: 600636 updated 15-May-2005. Other Aliases: HGNC:1504, APOPAIN, CPP32, CPP32B, SCA-1 ; Other Designations: Human procaspase3 coding sequence; PARP cleavage protease; SREBP cleavage activity 1 ; Yama; caspase 3; cysteine protease CPP32).
[00274] Hergenrother PJ. Obtaining and screening compound collections: a user's guide and a call to chemists. Curr Opin Chem Biol. 2006
[00275] Silverman SK, Hergenrother PJ. Combinatorial chemistry and molecular diversity Tools for molecular diversification and their applications in chemical biology. Curr Opin Chem Biol. 2006.
[00276] Goode DR, Sharma AK, Hergenrother PJ. Using peptidic inhibitors to systematically probe the SV site of caspase-3 and caspase-7. Org Lett. 2005 Aug 4;7(16):3529-32. PMID: 16048334
[00277] Dothager RS, Putt KS, Allen BJ, Leslie BJ, Nesterenko V, Hergenrother PJ. Synthesis and identification of small molecules that potently induce apoptosis in melanoma cells through G1 cell cycle arrest. J Am Chem Soc. 2005 Jun 22;127(24):8686-96. PMID: 15954774
[00278] Putt KS, Hergenrother PJ. A nonradiometric, high-throughput assay for poly(ADP-ribose) glycohydrolase (PARG): application to inhibitor identification and evaluation. Anal Biochem. 2004 Oct 15;333(2):256-64. PMID: 15450800
[00279] Putt KS, Hergenrother PJ. An enzymatic assay for poly(ADP-ribose) polymerase-1 (PARP-1 ) via the chemical quantitation of NAD(+): application to the high-throughput screening of small molecules as potential inhibitors. Anal Biochem. 2004 Mar 1 ;326(1 ):78-86. PMID: 14769338
[00280] Nesterenko V, Putt KS, Hergenrother PJ. Identification from a combinatorial library of a small molecule that selectively induces apoptosis in cancer cells. J Am Chem Soc. 2003 Dec 3;125(48):14672-3. PMID: 14640619
[00281] Putt, Karsone et al., Small scale activation of procaspase-3 as a personalized anticancer strategy, Nature Chemical Biology 2(10):543-550, S543/1 - S543/29 (2006).
Claims
We claim:
A compound having formula:
wherein Y is selected from Y2-Y6 where:
Y1 = -CH2-CO-NR6-N=CH- Y2 = -CH2-CO-NR6-N R'6-CH2- Y3 = -CH2-CH2-NR6-N=CH- Y4 = -CH2-CH2-N R6-NRVCH2- Y5 = -CH2-CO-NH-CH2-CH2-, or Y6 = -CH2-CO-NH-CH2-
n = 0, 1 or 2;
each R, independently of each other R, is selected from hydrogen, halogen, C1 -C6 alkyl, or C2-C6 alkenyl;
R2X is a halogen or X is O, S, NR7, CO, OCO, or OCS, when X is O or S, R2 = hydrogen, C1 -C6 alkyl, aryl, R8CO-, R8OCO-, R8SCO, or R8OCS-, where R8 is C1 -C6 alkyl or aryl, when X is NR7, R2 and R7, independently, are selected from hydrogen, C1 -C6 alkyl, aryl, R8CO-, pr R8OCO-; when X is CO, OCO or OCS, R2 is hydrogen, C1 -C6 alkyl, or aryl;
R3 is selected from hydrogen, halogen, C1 -C6 alkyl, C1 -C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkenol, C1 -C6 alkanol, or C2-C6 haloalkenyl;
R5 is N or CH2; R6 and R'6 are selected from hydrogen or C1-C3 alkyl; and
B is aryl, heteroaryl or R9-O-CO-, where R9 is C1 -C6 alkyl or aryl.
2. The compound of claim 1 wherein In R3 is allyl.
3. The compound of claim 1 wherein R2X is OH.
4. The compound of claim 1 wherein R2X is NH2.
5. The compound of claim 1 wherein Y is Y3.
6. The compound of claim 1 wherein Y is Y5 or Y6.
7. The compound of claim 1 wherein Y is Y2 or Y4.
8. The compound of claim 1 wherein B is an optionally substituted phenyl ring.
9. The compound of claim 8 wherein n is 1.
10. The compound of claim 1 wherein B is R9-O-CO-.
11. The compound of claim 9 wherein n is O.
12. The compound of claim 10 wherein R9 is t-butyl.
13. A compound of formula:
and salts thereof,
wherein n = 0, 1 or 2;
each R, independently of other R, is selected from hydrogen, halogen, alkyl, or alkenyl; R2X is a halogen or X is O, S, NR7, CO, OCO, or OCS, when X is O or S, R2 = hydrogen, alkyl, aryl, R8CO-, R8OCO-, R8SCO, or R8OCS-; where R8 is C1 - C6 alkyl or aryl, when X is NR7, R2 and R7, independently, are selected from hydrogen, C1 -C6 alkyl, aryl, R8CO-, or R8OCO- ; when X is CO, OCO or OCS, R2 is hydrogen, C1 -C6 alkyl, or aryl;
R3 is selected from hydrogen, halogen, C1 -C6 alkyl, C1 -C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkenol, C1 -C6 alkanol, or C2-C6 haloalkenyl;
R4 and R5 are both N; R4 is N and R5 is CH; R4 is CH and R5 is N or R4 and R5 are both CH;
R6 is hydrogen or C1 -C6 alkyl;
A = oxygen or sulfur; and
B is heteroaryl or R9-O-CO-, where Rg is C1 -C6 alkyl or aryl.
14. The compound of claim 13 wherein B is R9-O-CO-.
15. The compound of claim 14 wherein R9 is t-butyl.
16. The compound of claim 13 wherein B is heteroaryl.
17. The compound of claim 13 wherein A is oxygen.
18. The compound of claim 13 wherein R3 is allyl.
19. The compound of claim 13 wherein both R4 and R5 are N.
20. A compound of formula:
and salts thereof, wherein n = 0, 1 or 2;
each R, independently of other R, is selected from hydrogen, halogen, C1 -C6 alkyl, or C2-C6 alkenyl;
R2X is a halogen or X is S, NR7, CO, OCO, or OCS, when X is S, R2 = hydrogen, C1 -C6 alkyl, aryl, R8CO-, R8OCO-, R8SCO, or R8OCS-, where R8 is
C1 -C6 alkyl or aryl, when X is NR7, R2 and R7, independently, are selected from hydrogen, C1 -C6 alkyl, aryl, R8CO-, R8OCO-, or a moiety that is removable under physiological conditions; when X is CO, OCO or OCS, R2 is hydrogen, C1 -C6 alkyl, or aryl;;
R3 is selected from hydrogen, halogen, C1 -C6 alkyl, C1 -C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkenol, C1 -C6 alkanol, or C2-C6 haloalkenyl;
R4 and R5 are both N; R4 is N and R5 is CH; R4 is CH and R5 is N or R4 and R5 are both CH;
R6 is hydrogen or C1 -C6 alkyl;
A = oxygen or sulfur; and
B is aryl.
21. The compound of claim 20 wherein A is oxygen.
22. The compound of claim 20 where both R4 and R5 are N.
23. The compound of claim 20 wherein X is S.
24. The compound of claim 20 wherein X is R7N.
25. The compound of claim 20 wherein X is -CO-, -OCO- or -R7NCO-.
and salts thereof;
where and salts thereof,
wherein Y is selected from Y1 -Y6 where:
Y1 = -CH2-CO-NR6-N=CH- Y2 = -CH2-CO-NR6-N R1S-CH2- Y3 = -CH2-CH2-NR6-N=CH- Y4 = -CH2-CH2-N R6-NRVCH2- Y5 = -CH2-CO-NH-CH2-CH2-, or Y6 = -CH2-CO-NH-CH2-
n = 0, 1 or 2;
each R, independently of each other R, is selected from hydrogen, halogen, C1 -C6 alkyl, C1 -C3 alkoxyl or C2-C6 alkenyl;
R3 is selected from hydrogen, halogen, C1 -C6 alkyl, C1 -C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkenol, C1 -C6 alkanol, or C2-C6 haloalkenyl;
R5 is N or CH2;
Re and R'β are selected from hydrogen or C1-C3 alkyl; and
B is aryl, heteroaryl or Rg-O-CO-, where Rg is C1 -C6 alkyl or aryl.
27. The compound of claim 26 where B is aryl.
28. The compound of claim 27 wherein B is
where Ra, Rb, Rc, Rd, and Re are selected from the group hydrogen, halogen, C1 -C3 alkyl, and C1 -C3 alkoxy.
29. The compound of claim 28 wherein one or two of Ra, Rb, Rc, Rd, or Re are halogen, C1 -C3 alkyl, or C1 -C3 alkoxy and the remaining groups are hydrogen.
30. A compound of formula:
and salts thereof;
where wherein n = 1 or 2;
each R, independently of other R, is selected from hydrogen, halogen, C1 -C6 alkyl, C1 -C6 alkoxy or C2-C6 alkenyl;
R3 is selected from hydrogen, halogen, C1 -C6 alkyl, C1 -C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkenol, C1 -C6 alkanol, or C1 -C6 haloalkenyl; R4 and R5 are both N; R4 is N and R5 is CH; R4 is CH and R5 is N or R4 and R5 are both CH;
Ra, Rb, Rc, Rd, and Re are independently selected from hydrogen, halogen, C1 -C6 alkyl, and C1 -C6 alkoxy;
R6 is hydrogen or alkyl; and
A = oxygen or sulfur.
31. The compound of claim 30 where A is O.
32. The compound of claim 30 where R3 is hydrogen.
33. The compound of claim 30 where R6 is hydrogen.
34. A compound having a formula selected from the group consisting of DX2,
DX4, DX6, DX7, DX8, DX9, DX10, DX11 , DX12, DX13, DX14, DX15, DX16, and DX17.
35. A compound having a formula selected from the group consisting of DX6, DX7, DX8, DX9, DX10, DX11 , DX12, and DX15.
36. A compound having a formula selected from the groups consisting of FX1 , FX2, FX3, FX4, FX5, FX6, FX7, FX8, and FX9.
37. A compound having formula GX1.
38. A method of selectively inducing apoptosis in a cancer cell, comprising administering to said cancer cell a compound capable of modifying a procaspase-3 molecule of said cancer cell; wherein said compound is the compound of any one of claims 1 -37.
39. A method of selectively inducing apoptosis in a cancer cell, comprising administering to said cancer cell a compound capable of modifying a procaspase-3 molecule of said cancer cell; wherein said compound is the compound of any one of claims 1 -37 and wherein said cancer cell is in a patient in need of treatment.
40. A method of treating a cancer cell, comprising (a) identifying a potential susceptibility to treatment of a cancer cell with a procaspase activator compound; and (b) exposing said cancer cell to an effective amount of the procaspase activator compound; wherein the procaspase activator compound is the compound of any one of claims 1 -37.
41. A method of treating a cancer cell, comprising (a) identifying a potential susceptibility to treatment of a cancer cell with a procaspase activator compound; and (b) exposing said cancer cell to an effective amount of the procaspase activator compound; wherein the procaspase activator compound is the compound of any one of claims 1 -37 wherein said procaspase activator compound is capable of activating at least one of procaspase-3 and procaspase-7.
42. A method of inducing death in a cancer cell, comprising administering to said cancer cell a compound capable of activating a procaspase-3 molecule of said cancer cell, wherein said compound is the compound of any one of claims 1 -37.
43. A medicament comprising and effective amount of one or more compounds of any one of claims 1 -37.
44. A method of making a medicament for treatment of a cancer cell which comprises one or more compounds of any one of claims 1 -37.
45. A method of inducing apoptosis in a cell, comprising administering to said cell a compound of any one of claims 1 -37.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/087,595 US8592584B2 (en) | 2005-05-26 | 2011-04-15 | Compositions and methods including cell death inducers and procaspase activation |
US13/893,936 US9522901B2 (en) | 2005-05-26 | 2013-05-14 | Compositions and methods including cell death inducers and procaspase activation |
US15/385,040 US10166229B2 (en) | 2005-05-26 | 2016-12-20 | Compounds and methods for the treatment of cancer |
US16/230,676 US11612598B2 (en) | 2005-05-26 | 2018-12-21 | Compounds and methods for the treatment of cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91459207P | 2007-04-27 | 2007-04-27 | |
US60/914,592 | 2007-04-27 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/420,425 Continuation-In-Part US20070049602A1 (en) | 2005-05-26 | 2006-05-25 | Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/597,287 A-371-Of-International US20080249104A1 (en) | 2004-02-04 | 2005-02-03 | Salt Forms of 4- (4-Methylpiperazin-1-Ylmethyl) -N- [4-Methyl-3- (4-Pyridin-3-Yl) Pyrimidin-2-Ylamino) Phenyl]- Benzamide |
US13/087,595 Continuation US8592584B2 (en) | 2005-05-26 | 2011-04-15 | Compositions and methods including cell death inducers and procaspase activation |
US13/087,595 Continuation-In-Part US8592584B2 (en) | 2005-05-26 | 2011-04-15 | Compositions and methods including cell death inducers and procaspase activation |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008134474A2 true WO2008134474A2 (en) | 2008-11-06 |
WO2008134474A3 WO2008134474A3 (en) | 2009-01-08 |
Family
ID=39643172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/061510 WO2008134474A2 (en) | 2005-05-26 | 2008-04-25 | Compositions and methods including cell death inducers and procaspase activation |
Country Status (2)
Country | Link |
---|---|
US (4) | US8592584B2 (en) |
WO (1) | WO2008134474A2 (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010091382A1 (en) * | 2009-02-09 | 2010-08-12 | The Board Of Trustees Of The University Of Illinois | Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs |
CN101805338A (en) * | 2010-04-06 | 2010-08-18 | 沈阳药科大学 | Oxadiazole-based piperazine derivative and application thereof |
WO2011020288A1 (en) | 2009-08-19 | 2011-02-24 | 沈阳亿利奥医药科技有限公司 | Substituted hydrazide compounds and application thereof |
US20130096133A1 (en) * | 2011-10-14 | 2013-04-18 | The Board of Trustees of the University lllinois | Procaspase-activating compounds and compositions |
WO2013134407A2 (en) | 2012-03-06 | 2013-09-12 | The Board Of Trustees Of The University Of Illinois | Procaspase 3 activation by combination therapy |
WO2013137832A1 (en) * | 2012-03-16 | 2013-09-19 | Nanyang Technological University | Myostatin inhibitors |
US8592584B2 (en) | 2005-05-26 | 2013-11-26 | The Board of Trustees of the of The University of Illinois | Compositions and methods including cell death inducers and procaspase activation |
WO2014022858A1 (en) | 2012-08-03 | 2014-02-06 | The Board Of Trustees Of The University Of Illinois | Enzyme-activating compounds and compositions |
JP2014024759A (en) * | 2012-07-24 | 2014-02-06 | National Institute Of Advanced Industrial & Technology | 2-hydroxybenzaldehyde compound, and collagen extracellular secretion inhibitor and pharmaceutical composition containing the same |
US20150094314A1 (en) * | 2012-03-21 | 2015-04-02 | Case Western Reserve University | Method of modulating ribonucleotide reductase |
US9421202B2 (en) | 2012-03-06 | 2016-08-23 | The Board Of Trustees Of The University Of Illinois | Procaspase combination therapy for glioblastoma |
US9592229B2 (en) | 2012-03-02 | 2017-03-14 | The Board Of Trustees Of The University Of Illinois | Potent anticancer activity via dual compound activation |
CN108409627A (en) * | 2018-03-14 | 2018-08-17 | 河北科技大学 | The acetyl virtue hydrazone analog derivative of the segment containing indoles and its application |
EP3326631A4 (en) * | 2015-07-23 | 2019-03-27 | Zhimin Wang | Compound pac-1 or salt thereof, and pharmaceutical composition comprising same |
US10350207B2 (en) | 2015-06-05 | 2019-07-16 | The Board Of Trustees Of The University Of Illinois | PAC-1 combination therapy |
US11510919B2 (en) | 2017-11-17 | 2022-11-29 | The Board Of Trustees Of The University Of Illinois | Cancer therapy by degrading dual MEK signaling |
US11530289B2 (en) | 2017-09-27 | 2022-12-20 | King Fahd University Of Petroleum And Minerals | Crosslinked polymers and a method for heavy metal ion removal |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3227437A4 (en) | 2014-12-05 | 2018-08-22 | An2H Discovery Limited | Parkin ligase activation methods and compositions |
US10308617B2 (en) | 2016-06-03 | 2019-06-04 | An2H Discovery Limited | Triazole benzamide derivatives and the compositions and methods of treatment regarding the same |
US10889553B2 (en) | 2017-12-01 | 2021-01-12 | Nysnobio Ireland Dac | Asymmetric triazole benzamide derivatives and the compositions and methods of treatment regarding the same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006128173A2 (en) * | 2005-05-26 | 2006-11-30 | The Board Of Trustees Of The University Of Illinois | Selective apoptotic induction in cancer cells including activation of procaspase-3 |
WO2007008529A2 (en) * | 2005-07-08 | 2007-01-18 | Kalypsys, Inc | Celullar cholesterol absorption modifiers |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1263001B (en) | 1965-07-12 | 1968-03-14 | Dr Miltiadis Ioannu Hiopulos | Process for the preparation of 1,1-bis (p-hydroxyphenyl) -alkane-1-phosphonic acid diesters |
US3847866A (en) | 1965-07-12 | 1974-11-12 | H Bredereck | Bis-(p-hydroxyphenyl)alkylphosphonic acid esters |
US3879498A (en) | 1971-08-31 | 1975-04-22 | Miltiadis I Iliopulos | Dialkyl 1-acryloyloxy-2-alkenyl-1-phosphonates and dialkyl 1-methacryloxy-2-alkenyl-1-phosphonates |
DE3222571A1 (en) | 1982-06-16 | 1983-12-22 | Röhm GmbH, 6100 Darmstadt | POLYARYLENESTERS CONTAINING PHOSPHORUS AND METHOD FOR THE PRODUCTION THEREOF |
US5569673A (en) | 1994-05-24 | 1996-10-29 | Purdue Research Foundation | Capsacinoid compounds as proliferation inhibitors |
CA2246734A1 (en) | 1996-02-20 | 1997-08-21 | Sloan-Kettering Institute For Cancer Research | Combinations of pkc inhibitors and therapeutic agents for treating cancers |
US6558900B2 (en) | 1996-07-12 | 2003-05-06 | Emory University | Regulation of apoptosis and in vitro model for studies thereof |
AU762756B2 (en) | 1998-05-18 | 2003-07-03 | Apoptosis Technology, Inc. | Compounds, screening methods, and uses involving anti-apoptotic genes and gene products |
US6403765B1 (en) | 1998-06-16 | 2002-06-11 | Thomas Jefferson University | Truncated Apaf-1 and methods of use thereof |
US6303329B1 (en) | 1998-07-27 | 2001-10-16 | Pharmacia & Upjohn Company | Method for autoactivation of procaspase 8 |
AU5446499A (en) | 1998-08-31 | 2000-03-21 | Kyowa Hakko Kogyo Co. Ltd. | Apoptosis inducing agents |
CA2343027A1 (en) | 1998-09-09 | 2000-03-16 | Metabasis Therapeutics, Inc. | Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase |
US6110691A (en) | 2000-01-06 | 2000-08-29 | Board Of Regents, The University Of Texas System | Activators of caspases |
US6605589B1 (en) | 2000-03-31 | 2003-08-12 | Parker Hughes Institute | Cathepsin inhibitors in cancer treatment |
US6608026B1 (en) | 2000-08-23 | 2003-08-19 | Board Of Regents, The University Of Texas System | Apoptotic compounds |
WO2002048329A2 (en) | 2000-11-20 | 2002-06-20 | Idun Pharmaceuticals, Inc. | Membrane derived caspase-3, compositions comprising the same and methods of use therefor |
WO2002067964A1 (en) | 2001-02-21 | 2002-09-06 | Rutgers, The State University Of New Jersey | Compositions and methods for cancer prevention and treatment derived from $i(inula britannica) |
KR100439425B1 (en) | 2001-03-22 | 2004-07-05 | (주)바이오케어 | Compositions Comprising Xanthorrhizol And The Use Thereof |
AU2002310099A1 (en) * | 2001-05-22 | 2002-12-03 | President And Fellows Of Harvard College | Identification of anti-protozoal agents |
WO2003024955A2 (en) | 2001-09-18 | 2003-03-27 | Sunesis Pharmaceuticals, Inc. | Small molecule inhibitors of caspases |
WO2003048101A1 (en) | 2001-11-30 | 2003-06-12 | The Burnham Institute | Induction of apoptosis in cancer cells |
US20030148966A1 (en) | 2002-01-30 | 2003-08-07 | Hiremagalur Jayaram | Method and composition for inducing apoptosis in cells |
WO2004066958A2 (en) | 2003-01-30 | 2004-08-12 | The Trustees Of Princeton University | Caspase-9:bir3 domain of xiap complexes and methods of use |
US7632972B2 (en) | 2003-10-30 | 2009-12-15 | The Board Of Trustees Of The University Of Illionis | Compounds and methods for treatment of cancer and modulation of programmed cell death for melanoma and other cancer cells |
WO2005090370A1 (en) | 2004-02-05 | 2005-09-29 | The Regents Of The University Of California | Pharmacologically active agents containing esterified phosphonates and methods for use thereof |
WO2008134474A2 (en) | 2007-04-27 | 2008-11-06 | The Board Of Trustees Of The University Of Illinois | Compositions and methods including cell death inducers and procaspase activation |
CN106946812B (en) * | 2009-02-09 | 2020-10-09 | 伊利诺伊大学评议会 | Design, synthesis and evaluation of procaspase activating compounds as personalized anticancer agents |
US8916705B2 (en) * | 2011-10-14 | 2014-12-23 | The Board of Trustees of The University of Illilnois | Procaspase-activating compounds and compositions |
EP2819661B1 (en) * | 2012-03-02 | 2016-11-09 | The Board of Trustees of the University of Illionis | Potent anticancer activity via dual compound activation |
IN2014MN01945A (en) * | 2012-03-06 | 2015-07-10 | Univ Illinois | |
MX359209B (en) * | 2012-03-06 | 2018-09-19 | Univ Illinois | Procaspase combination therapy for glioblastoma. |
CN104981461B (en) * | 2012-08-03 | 2017-09-29 | 伊利诺伊大学评议会 | The compound and composition of kinase |
-
2008
- 2008-04-25 WO PCT/US2008/061510 patent/WO2008134474A2/en active Application Filing
-
2011
- 2011-04-15 US US13/087,595 patent/US8592584B2/en active Active
-
2013
- 2013-05-14 US US13/893,936 patent/US9522901B2/en active Active
-
2016
- 2016-12-20 US US15/385,040 patent/US10166229B2/en active Active
-
2018
- 2018-12-21 US US16/230,676 patent/US11612598B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006128173A2 (en) * | 2005-05-26 | 2006-11-30 | The Board Of Trustees Of The University Of Illinois | Selective apoptotic induction in cancer cells including activation of procaspase-3 |
WO2007008529A2 (en) * | 2005-07-08 | 2007-01-18 | Kalypsys, Inc | Celullar cholesterol absorption modifiers |
Non-Patent Citations (3)
Title |
---|
KHANNA, RAMA ET AL: "Newer piperazino oxadiazoles, formazans, and tetrazolium salts as antiparkinsonian agents" INDIAN JOURNAL OF CHEMISTRY, SECTION B: ORGANIC CHEMISTRY INCLUDING MEDICINAL CHEMISTRY, vol. 29B, no. 1, 1990, pages 91-94, XP009104194 * |
PUTT K S ET AL: "Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy" NATURE CHEMICAL BIOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 2, no. 10, 1 October 2006 (2006-10-01), pages 543-550, XP003013055 ISSN: 1552-4450 cited in the application * |
SENGUPTA, ANIL K. ET AL: "Search for potential psychotropic agents. Part II. N-Benzylidene derivatives of 4-arylpiperazine-1-acetic acid hydrazides" POLISH JOURNAL OF PHARMACOLOGY AND PHARMACY, vol. 30, no. 1, 1978, pages 89-94, XP009104195 * |
Cited By (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10166229B2 (en) | 2005-05-26 | 2019-01-01 | The Board Of Trustees Of The University Of Illinois | Compounds and methods for the treatment of cancer |
US9522901B2 (en) | 2005-05-26 | 2016-12-20 | The Board Of Trustees Of The University Of Illinois | Compositions and methods including cell death inducers and procaspase activation |
US11612598B2 (en) | 2005-05-26 | 2023-03-28 | The Board Of Trustees Of The University Of Illinois | Compounds and methods for the treatment of cancer |
US8592584B2 (en) | 2005-05-26 | 2013-11-26 | The Board of Trustees of the of The University of Illinois | Compositions and methods including cell death inducers and procaspase activation |
US8778945B2 (en) | 2009-02-09 | 2014-07-15 | The Board Of Trustees Of The University Of Illinois | Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs |
US9643960B2 (en) | 2009-02-09 | 2017-05-09 | The Board Of Trustees Of The University Of Illinois | Procaspase activating compounds |
JP2012517442A (en) * | 2009-02-09 | 2012-08-02 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ | Design, synthesis and evaluation of procaspase activating compounds as individualized anticancer drugs |
EP2393794A4 (en) * | 2009-02-09 | 2012-10-31 | Trustees Of The Universityof Illinois Board Of | Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs |
US20150344452A1 (en) * | 2009-02-09 | 2015-12-03 | The Board Of Trustees Of The University Of Illinois | Procaspase activating compounds |
EP2393794A1 (en) * | 2009-02-09 | 2011-12-14 | The Board Of Trustees Of The UniversityOf Illinois | Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs |
AU2010210403B2 (en) * | 2009-02-09 | 2016-07-28 | The Board Of Trustees Of The University Of Illinois | Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs |
US9102661B2 (en) | 2009-02-09 | 2015-08-11 | The Board Of Trustees Of The University Illinois | Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs |
WO2010091382A1 (en) * | 2009-02-09 | 2010-08-12 | The Board Of Trustees Of The University Of Illinois | Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs |
US20120040995A1 (en) * | 2009-02-09 | 2012-02-16 | The Board Of Trustees Of The University Of Illinois | Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs |
WO2011020288A1 (en) | 2009-08-19 | 2011-02-24 | 沈阳亿利奥医药科技有限公司 | Substituted hydrazide compounds and application thereof |
WO2011124087A1 (en) * | 2010-04-06 | 2011-10-13 | 沈阳药科大学 | Oxadiazole-based piperazine derivatives and applications thereof |
CN101805338A (en) * | 2010-04-06 | 2010-08-18 | 沈阳药科大学 | Oxadiazole-based piperazine derivative and application thereof |
US8916705B2 (en) * | 2011-10-14 | 2014-12-23 | The Board of Trustees of The University of Illilnois | Procaspase-activating compounds and compositions |
US10525056B2 (en) | 2011-10-14 | 2020-01-07 | The Board Of Trustees Of The University Of Illinois | Procaspase-activating compounds and methods |
US10022371B2 (en) | 2011-10-14 | 2018-07-17 | The Board Of Trustees Of The University Of Illinois | Procaspase-activating compounds and methods |
US20130096133A1 (en) * | 2011-10-14 | 2013-04-18 | The Board of Trustees of the University lllinois | Procaspase-activating compounds and compositions |
US9592229B2 (en) | 2012-03-02 | 2017-03-14 | The Board Of Trustees Of The University Of Illinois | Potent anticancer activity via dual compound activation |
WO2013134407A2 (en) | 2012-03-06 | 2013-09-12 | The Board Of Trustees Of The University Of Illinois | Procaspase 3 activation by combination therapy |
US11844798B2 (en) | 2012-03-06 | 2023-12-19 | The Board Of Trustees Of The University Of Illinois | Procaspase combination therapy for glioblastoma |
US11833147B2 (en) | 2012-03-06 | 2023-12-05 | Vanquish Oncology, Inc. | Procaspase 3 activation by combination therapy |
US9421202B2 (en) | 2012-03-06 | 2016-08-23 | The Board Of Trustees Of The University Of Illinois | Procaspase combination therapy for glioblastoma |
US10888560B2 (en) | 2012-03-06 | 2021-01-12 | The Board Of Trustees Of The University Of Illinois | Procaspase 3 activation by combination therapy |
CN104507479A (en) * | 2012-03-06 | 2015-04-08 | 伊利诺伊大学评议会 | Procaspase 3 activation by combination therapy |
US10085977B2 (en) | 2012-03-06 | 2018-10-02 | The Board Of Trustees Of The Univerity Of Illinois | Procaspase 3 activation by combination therapy |
US9399035B2 (en) | 2012-03-06 | 2016-07-26 | The Board Of Trustees Of The University Of Illinois | Procaspase 3 activation by combination therapy |
US10874666B2 (en) | 2012-03-06 | 2020-12-29 | The Board Of Trustees Of The University Of Illinois | Procaspase combination therapy for glioblastoma |
CN104507479B (en) * | 2012-03-06 | 2017-08-18 | 伊利诺伊大学评议会 | Pass through the Caspase-3 activation of zymogen of therapeutic alliance |
US10085978B2 (en) | 2012-03-06 | 2018-10-02 | The Board Of Trustees Of The University Of Illinois | Procaspase combination therapy for glioblastoma |
WO2013134407A3 (en) * | 2012-03-06 | 2013-10-24 | The Board Of Trustees Of The University Of Illinois | Procaspase 3 activation by combination therapy |
WO2013137832A1 (en) * | 2012-03-16 | 2013-09-19 | Nanyang Technological University | Myostatin inhibitors |
US9889129B2 (en) * | 2012-03-21 | 2018-02-13 | Case Western Reserve University | Method of modulating ribonucleotide reductase |
US20150094314A1 (en) * | 2012-03-21 | 2015-04-02 | Case Western Reserve University | Method of modulating ribonucleotide reductase |
JP2014024759A (en) * | 2012-07-24 | 2014-02-06 | National Institute Of Advanced Industrial & Technology | 2-hydroxybenzaldehyde compound, and collagen extracellular secretion inhibitor and pharmaceutical composition containing the same |
US9249116B2 (en) | 2012-08-03 | 2016-02-02 | The Board Of Trustees Of The University Of Illinois | Enzyme-activating compounds and compositions |
WO2014022858A1 (en) | 2012-08-03 | 2014-02-06 | The Board Of Trustees Of The University Of Illinois | Enzyme-activating compounds and compositions |
JP2015524445A (en) * | 2012-08-03 | 2015-08-24 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ | Enzyme activating compounds and compositions |
RU2652989C2 (en) * | 2012-08-03 | 2018-05-04 | Зэ Борд оф Трастиз оф зэ Юниверсити оф Иллинойс | Enzyme-activating compounds and compositions |
US9663482B2 (en) | 2012-08-03 | 2017-05-30 | The Board Of Trustees Of The University Of Illinois | Substituted piperazinyl acetohydrazide procaspase-activating compounds |
AU2013296187B2 (en) * | 2012-08-03 | 2016-09-29 | The Board Of Trustees Of The University Of Illinois | Enzyme-activating compounds and compositions |
US11129830B2 (en) | 2015-06-05 | 2021-09-28 | The Board Of Trustees Of The University Of Illinois | PAC-1 combination therapy |
US10350207B2 (en) | 2015-06-05 | 2019-07-16 | The Board Of Trustees Of The University Of Illinois | PAC-1 combination therapy |
EP3326631A4 (en) * | 2015-07-23 | 2019-03-27 | Zhimin Wang | Compound pac-1 or salt thereof, and pharmaceutical composition comprising same |
US11530289B2 (en) | 2017-09-27 | 2022-12-20 | King Fahd University Of Petroleum And Minerals | Crosslinked polymers and a method for heavy metal ion removal |
US11760827B2 (en) | 2017-09-27 | 2023-09-19 | King Fahd University Of Petroleum And Minerals | Melamine-based crosslinked polymer Mannich product |
US11773201B2 (en) | 2017-09-27 | 2023-10-03 | King Fahd University Of Petroleum And Minerals | Bisphenol-S containing mannich polycondensation product |
US11510919B2 (en) | 2017-11-17 | 2022-11-29 | The Board Of Trustees Of The University Of Illinois | Cancer therapy by degrading dual MEK signaling |
CN108409627B (en) * | 2018-03-14 | 2021-11-23 | 河北科技大学 | Acetyl aryl hydrazone derivative containing indole fragment and application thereof |
CN108409627A (en) * | 2018-03-14 | 2018-08-17 | 河北科技大学 | The acetyl virtue hydrazone analog derivative of the segment containing indoles and its application |
Also Published As
Publication number | Publication date |
---|---|
US10166229B2 (en) | 2019-01-01 |
WO2008134474A3 (en) | 2009-01-08 |
US20110257398A1 (en) | 2011-10-20 |
US20190201394A1 (en) | 2019-07-04 |
US20170105989A1 (en) | 2017-04-20 |
US8592584B2 (en) | 2013-11-26 |
US11612598B2 (en) | 2023-03-28 |
US20140073609A1 (en) | 2014-03-13 |
US9522901B2 (en) | 2016-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11612598B2 (en) | Compounds and methods for the treatment of cancer | |
EP1893210B1 (en) | Selective apoptotic induction in cancer cells including activation of procaspase-3 | |
Yuan et al. | Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy | |
US11325892B2 (en) | Compounds and methods for treating cancer | |
US8367644B2 (en) | Methods and compounds useful to induce apoptosis in cancer cells | |
CN106946812B (en) | Design, synthesis and evaluation of procaspase activating compounds as personalized anticancer agents | |
US7960435B2 (en) | Anti-cancer agents and androgen inhibition activity compound | |
Yan et al. | Discovery of a PROTAC targeting ALK with in vivo activity | |
CN101184491A (en) | Selective apoptotic induction in cancer cells including activation of procaspase-3 | |
KR20210027382A (en) | Activator of the unfolded protein reaction | |
Sun et al. | Discovery of 5-bromo-4-phenoxy-N-phenylpyrimidin-2-amine derivatives as novel ULK1 inhibitors that block autophagy and induce apoptosis in non-small cell lung cancer | |
Pu et al. | Synthesis and biological evaluation of a tumor-selective degrader of PARP1 | |
He et al. | Targeting cullin neddylation for cancer and fibrotic diseases | |
KR101400505B1 (en) | Small molecules that replace or agonize p53 function | |
Jiangzhou et al. | Discovery of proqodine A derivatives with antitumor activity targeting NAD (P) H: quinone oxidoreductase 1 and nicotinamide phosphoribosyltransferase | |
Wei et al. | Drug repurposing of propafenone to discover novel anti-tumor agents by impairing homologous recombination to delay DNA damage recovery of rare disease conjunctival melanoma | |
KR20230058258A (en) | Probe for detecting uch37 and uses thereof | |
WO2009067697A1 (en) | Therapeutic compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08746856 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08746856 Country of ref document: EP Kind code of ref document: A2 |